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Cardiorenal interaction: experimental and clinical studies L---------­
Door Mariusz K. Szymanski 
I. There is an urgent need for better animal models to study the cardiorenal interaction. (dit 
proefschrift). 
2. There are other mechanisms than only cardiac remodeling that lead to increased sensitivity to cardiac 
ischemia in the presence of reduced kidney function (dit proefschrift). 
3. Endothelial dysfunction plays an intermediate role in the interaction between heart and kidney in a 
new animal model for cardiorenal interaction (dit proefschrift). 
4. 3N-NH3 micro-PET can be used as a non-invasive method for assessment of the cardiorenal axis in 
experimental models (dit proefschrift). 
5. Excessive increase in renin concentration during treatment with ACE inhibitors has a prognostic value 
in heart failure patients with decreased kidney function (dit proefschrift). 
6. Voor welke klus dan ook, staat ergens in dit land een Pool klaar. (zo ook voor dit proefschrift) 
7. Net als bij een hardloopwedstrijd is bij promotieonderzoek de weg naar de eindstreep !anger dan 
verwacht en 'vals plat'. 
8. My home is where my bike is. 
9. The distance from The Hague to Groningen seems to be significantly longer than from Groningen to 
The Hague. 
I 0. Homage to thee, 0 my heart! Homage to you, 0 my kidneys! (Book of the Dead, 1600-1240 BC) 
I I . Science is facts; just as houses are made of stones, so is science made of facts; but a pile of stones is 
not a house and a collection of facts is not necessarily science (Henri Poincare) 
12. The roots of education are bitter, but the fruit is sweet (Aristotle) 
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Heart failure is a complex clinical syndrome characterized by reduced cardiac function 
and increased venous congestion. According to recent data, the prevalence is estimated at 
approximately 1-2% of the general population [I]. Despite the introduction of many treatment 
modalities over the past decades, heart failure related morbidity and mortality rates remain 
high [!].This may be explained by several factors, such as better survival following myocardial 
infarction, advanced ageing of heart failure population, as well as the presence of the common 
co-morbidities, which limit the efficacy of heart failure treatment and worsen overall prognosis. 
Heart failure is often accompanied by dysfunction of other organs, such as the endothelium, 
the kidney, the liver and the bone marrow. Renal dysfunction in heart failure has received 
increasing attention in last years [2 ,3]. The co-existence of these entities has been shown to 
further increase the risk for mortality and hospitalizations [ 4]. Interestingly, the extent of kidney 
dysfunction has been shown to predict the outcome of heart failure patients more accurately 
than cardiac contractile function (measured by left ventricular ejection fraction) itself [5]. 
Moreover; renal dysfunction has been shown an independent risk factor for the development 
of cardiovascular diseases and has been associated with poor outcome in a broad spectrum 
of cardiovascular patients [6-9]. Conversely, cardiac dysfunction is more likely to develop in 
patients with chronic renal dysfunction and leads to further decrease in renal function [ I OJ. 
This interaction between heart and kidney, where dysfunction of either one of them leads to 
disorder of the other; is usually referred to as the cardiorenal syndrome [ I I]. 
Cardiorenal syndrome 
It has been suggested that cardiac and renal dysfunction influence each other through shared 
pathological pathways [ I I ,  12]. Hemodynamic changes are considered the main driving force 
in the pathophysiology of the cardiorenal syndrome. A decrease in cardiac output, a hallmark 
of heart failure, below the autoregulatory range, leads to a decreased renal blood flow (RBF), 
which is the main determinant of decreased glomerular filtration rate (GFR) in heart failure 
population [ 13]. Moreover; recent studies have shown that not only forward failure but also 
venous congestion plays an important role in the pathophysiology of renal dysfunction in heart 
failure. Increased central venous pressure has been shown to be associated with impaired renal 
function and to be independently related to all cause mortality [ 14]. 
Upon the appearance of the above described hemodynamic changes, multiple regulatory 
mechanisms are activated, including the renin-angiotensin-aldosterone system (RAAS), the 
sympathetic nervous system (SNS) and the nitric oxide/reactive oxygen species balance 
[ I I ,  12]. The activation of RAAS has been suggested to be of special interest. Initially aimed 
to preserve cardiac and renal homeostasis, long-term activation of the RAAS eventually leads 
to changes in the myocardium and the progression of heart failure as well as salt and water 




1' Renln-Ang10tensin-Aldosterone System act,v,ty --------, 
,I, Renal Blood Flow I ,I, GFR 
Renal dysfunction 
Figure I. Pathophysiofogicaf connections in the cardiorenal syndrome ( Adapted from Bock et al.[ I 7]) 
flow. Activated RAAS interacts also with other cardiorenal connectors, such as SNS and the 
oxidative stress cascade [ 15, 16]. Recent studies have underscored the important role of other 
newly identified factors such as anemia and endothelial dysfunction (figure I). Because of close 
interaction between different pathophysiological mechanisms involved in the cardiorenal axis, 
activation of one of such factors often effect the others. Like wrth the RAAS, activation of these 
regulatory systems, at first compensatory, eventually leads on the long term to a vicious circle 
resulting in further structural and functional damage in heart and/or kidney. 
However; desprte new insights in the pathophysiology of the cardiorenal syndrome, the 
complex heart-kidney interactions are still only partially understood.Although we have gained 
insight in factors predicting outcome in heart failure patients with renal dysfunction, we are 
currently not able to define specific cardiorenal treatment strategies in heart failure patients. 
This could also be addressed by findings in the recent clinical trials in heart failure patients, in 
which no improvement in renal function has been shown upon different treatments [ 18, 19,20]. 
Therefore, further research is needed to better understand the cardiorenal syndrome and 
improve treatment strategies in this patient population .. 
Experimental studies on cardiorenal interaction 
Because of the observational character; post-hoc conclusions obtained from clinical studies 
have not led to new insights and treatments for the pathophysiology of cardiorenal interaction. 
This may be achieved by well-designed animal studies.The main requirements for such studies 
are: use of the proper animal model and use of techniques that allow studying important 
aspects of this interaction. 
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There are few rodent models described in literature, which have been used in studies on 
cardiorenal interaction [21-24]. However, none of the models entirely reproduce the 
pathophysiology and characteristics of the cardiorenal syndrome observed in humans. 
Therefore, future research should focus on developing a better model, which would mimic 
clinical characteristics of this syndrome by cardiac, renal, hemodynamic, and neurohumoral 
alterations, and allow the evaluation of various treatment strategies. 
Not only a relevant model is needed for the adequate study on cardiorenal interaction, but also 
techniques that will allow assessment of the cardiorenal connectors in this model.Whereas the 
activation of various systems, such as RAAS or SNS, can be quantified with the use of available 
plasma and tissue assessments, the proper assessment of hemodynamic changes remains a 
challenge. Introduction of various imaging techniques into preclinical research has already 
significantly improved our understanding of the global hemodynamic changes observed in 
cardiorenal axis. However.the quantification of regional organ perfusion still remains a challenge. 
The techniques used now are highly invasive and thus do not allow repetitive measurements. 
Therefore, there is a need for a noninvasive, preclinical method for the evaluation of cardiac 
and renal perfusion and research should focus on developing such a method. 
RMS blockade in the cardiorenal syndrome 
The described above interactions between various cardiorenal connectors lead not only to a 
vicious circle and deterioration of function of both organs, but may also substantially modulate 
the effectiveness of common treatment strategies used in heart failure. Drugs targeted to 
block one of the systems, may also, via feedback loops or compensatory mechanisms, yield an 
effect on other factors and systems involved in the cardiorenal interaction, which can limit the 
effects of the treatment. As an example, one of the most commonly used treatment strategies 
in cardiorenal patients is blocking of the RAAS.This has been proven to reduce heart failure­
centered morbidity and mortality [25-26]. On the other hand, although initially helping to 
preserve GFR to some extent [27], long-term RAAS blockade substantially disables regulatory 
mechanisms of the kidney [ 13] and can lead to further decrease in renal blood flow and GFR. 
Moreover RAAS-blocking agents increase the plasma levels of prorenin, renin and plasma renin 
activity (PRA). Although initially believed to be unharmful, more data are available suggesting 
they should be considered prognostic factors in the heart failure population [28,29].Taken into 
consideration the new findings, the efficacy of RAAS blockade and its effect on neurohormonal 
status and prognosis should be studied in patients without and with concomitant renal disease. 
14 
General introduction 
Aims of the thesis 
The aim of this thesis was to study various aspects of the pathophysiology of the cardiorenal 
syndrome in both experimental and clinical setting. 
Part I focuses on the animal models available for the experimental studies on the interaction 
between heart and kidney. Chapter 2 provides a review of the different animal models that 
have been used so far to study this interaction. In chapter 3 and chapter 4 we describe 
an animal model of combined heart and kidney dysfunction that might serve as a tool for 
experimental studies on cardiorenal interaction. 
In Part II we investigated the possibilities of imaging of cardiorenal axis in animal models with 
the use of 1 3N-NH3 micro-PIT. In chapter 5 we explored the possibilities to measure left 
ventricle parameters with this method, whereas chapter 6 focuses on the measurements of 
cardiac and renal regional perfusion. 
Finally, in Part Ill the role of activation and blockade of the RAAS in the cardiorenal interaction 
has been investigated in the clinical setting. In chapter 7 we studied the prognostic role of renin 
and prorenin in heart failure patients treated with RAAS blocking agents. 
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Chapter 2 
Abstract 
The incidence of heart fai lure and renal failure is increasing and is associated with poor 
prognosis. Moreover;these conditions do often coexist and this coexistence results in worsened 
outcome. Various mechanisms have been proposed as an explanation of this interrelation, 
including changes in hemodynamics, endothel ial dysfunction, inf lammation, activation of renin­
angiotensin-aldosterone system, and/or sympathetic nervous system. However; the exact 
mechanisms initializing and maintaining this interaction are sti l l  unknown. In many experimental 
studies on cardiac or renal dysfunction, the function of the other organ was either not addressed 
or the authors failed to show any decline in its function despite histological changes.There are 
few studies in which the dysfunction of both heart and kidney function has been described. 
In this review, we discuss animal models of combined cardiorenal dysfunction. We show that 
translation of the results from animal studies is l imited, and there is a need for new and better 
models of the cardiorenal interaction to improve our understanding of this syndrome. Finally, 
we propose several requirements that a new animal model should meet to serve as a tool for 
studies on the cardiorenal syndrome. 
20 
Animal models of cardiorenal interaction 
Introduction 
Recent observations from clinical trials have enhanced the interest in the interaction 
between heart and kidney. Renal dysfunction has been shown an independent risk factor 
for the development of cardiovascular (CV) diseases [ I ,  2] and is associated with worsened 
outcome in patients with hypertension [3], post myocardial infarction (Ml) [ 4, SJ, and a broad 
spectrum of patients with left ventricular dysfunction [6, 7] . Moreover; in chronic renal failure, 
CV morbidities are the main cause of mortality. Conversely, cardiac dysfunction, for instance 
post-Ml ,  leads to a gradual decrease in renal function as reflected by an increase in creatinine 
levels [BJ.This interaction between heart and k idney, where dysfunction of either one of them 
leads to disorder of the other; is usually referred to as the cardiorenal syndrome. It has been 
proposed that mechanisms of this organ crosstalk include various changes in hemodynamics, 
dysregulation of salt and f luid balance, endothelial dysfunction, inflammation, and activation of 
regulatory systems such as the renin-angiotensin-aldosterone system (RAAS), and sympathetic  
nervous system (SNS) [9, I OJ. The described alterations may disturb other factors and lead 
to a vicious circle, resulting in further structural and functional damage in heart and/or kidney. 
Commonly used drugs such as RAAS blockers or beta-blockers may affect not only the targeted 
system, but may also cause, via feedback loops or compensatory mechanisms, an increase in 
other factors involved in the cardiorenal interaction. However; the exact pathophysiological 
mechanisms behind the cardiorenal syndrome still remain unclear: The design of most clinical 
studies on the cardiorenal interaction does not allow drawing conclusions and explanations 
for the heart-kidney interaction. Alternatively, this may be achieved by well-designed animal 
studies. Many animal studies on cardiac or renal dysfunction have been performed and 
described in literature . However; the authors either did not address the function of the 
other organ of interest or the models they used did not mimic the characteristics of the 
clinical cardiorenal syndrome. There are also few animal models described, which combine 
cardiac and renal dysfunction.The objective of this review is to discuss these combined animal 
models used in studies on cardiorenal interaction. To this purpose, we will briefly describe 
the main pathophysiological characteristics of chronic cardiorenal failure and then discuss the 
available animal models. Because an adequate animal model would be instrumental for better 
understanding of this important clinical condition, we also discuss the need for a new model 
and characteristics of a new model, which would help to study the pathophysiology of the 
cardiorenal syndrome. 
Pathophysiology of the cardiorenal interaction 
Cardiorenal interaction is usually defined as a disorder of heart and kidney where dysfunction 
of one of the organs induces disorder of the other: Several pathophysiological mechanisms 
have been proposed to underlie the interaction between heart and kidney in the cardiorenal 
2 1  
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syndrome [9- 1 2] .  Guyton [ I 3] described a model of complex hemodynamic connections 
between heart and kidney. Bongartz et al. [9] proposed a model based on Guyton's model 
and extended it by 4 cardiorenal connectors responsible for the progression of the cardiorenal 
syndrome: the RAAS, the SNS, inflammation, and nitric oxide/reactive oxygen species (ROS) 
balance. Hemodynamic changes are considered the main driving force in the pathophysiology 
of the cardiorenal syndrome. If the failing heart cannot maintain cardiac output, this results in 
reduction in perfusion of peripheral organs [ I I ] , including decrease in renal blood flow (RBF) . 
Decreased renal perfusion has been shown the main determinant of reduced glomerular 
filtration rate (GFR) in heart failure patients [ 1 4]. Recent publications have shown that GFR 
reduction in heart failure patients is  also inversely related to central venous pressure (CVP). 
In the ESCAPE trial, the only hemodynamic parameter associated with renal insufficiency was 
right atrial pressure [ 1 5] ,  suggesting an important role of (renal) congestion. Increased CVP in 
the situation of unchanged systemic arterial pressure leads to decrease in pressure gradient 
across the glomerul i  and subsequent decrease in RBF, but also to increased hydrostatic pressure 
in the kidney and subsequently to hypoxia and/or activation of intrarenal RAAS. It has been 
suggested that the contribution of CVP to kidney dysfunction is independent of cardiac output; 
however; it occurs only when forward fai lure is present [ 1 6]. The relationship between CVP 
and GFR seems to be bidirectional, as impairment in renal function may lead to salt and water 
retention and thus to increased venous pressures [ 1 7] .  
Hemodynamic changes in  heart failure activate multiple regulatory mechanisms, among which 
the RAAS is the most important system .  I nitially aimed to preserve cardiac homeostasis, 
long-term activation of the RAAS eventually leads to the progression of HF [ 1 7] ,  myocardial 
remodeling [ 1 8] ,  and fibrosis and necrosis in the myocardium [ 1 9]. Blocking RAAS reverses 
histological changes in the myocardium, improves endothelial function, and reduces adrenergic 
tone, resulting in improved prognosis. Less is however known about the effects of long-term 
RAAS inhibition on renal function in HF. It may help to preserve GFR to some extent [20]; 
however; long-term RAAS blockade substantially disables regulatory mechanisms of the kidney 
[ 1 4]. Progression of heart failure leads also to compensatory activation of baroreceptors and 
increase in sympathetic activity. This on one hand preserves the cardiac output, but has also 
adverse effects such as sympathetic overdrive, cardiomyocyte apoptosis and necrosis, and 
arrhythmias on the long term. Sympathetic activation has been also suggested to have direct 
vascular effects on renal vasculature, as renal sympathetic denervation may improve GFR [2 1 ] . 
Moreover; the activated SNS interacts with other cardiorenal connectors, such as the RAAS 
[22, 23] and the oxidative stress cascade [9] . 
There is growing evidence that one of the connectors of the cardiorenal syndrome is oxidative 
stress . In heart failure patients, increased oxidative stress has been demonstrated [24] and 
impaired NO-mediated endothelial vasodilatation has been related to reduction in renal 
perfusion [25] . Lower availability of NO and increased production of ROS lead to endothelial 
dysfunction that has been related to reduction in renal perfusion [25], inflammation, and organ 
22 
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damage. Inflammation is considered a risk factor for incidence of Ml and death in uremic 
patients [26] and a marker of severity and progression of heart failure [27-30] . Moreover; 
interaction between oxidative stress, inflammation, and activation of RAAS has been reported 
[3 1 ,  32] .  
Another observed phenomenon o f  the relationship between heart and renal failure is anemia 
[33] . Presence of anemia has been shown to be associated with poor prognosis in heart failure 
[34].The pathogenesis of anemia in heart failure seems to be multifactorial and to some extent 
is a result of decreased renal function [35, 36] .The combination of anemia and renal dysfunction 
in heart failure patients is associated with much worse outcome suggesting interaction between 
those two entities [37, 38] .  Correction of anemia improves cardiac performance in patients 
with chronic kidney disease [39, 40] and both cardiac and renal function in heart failure [4 1 ,  42] . 
The vicious circle of pathophysiological changes in cardiorenal interaction leads to dysfunction 
of one or both organs, accompanied by structural changes in both heart and kidney. Pathological 
cardiac remodeling includes changes in tissue architecture and myocyte/capillary ratio, 
increased fibrosis and apoptosis, and occurs not only in response to cardiac, but also to renal 
stimuli. Presence of albuminuria as a sign of glomerular injury has been shown to be a strong 
predictor of 0/ outcome in the general population [43] and in patients with hypertension 
[44]. However; the pathophysiology of albuminuria and its relation with prognosis is unclear in 
heart failure.There is also evidence that tubular damage is present in HF population [45] and is 
associated with prognosis [46].The pathophysiological mechanisms underlying tubular damage 
in heart failure are still unknown, but possible explanations include regional hypoxia due to 
decreased RBF and diuretic therapy. Pathophysiological connections behind the cardiorenal 
interactions are presented in figure I ,  and the most important clinical characteristics of this 
syndrome are summarized in table I . 
Table I. Pathophysiological characteristics of cardiorenal syndrome 
Char;-acteAStics CfinicaJ manifestation 
Forward failure Decreased cardiac output 
Reduced RBF 
Backward failure Increased Venous Congestion 
Neurohormonal activation Activation of RAAS 
Activation of SNS 
Oxidative stress Lower availability of nitric oxide 
Increased production of ROS 
Inflammation Circulating cytokines 
Endothelial dysfunction 
Anemia Low hemoglobine / hematocit levels 
RBF, renal bloof �ow; RAAS, renin-angiotensin-aldosterone system; SNS, sympathetic nervous system; ROS, 
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Figure I. Pathophysiological connections in the cardiorenal syndrome ( adapted from Bock et al. [ I 2]) 
Animal models for cardiorenal interaction 
Only a few animal models have been proposed so far as a model for further studies on the 
card iorenal syndrome in which both card iac and renal dysfunction have been induced (Table 
2). They are all based on the use of rodents. Advantages of small an imals include lower costs, 
avai labi l ity, and housing conditions. There are multiple ways of inducing card iac dysfunction in 
rodent models.They comprise of volume or pressure overload, myocardial ischemia/infarction, 
administration of toxic agents, and rapid ventricu lar pacing. 
The most commonly used technique of inducing cardiac dysfunction in stud ies on the cardiorenal 
interaction is Ml resulting from l igation of the left coronary artery. Main advantages of this 
model are simplicity, reproducibi l ity, and its relation to human pathophysiology. I n  this model, 
the cardiac output is significantly reduced 3-5 weeks after surgery [47] and the impairment of 
left ventricular function is directly related to the loss of myocardium [48]. Hemodynamic and 
neurohormonal changes in this model resemble those of heart failure observed in humans 
[49] and are also dependent on the extent of cardiac damage [50-52] . The use of the Ml 
model has been essential in establ ishing the beneficial effects of RAAS blockade [5 3, 54], which 
were later confirmed in cl in ical trials, underscoring the agreement between this model and 
human heart fai lure with respect to the pathophysiology and treatment possibi l ities. 
The most commonly used techn iques of inducing renal fai lure are based on the reduction 
of viable kidney tissue in different ways. The main d ifference between them is the extent of 
the removal and thus the degree of renal dysfunction they cause. Uni lateral nephrectomy 
(U NX) leads to mi ld renal function impairment without a substantial increase in proteinuria 
or histological changes [55], whereas subnephrectomy (SNX) leads to more severe renal 
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Table 2. Rodent models of combined cardiorenal failure 
Moiel Reference CarGtiac changes Renal changes 
UNX+MI Van Dokkum [55] Increased SBP I ncreased plasma creatin ine 
Decreased dP/dt max and Increased proteinuria 
dP/dt min FGS 
LVH 
SNX+MI Windt [57] Increased SBP Decreased creatinine 
Decreased dP/dt max and clearance 
dP/dt min Decreased renal blood flow 
LVH Increased proteinuria 
Decreased capillary density FGS 
Fibrosis 
Dikow [62] Increased SBP Increased serum urea 
Higher susceptibil ity to Increased serum creatinine 
myocardial ischemia 
Dikow [56] Increased SBP I ncreased serum urea 




Decreased capillary density 
SNX+L-NNA Bongartz [ 66] Increased blood pressure I ncreased plasma creatinine 
Decreased EF I ncreased plasma urea 
Increased LVEDV Decreased creatinine 
LVH clearance 
Fibrosis Increased proteinuria 
FGS 
Tubule-interstitial injury 
Adriamycin Noiri [70] LVH Increased plasma creatin ine 





UNX, uninephreetomy; SNX, subnephreetomy; Ml, myocardial infarction; L-NNA, Nw-nitro-L-arginine, SBP, 
systolic blood pressure; LVH, left. ventricle hypertrophy; EF, ejection fraction; LVEDD, left. ventricle end-diastolic 
diameter; LVEDV, left. ventricle end-diastolic volume; FGS, focal glomerulosclerosis; 
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dysfunction and eventually to uremia and chronic kidney disease complications similar 
as in humans [56, 57]. Changes in cardiac tissue architecture have also been reported in 
subnephrectomized animals [58-60]. 
Van Dokkum et al. [55] have described a model of U NX followed by Ml I week later. They 
have shown an accelerated renal dysfunction in uninephrectomized rats when combined with 
cardiac dysfunction.This has been evidenced by increased levels of proteinuria. Also more renal 
damage, as measured by focal glomerulosclerosis, has been reported in  animals with combined 
cardiac and renal dysfunction. Creatinine levels were increased, as expected, after nephrectomy; 
however; addition of Ml did not lead to further i ncrease. I nterestingly, the decrease in renal 
function was more pronounced in animals with large infarcts.This might be due to the severity 
of cardiac dysfunction and its effect on renal hemodynamics. It has been shown that in rats 
after Ml, the severity of ventricular dysfunction and subsequent hemodynamic changes depend 
on infarct size [ 48, 6 1 ]  as well as time between intervention and measurements [ 47, 52]. 
Decrease in cardiac function due to small and moderate infarcts, results in either small or 
no decrease in RBF [50-52] .When RBF is minimally decreased, the animal upkeeps its GFR by 
a compensatory increase in renal vascular resistance, like in humans [5 1 ]. More severe cardiac 
dysfunction as a result of large infarction leads to a larger fall in RBF and a subsequent decrease 
in GFR despite further increase in venous resistance [5 I ,  52]. However; the data on RBF in this 
model are missing, and the only indication of more severe cardiac dysfunction in the group with 
larger Ml was more advanced hypertrophy of the heart. No differences in brain natriuretic 
peptide (BNP) levels, LV pressures nor contractility or relaxation between groups have been 
reported.The blood pressure was higher in the animals with combined damage in comparison 
with other experimental groups.This suggests that the compensated stage of heart failure was 
not present in this model.The more pronounced progression of cardiac dysfunction due to the 
concomitant renal dysfunction has also not been observed. However; it must be remembered 
that the renal damage in this model was only mild, and there was a short period of time 
between induction of renal and cardiac damage. This might have resulted in limited effects of 
renal dysfunction on heart tissue and its function. 
The same group studied cardiorenal interaction in a combined model with a more severe renal 
dysfunction, introduced by means ofSNX and 2 weeks later fol lowed by coronary ligation [57]. 
In this model, the SNX induced proteinuria, decreased the creatinine clearance and increased 
histological changes, such as focal glomerulosclerosis, fibrosis, and mesangial matrix expansion. 
Introduction of the cardiac dysfunction on top of existing renal dysfunction did not influence 
the levels of proteinuria nor the histological changes, but led to decrease in creatinine clearance 
and RBF.With regard to cardiac function, combination of renal and cardiac function did not yield 
additional effects, different from the effects of SNX or Ml alone. Animals with combined organ 
damage had high blood pressure, similar to the animals with renal damage alone, and decreased 
contractility and relaxation comparable with the animals that underwent coronary ligation only. 
Also, decrease in capillary density was the same as in the Ml  alone group, showing no effect of 
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preexisting renal dysfunction on myocardium.This is somewhat in contrast to literature findings 
that showed histological changes in the myocardium of the subnephrectomized animals [58, 
59] .  However; again short period of time for the development of renal dysfunction and lack 
of signs of severe cardiac failure have to be considered. This model has also been used in 
studies on the effects of RAAS inhibition on the cardiorenal interaction. It has been shown 
that treatment with lisinopril for 6 weeks prevented further histological changes in the kidney 
tissue or even reversed some of them. Moreover; it restored the decreased RBF and creatinine 
clearance levels. It also increased capillary density and reversed the cardiac hypertrophy, 
proving the beneficial effects of this treatment and usefulness of this model in studies on 
RAAS activation in the cardiorenal syndrome. A combined model of Ml and SNX has been 
used by Dikow et al. [62] to study cardiac histological changes as an underlying mechanism of 
progression of cardiac disease in cardiorenal interaction. In this study with transient coronary 
ligation followed by reperfusion, it has been shown that myocardium of the rats with renal 
dysfunction is more susceptible to ischemia injury, which may explain the higher death rate 
after Ml in renal patients.Whereas the total unperfused area was not different between animals 
with and without renal dysfunction, which would be unlikely as it reflects the anatomy of the 
coronary vasculature in the rat, the infarcted area was significantly higher in uremic animals. 
This effect was also present in animals treated with antihypertensive treatment and low- and 
highsalt diet, which excludes the underlying confounding effects of hypertension, sympathetic 
overactivity, and salt retention. The same group analyzed also the myocardial remodeling 
in a model of more permanent Ml [56] . They have shown more advanced left ventricular 
remodeling in a model with cardiorenal failure as documented by left ventricular hypertrophy, 
decreased capillary density and increased fibrosis. Moreover; these changes were accompanied 
by decrease in cardiac function as assessed by echocardiography. Interestingly, the presence of 
anemia has also been reported in the animals with combined organ damage.This could be of 
special interest, since anemia is being considered one of the cardiorenal connectors [33, 63] 
and beneficial effects of treatment for anemia have been shown in experimental studies. In M l  
heart failure model, erythropoietin has been shown to improve cardiac function and induce 
neovascularization [64]. On the other hand, in subnephrectomized rats, anemia seemed to 
have protective effect on kidney structure [65]; however; this effect has not been investigated 
in a model with concomitant heart failure.Therefore, this model could also help to understand 
the role of anemia in the cardiorenal syndrome. 
Bongartz et al. [66] have recently developed a new animal model of combined cardiorenal 
failure.This model is based on the hypothesis that oxidative stress and the dysbalance between 
nitric oxide (NO) and ROS are one of the cardiorenal connectors [9,63]. The inhibition of 
NO synthase in rats has already been shown to cause hypertension, cardiac dysfunction, and 
glomerular damage [67, 68]. In the Ml model, oxidative stress has been proven to decrease 
endothelial-dependent relaxation [50], whereas antioxidant therapy prevents cardiac structure 
alterations [69] . In the described model, renal dysfunction has been induced by means of SNX, 
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_whereas cardiac dysfunction was a result of N OS inhibition wrth N x-nitro-L-arginine (L-N NA). 
The combination of the above led to severe cardiac dysfunction with increased blood pressure, 
enddiastolic volume, and decreased ejection fraction. Signs of congestion, increased cardiac 
fibrosis, and myocyte hypertrophy accompanied the functional changes. With regard to the 
kidney function, the combination of SNX and L-NNA resulted in increased plasma urea and 
creatinine levels and proteinuria. However; only the latter was significantly higher than in animals 
with SNX alone. On the histological level, combined cardiorenal damage was characterized 
by increased FGS and tubulointerstitial injury. Interestingly, the above changes had permanent 
character and were not reversed even when treatment with L-NNA was stopped.This model 
proves the importance of oxidative stress in cardiorenal interaction and might serve as a 
promising tool for further investigation of cardiorenal connectors. 
An alternative model, which does not require surgical intervention, is the model of adriamycin­
induced renal damage. It has been shown that administration of adriamycin leads not only 
to deterioration of kidney function, but heart function is also affected [70]. Both cardiac and 
renal dysfunction resulting from adriamycin administration are characterized by many features 
observed in humans with cardiorenal failure-both on functional as well as on the histological 
level [7 1 -73]. However. the dose required to induce the cardiac cardiomyopathy is much higher 
than the one resulting in severe kidney dysfunction.Therefore, the possibi lities for investigation 
of dysfunction of both organs at the same time are limited. Moreover; it is important to mention 
that many of those changes are rather the effect of the toxicity of adriamycin than involvement 
of known cardiorenal connectors. 
Discussion and future perspectives 
In this review, we summarized the available data on animal models used in the studies on 
cardiorenal interaction. The choice of a proper model is crucial, because results obtained 
in experimental studies may contribute to better understanding of this important clinical 
syndrome and help in establishing new treatment strategies. At this moment, this translation is 
limrted, because none of the models described above entirely reproduce the pathophysiology 
and characteristics of the cardiorenal syndrome observed in humans.Therefore, there is a need 
for better models of cardiorenal interaction that not only should mimic clinical characteristics 
of this syndrome by cardiac, renal, hemodynamic, and neurohumoral alterations, but also allow 
evaluation of the effectiveness of treatment. Such a model should consist of combined renal 
and cardiac injury characterized by progressive deterioration of function of both organs. Wrth 
regard to the cardiac function, it should be characterized by systolic dysfunction confirmed by 
echocardiography or hemodynamic measurements, resulting in decrease in cardiac output and 
subsequent reduction in RBF. Also, increased end-diastol ic pressure and venous congestion 
should be present in order to further investigate latest findings from clinical observations. On 
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the histological level, cardiac i njury should be characterized by hypertrophy and fi brosis and 
preferably with card iomyocyte/ capi l lary mismatch. With regard to renal injury, such a model 
should be characterized by a progressive decrease in  renal function reflected in increased levels 
of creatin ine and proteinuria or increased albumin excretion and decreased GFR/creatin ine 
clearance. The presence of glomerulosclerosis and interstitial fibrosis should be documented. 
Important in developing a new model is to reduce the function of both organs to such a 
degree that leads to development of s ignificant dysfunction as wel l  as to provide enough time 
for its development. Both organ fai lures should also preferably develop gradual ly to al low 
studies on treatment for advanced stages as well as more preventive treatment strategies.This 
can help in  drawing conclusions and give more i nsight into pathophysiology behind cardiorenal 
interaction on d ifferent stages of its development. 
There are multiple ways of inducing cardiac [74, 75] and renal dysfunction [76] i n  rodents, 
which can be combined for the development of a new model of cardiorenal i nteraction. 
They al l have their advantages and drawbacks, and none of them presents all the above­
mentioned features of the ideal model. Most of the models require surgery intervention or 
administration of exogenous substances, which already reduces their simi larity to the c l in ical 
situation. Furthermore, the surgical interventions, such as Ml or reduction in  kidney tissue, are 
performed on healthy organs i n  a situation where the regulatory mechanisms are not being 
activated. In  humans, on the other hand, the fai lure is usually preceded by gradual loss of the 
function of chronically affected organs. The acute onset of the organ failure substrate is one 
of the common drawbacks that l imit the cl in ical relevance of many popular models ,  such as 
transverse aortic constriction.An important issue in the use of animal models is also the severity 
of the induced organ failure. Moderate interventions result either i n  the development of mi ld 
organ dysfunction or the organ fai lure wi l l  develop only in a subset of the animals [48, 55 ,  75]. 
A more severe approach leads to the development of overt organ failure [48, 77], but results 
in high mortal ity rates [78] and more acute onset of the heart fai lure substrate.This l im its the 
cl in ical relevance of such models.The usefulness of the models based on surgical interventions 
is also l imited by the fact that they lead to significant reduction in  remain ing tissue mass, l ike i n  
the SNX model or  the Ml  model.This reduces the potential target and the effects of treatment, 
as well as possibi l ities for molecular analysis. Important to remember is also that the d ifferences 
in response to surgical i nterventions have been reported between d ifferent genders [79] or 
animal strains [80, 8 1 ] . Above-described drawbacks of avai lable animal models might question 
the possib i l ity of designing one perfect animal model of the card iorenal syndrome. However; 
it should be remembered that heart and renal failure are heterogeneous d isorders that resu lt 
from multiple underlying d iseases and involve various regu latory mechanisms. Due to the 
complexity of the pathophysiology of heart and/or renal fai lure alone and in combination, its 
proper understanding might as wel l  require the use of more than one animal model and the 
choice must be made depending on the research question. The heterogeneous character and 
origin of cardiorenal fai lure require also that al l potential new models as wel l  as the models 
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already known, including those described in th is review, should be studied in more detai l .  
Not only well-establ ished cardiorenal connectors, but also new findings in the cardiorenal 
interaction, such as increased venous congestion, anemia, and tubular damage need further 
investigation and should be addressed in these models. Only then, the usefulness of these 
models in studies on the card iorenal syndrome can be evaluated. 
Interesting alternative for the models described above might be the use of genetic models of 
card iac and renal dysfunction. One of the biggest advantages of such models is that they do not 
require surgery or pharmacological intervention for induction of the disease.The onset of the 
stimulus for organ failure is more gradual , which al lows studies on progression of the disease 
and prevention therapy. Wel l-studied genetic models of heart fai lure are the spontaneously 
hypertensive rat (SHR) [82] and the Dah l  salt-sensitive rat [83]. However, both strains require 
long time before they develop overt heart fai lure, which is their main drawback.The Munich 
Wistar Fromter (MWF) rats present many of the cl inical characteristics of renal dysfunction 
[84]. However; again an extended period of time is required for the development of the 
renal fai lure. Moreover, some gender differences have been reported [85]. The genome of 
rodents has recently been wel l  characterized, which provides new opportunities in  finding a 
new better model for cardiorenal interaction.The abi l ity of genetic manipu lation offers multiple 
possib i l ities for establ ishing new valuable models. Knocking out or overexpression of specific 
genes or proteins as wel l  as transgenesis may lead to the development of new models of 
organ failure [86-89] .This approach gives a good insight into role of a given gene or protein 
in the pathophysiology of the d isease. Knock-out models can help also in understand ing the 
pathophysiology of the d iseases preced ing the onset of organ fai lure, such as atherosclerosis 
[90]. However.the genetic manipulation does not allow control over the time of the occurrence 
or the level of intervention. Change in the expression of specific proteins may also influence 
the ir  biological properties and function [9 1 ]  as wel l  as activate the compensatory mechanisms 
at very early stages. 
Conclusion 
There are only few animal models proposed for further stud ies on the cardiorenal syndrome. 
They al l represent to some extent cl in ical characteristics of this syndrome and were used in 
experimental studies to better understand the pathophysiological connections between kidney 
and the heart. However; the heterogeneous character of heart and renal fai lure in humans 
l imits the possib i l ities of complete reproduction of this syndrome in an animal model. Moreover, 
the induction of the organs fai lure in animals has usual ly an acute character, whereas heart 
and/or kidney dysfunction in humans usual ly develop over years. The recent developments in 
molecular techniques provide promising possib i l ities of developing a new animal model , which 
could be used as a tool for better understand ing of the pathophysiology and treatment targets 
in the cardiorenal syndrome. 
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Background. Chronic renal dysfunction severely i ncreases cardiovascular risk. Adverse cardiac 
remodelling is suggested to play a major role as predisposition for increased cardiac ischemic 
vulnerability. Aim of the present study is to examine cardiac sensitivity to acute ischemia/ 
reperfusion damage in a rat model for renal dysfunction and to evaluate the role of adverse 
cardiac remodelling in this process. 
Methods. Munich Wistar Fromter rats (MWF), developing spontaneous progressive renal 
dysfunction and mild hypertension, were compared to healthy Wistar control, and to non­
proteinuric spontaneously hypertensive rats (SHR). In 1 2  weeks old MWF, renal dysfunction 
and mild hypertension were confirmed. Hearts were analyzed for adverse remodeling, 
including myocyte hypertrophy, capillary density and interstitial fibrosis, by histology. Sensitivity 
to cardiac ischemia/reperfusion damage was obtained from infarct size measured after 30 
minutes coronary artery occlusion, followed by 24 h of reperfusion. 
Results. Infarct size was higher in SH R (52±4%; p=0. 1 6) and in MWF (56±3%; p=0.04) , when 
compared to Wistar (45±4% of risk area) . However, whereas SHR showed pronounced 
adverse cardiac remodelling, MWF displayed 29% (NS) larger left ventricular myocytes (vs 72% 
in SHR) ,  without decreased capillary density (MWF + 34%; SH R - 1 3%) or interstitial fibrosis 
(MWF - 1 6%; SH R + 70%). 
Conclusion. Data indicate that chronic renal dysfunction in MWF induces increased cardiac 
sensitivity to acute ischemia/reperfusion damage, as reflected by h igher infarct sizes. Comparing 
results to SHR suggests that this increased susceptibility could not be attributed to hypertension 
or adverse cardiac remodeling. 
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Introduction 
Impaired renal function is an important risk factor for cardiovascular disease [ 1 -5] and its 
presence and severity is associated with worse outcome. In addition to factors associated with 
the kidney and circulation, including reduced renal perfusion, peripheral endothelial dysfunction, 
neurohumoral activation and hypertension [6-8], also cardiac factors could contribute to a 
reduced cardiac ischemic tolerance in renal dysfunction [9].These factors mainly include aspects 
of adverse cardiac remodeling: myocyte hypertrophy. cardiac capillary/myocyte mismatch 
[ I 0, I I J and loss of myocytes [ I ], as extensively reviewed by Tyralla and Amann [ 1 2], but also 
coronary endothelial dysfunction [ I 3] and metabolic changes [ 1 4, 1 5] may play a role . Data 
from animal models is scarce. Dikow and coworkers reported that rats, that are uremic due 
to acute subtotal nephrectomy, showed increased sensitivity to cardiac ischemia/reperfusion, 
which could not be attributed to hypertension, sympathetic overactivity or salt retention [9]. In 
the same model increased cardiac ischemic susceptibility was associated with abnormal cardiac 
energetics [ 1 4] ,  while infusion of insulin and glucose could protect the heart from ischemia/ 
reperfusion damage [ 1 5] .  
Since renal dysfunction in patients usually progresses slowly over time and even mild renal 
dysfunction is already associated with increased cardiovascular mortality and morbidity [ 1 6, 1 7] .  
Munich Wistar Fromter rats (MWF) that spontaneously and slowly develop proteinuria with 
concomitantly focal glomerulosclerosis and mild hypertension with age [ 1 8], may mimic the 
clinical condition. Although literature extensively describes the renal abnormalities in this 
model [ 1 9], cardiovascular effects have hardly been investigated. We have previously shown 
accelerated cardiac but not renal dysfunction after chronic myocardial infarction [20]. Moreover; 
we have observed the endothelial dysfunction present in coronary- but not in mesenteric 
arteries [ 1 3] ,  which was not observed in hypertensive non-proteinuric SHR rats, indicating a 
hypertension-independent effect. 
Aim of the present study was to investigate cardiac sensitivity to acute ischemia/reperfusion 
damage in MWF rats in comparison to healthy Wistars and hypertensive SHR Since adverse 
cardiac remodeling is suggested to present a predisposition for increased cardiac risk, its role 
in acute ischemia reperfusion damage was evaluated.The study reports on increases in infarct 
size, as measure of ischemic damage in rats with renal dysfunction, but without preexisting 
adverse cardiac remodeling. 
Material and Methods 
Animals 
The study was performed in male rats from 3 different strains: Wistar (HsdCpb:WU) obtained 
from Harlan The Netherlands and Munich Wistar Fromter (MWF/ZtmHsd) and Spontaneously 
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Hypertensive Rats (SHR/NHsd) both obtained from Harlan USA. Animals were housed in 
groups under standard conditions at 12 h light/dark cycle until they reached 12 weeks of age at 
the animal facilities of the University of Groningen.AII animals were fed standard diet (standard 
rat chow, Hope Farms, Woerden, The Netherlands) and received food and water ad libitum 
during the study. All experiments were conducted in accordance with the NIH Guide for 
the Care and Use of Laboratory Animals and were approved by the Committee for Animal 
Experiments of the University of Groningen. 
Experimental protocol 
All rats were placed in metabolic cages in order to measure water and food intake and 2 4 -
hour urine collection. Subsequently, under isoflurane in 0 2  anesthesia, blood samples were 
withdrawn from the tai l  vein and plasma was processed. Plasma and urine samples were stored 
at -80 °C for later analysis. Rats were left one week to recover from this procedure. 
Subgroups of 5 -6 rats of each strain were used as a control and sacrificed to obtain baseline 
measurements of cardiac hemodynamics and to collect cardiac tissue for analysis of adverse 
cardiac remodeling as predisposition for cardiac vulnerability. The remaining rats (N=2 0 per 
strain) were subjected to 3 0-minute coronary artery occlusion (CAO) followed by 2 4  h of 
reperfusion [2 1,2 2] .This time point was chosen, because it is long enough to exclude effects on 
velocity of infarct development [2 2],  but too short to exert effects on cardiac remodeling.The 
latter being important as we aimed to investigate adverse cardiac remodeling as predisposition 
for, rather than as consequence of, altered sensitivity to acute ischemic damage. Blood samples 
were collected from the abdominal vena cava and plasma was processed and stored for later 
analysis.The heart was dissected for measurement of area at risk and infarct size.The method 
for accurate measurement of infarct size does not allow cardiac tissue to be used for histology 
and/or molecular analysis. Renal tissues were collected, weighted and processed for further 
analysis. 
Urine measurements 
Total urinary protein level was determined using endpoint measurement with TCA 
precipitation (Nephelometer analyzer 11, Dade Behring, Marburg, Germany). Urine creatinine 
was determined using a standard kit (Roche Diagnostics, Basel, Switzerland). In addition to 
urinary protein excretion as a representation of renal function, creatinine clearance, as an 
estimate for glomerular filtration rate, was calculated from urinary and plasma creatinine levels. 
creatinine clearance = (urine creatinine x urine flow) / (plasma creatinine x body weight) and 
presented as mUmin/kg body weight. 
Blood measurements 
Measurements of plasma creatinine, electrolytes levels and hematocrit were performed 
using iSTAT handheld analyzer (ABBOTT) and appropriate cartridges (Creatinine; EG7+). 
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Catecholamines measurements were performed in plasma with glutathione added as a 
preservative as described before [23], brain natriuretic peptide (BNP) was measured with 
BNP-45 EIA kit (Phoenix Pharmaceuticals, Inc) (with protease inhibitor aprotinin added [24]) 
and Plasma Renin Activity (PRA) was determined by Gammacoat RIA kit (Diasorin, Minnesota, 
USA) and expressed as ngAngl/ml/h [25]. 
Cardiac and renal hemodynamic measurements 
Control rats were anesthetized in 2,5% isoflurane and cardiac performance was measured by 
a pressure catheter (Micro-Tip 3 French, Millar Instruments Inc. , Houston.TX) inserted through 
the right carotid artery and advanced into the left ventricle. After a period of stabilization, left 
ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP) and heart 
rate (HR) were recorded.The maximal rates of increase and decrease in left ventricular pressure 
(+dP/dtmax and -dP/dtmax) were measured as parameters of myocardial contractility and 
relaxation, respectively. 
Then, the catheter was withdrawn into the aortic root and arterial blood pressure was 
measured. Subsequently. the catheter was inserted in the jugular vene and advanced to just 
above the heart. After stabilization, central venous pressure (CVP) was measured. 
lschemia/reperfusion 
Under 2.5 % isoflurane anesthesia rats were subjected to experimental 30-minute coronary 
artery occlusion as described before [26]. Briefly, after left side intercostal thoracotomy, the 
pericardium was opened and the left descending coronary artery was occluded with a 6-0 silk 
suture, 1 -2 millimeters from its origin. After 30 minutes the suture was opened for reperfusion 
and subsequently the thorax was closed. Animals were allowed to recover. Occlusion and 
reperfusion were visually verified by appearance and disappearance of myocardial cyanosis. 
As body temperature affects sensitivity to ischemia/reperfusion [27], rectal temperature was 
continuously measured with an electronic thermometer and was maintained in the range 3 6.5 
- 37.5 C by either heating pad or cold-water filled packages. The adequacy of this procedure 
was verified before [26]. Rats that fibrillated during ischemia or reperfusion were allowed to 
complete the protocol if conversion to sinus rhythm occurred spontaneously or resuscitation 
by gently thumping on heart or thorax was successful within 5 minutes after onset of arrhythmia. 
Animals were allowed to recover and 24 hours later the rats were re-anesthetized to collect 
hearts for measurement of infarct size. 
Organ Isolation 
Hearts were rapidly excised and placed in ice-cold saline for diastolic arrest. Hearts of ischemia/ 
reperfusion rats were processed for evaluation of ischemic damage. From the hearts of rats 
that were sacrificed before ischemia/reperfusion to obtain baseline measurements, a mid­
ventricular slice has been processed for histochemical analysis. 
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Both kidneys were excised, weighted and fixated in 2% paraformaldehyde.The fixated tissues 
were then processed for paraffin embedding according to standard procedures. Lungs were 
excised and weighted. 
Measurement of area at risk and infarcted area 
Measurements of area at risk and infarcted area were performed as described before in details 
[22]. Briefly, the cooled heart was mounted to a modified Langendorff apparatus and perfused 
with ice-cold saline to wash out blood. After closing the l igature, heart was perfused with 
Trypan Blue to delineate normally perfused myocardium from the non-perfused area at risk 
(AR) .The heart was then frozen in  -80°C for I O  minutes and cut into slices of approximately 
I mm from apex to base. Each slice was d ivided i nto right ventricle, normally perfused left 
ventricle and AR.The AR was subsequently incubated in Nitro-Blue-Tetrazol ium to dist inguish 
between irreversible damaged (unstained) and stained viable tissue. Unstained infarcted tissue 
was then isolated and all d ifferent areas of LV were dried and weighted separately. Infarct size 
was expressed as a percentage of total LV as well as percentage of AR. 
Histology 
Hearts of the rats that were sacrificed before ischemia/reperfusion were processed for 
histological analysis. For that, at mid-ventricular level, a transversely cut sl ice was fixated in  
3.6% phosphate buffered formaldehyde for at least 24 h,  slices were dehydrated and paraffin 
embedded. Deparaffin ized 5 µm sections were either stained with Gomori's si lver stain ing in  
order to visualize ind ividual myocytes or with Lectin GSI  to visualize capillaries or with Sirius 
Red to visualize interstitial collagen. Methods as well as the measurements of myocyte size, 
capillary density and interstitial fibrosis have been described before [28]. Brief ly, as concentric 
rather than eccentric left ventricular hypertrophy is associated with sensitivity to ischemia [29], 
myocyte size was measured as cross-sectional area of transversally cut myocytes at the level 
of the nucleus, in the free wal l  of the left ventricle . In the same area, the number of capillary 
profiles were counted and expressed per tissue area. Interstitial fibrosis was obtained as the 
volume fraction of the Sirius Red positive area. 
Kidneys were stained with PAS staining and scored on presence and degree of focal 
glomerulosclerosis (FGS) as described before [30].  Briefly, the degree of mesengial matrix 
expansion (MM E) and FGS were assessed in 50 glomeruli by scoring semi quantitatively from 
0 to 4, referring to number of quadrants affected. FGS was scored positive when M M E  and 
adhesion to Bowman's capsule were present in the same quadrant. FGS score was expressed 
in arbitrary units (AU) .  
Statistical analysis 
Data are presented as mean ± standard error of the mean (S.E.M .). Parameters were 
compared using one-way analysis of variances (ANOVA) with Dunnett's test (against Wistar 
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group as control) for post-hoc analysis for multiple comparisons. In case data was not normally 
distributed, a non-parametric Kruskal-Wal lis test followed by a Mann-Whitney U test with 
correction for multiple comparisons was used. Differences were considered significant at the 
level of 0.05. 
Results 
Primary renal dysfunction 
General characteristics of the experimental groups are presented in table I . At the same age, 
MWF as well as SHR had significantly lower body weights than Wistar, which could not be 
attributed to lower food- or water intake. Plasma electrolytes levels were not different among 
the groups. MWF, but not SHR. had a significantly lower plasma hematocrit. Renal dysfunction 
in MWF was confirmed by significantly increased urinary protein excretion. However, neither 
absolute plasma creatinine levels nor creatinine clearance were different between MWF and 
Wistar (table I ) . 
Renal histology was analyzed in order to confirm that observed renal functional changes had 
Table I .  Baseline characteristics of ischemia/reperfusion animals .. Data are presented as mean ±SEM. 
SHR: Spontaneously Hypertensive Rats; MWF: Munich Wistar Fromter rats; * p<0,05 vs Wistar 
Wistar SHR MWF 
N 1 7  1 9  1 9  
Body weight (g) 394±8 300±5* 274±7* 
Food intake (g/24h) 1 1 ± 1  7± 1 1 3± 1  
Water intake (ml/24h) 2 1 ±2 1 9± 1  23± 1 
Urine production (ml/24h) 1 4± 1  1 1 ± 1  1 2± 1  
Plasma Na (mmol/L) 1 37± 1 1 37± 1 1 36± 1 
Plasma K (mmol/L) 4.6±0. 1 4.3±0. 1 4.8±0.2 
Plasma Ca (mmol/L) 1 . 1 9±0.06 1 .07±0.07 1 .07±0.06 
Hematocrite (%) 43±0 44±0 40± 1 *  
Urinary protein excretion (mg/24h) 3 1 ±2 32± 1 80± 1 3* 
Plasma creatinine (mmol/L) 32±2 27± 1 *  3 1 ± 1  
Urinary creatinine (mmol/L) 1 1 .6± 1 . 1  8.5±0.7 9.3±0.6 















Wistar SHR MWF 
Figure I. Representative photographs of glomeruli in Wistar, SHR and MWF rats as well as results of scoring 
focal g/omerular sclerosis (FGS). SHR: Spontaneously Hypertensive Rats; MWF: Munich Wistar Fromter rats. 
* p<0.05 vs Wistar 
lead to, or resulted from, a structural substrate. Figure I shows representative photographs of 
glomerular changes in the different rat strains, as well as the results of the quantification of these 
changes; MWF, but not SHR, displayed significantly higher scores of focal glomerulosclerosis 
(FGS). FGS was significantly correlated with urinary protein excretion in MWF (r2=0.374; 
p<0.0 I )  but not in SHR or Wistar: There was no correlation between FGS and creatinine 
clearance in any of the groups. 
Cardiac predispositions 
Hemodynamics 
Baseline measurements revealed mild hypertension in MWF and pronounced hypertension 
in SHR, without differences in heart rate or central venous pressure (CVP) (table 2). Cardiac 
function parameters are presented in figure 2, showing significantly increased LVSP in MWF 
and SHR, but with substantially higher values in SHR, without effects on LVEDP, +dP/dt or -dP/ 
dt. Heart weight was significantly increased in both MWF and SHR; lung weight only in MWF. 
Kidney weight was highly preserved in the rat strains (table 3) . 
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Table 2. Baseline characteristics of control animals. Data are presented as mean ±SEM. MAP: mean arterial 
pressure; HR: heart rate; CVP: central venous pressure; SHR: Spontaneously Hypertensive Rats; MWF: Munich 
Wistar Fromter rats; ·:If p<0.05 vs Wistar; 
Wistar SHR I MWF 
N 5 6 5 
MAP (mmHg) 89±4 1 36±6* 1 02±3* 
HR (beats/min) 364± 1 3  354± 1 7  359± 1 8  
CVP (mmHg) 1 .2± 1 .8 - 1 .7± 1 .7 2. 1 ± 1 .7 
Heart weight/body weight (g/kg) 3.2±0.2 4.5±0.1 * 4.5±0.5* 
Lung weight/body weight (g/kg) 3.3±0.1 3.7±0. 1 4.8±0. 1 *  
Table 3. Organ characteristics at termination; Data are presented as mean±SEM; BW; body weight; LV left 
ventricle; RV right ventricle SHR: Spontaneously Hypertensive Rats; MWF: Munich Wistar Fromter rats. 
·:If p<0.05 vs Wistar; 
I Wtstar SHR I MWf 
i 
N 1 7  1 9  1 9  
Ventricular weight/body weight (g/kg) 2.5±0. 1 3.7±0. 1 *  3.0±0.1 * 
LV weight/body weight (g/kg) 2.2±0. 1 3.2±0.1 * 2.6±0. 1 *  
RV weight/body weight (g/kg) 0.49±0.02 0.7 1 ±0.04* 0.57±0.02* 
Lung weight/body weight (g/kg) 4.5±0.1 5.0±0. 1 *  4.8±0.1 
Left kidney weight/body weight (g/kg) 3.6±0. 1 3.5±0.1 3.6±0.1 
Cardiac remodeling 
Adverse cardiac remodeling as predisposition for increased sensitivity to ischemia was analyzed 
in control rats. Representative photographs of histological sections stained for myocytes, 
capillaries and interstitial collagen are shown in figure 3A. In general, tissue density was not 
different among the strains, ranging from 9 I to 94 %. Myocyte hypertrophy was indicated by 
a mild and non-significant increase in cross-sectional area of myocytes in MWF (NS) , but a 
significant increase in S H R  (p<0.05) . Staining of tissue area in MWF compared to Wistar, 
resulting in significantly higher capillary/myocyte ratios in MWF than in Wistar ( 1 .92±0.28 vs 
I . 1 4±0. 1 9; p=0.05) .Volume percentage of collagen was similar in MWF and Wistar. In contrast, 
SHR did show increased interstitial fibrosis. Quantification of these observations is summarized 
in figure 3B .  
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Figure 2. Cardiac function in control rat.s; presented by left ventricular systolic pressure (LVSP), left ventricular 
enddiastolic pressure (LVEDP), velocity of contraction (+dP/dtmax), velocity of relaxation (-dP/dtmax) for the 3 
groups. SHR: Spontaneously Hypertensive Rat.s; MWF: Munich Wistar Fromter rats::i, p<0.05 vs Wistar; 
substantially lower body weight) survived the ischemia/reperfusion protocol; 1 7  of Wistar, 1 9  
of MWF and 1 9  of SHR. Death usually occurred within the first hour after ischemia. 
Occlusion of the left descending coronary artery resulted in a risk area of about 45% of the 
left ventricle. On average, risk area was significantly higher in both MWF (47±2%) and SHR 
(49±3%) compared to Wistar (39±3%). Infarct size, expressed as a percentage of total left 
ventricle (LV) was significantly increased in MWF (28±2%) and SHR (26±2%) in comparison 
to Wistar ( I 7±2%) (figure 4A). S ince infarct size has been found linearly related to risk area 
[2 1 ], infarct size expressed as percentage of the individual capillaries revealed even higher 
number of capillaries per risk area, was used to present sensitivity to ischemia/reperfusion. 
A significantly higher infarct to risk area in comparison to Wistars (45±4%) was found in MWF 
(56±3%; p<0.04), whereas only a trend was observed in SHR (52±4%, p=0. 1 6) (figure 4B). 
There was no significant correlation found between any of the renal parameters and infarct 
size. 
At termination, increased ventricular weight corrected for body weight was present in both 
MWF en SH R, and both the left and the right ventric le had contributed to this increased 
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Figure 3.A: Representative photographs ofGomori staining to show individual myocytes (top); Lectin staining to 
visualize capillaries (mid) and Sirius Red staining to identify cardiac fibrosis (bottom) in MWF, SHR and Wistar. 
B: Accordingly, quantification of the observations in the 3 strains. SHR: Spontaneously Hypertensive Rats; MWF: 
Munich Wistar Fromter rats. * p<0.05 vs Wistar; 
A B 
40 
70 * * * � 
GI 'o" 60 
30 ;i 
C I! 50 GI .II: > ·! 
-:; 40 s 20 c,s 









Wistar SHR MWF Wlstar SHR MWF 
Figure 4. Infarct size presented as A: percentage of total LV and B: percentage of area at risk in Wistar; SHR 
and MWF rats. SHR: Spontaneously Hypertensive Rats; MWF: Munich Wistar Fromter rats. *: significantly 
different from Wistar (p<0.05) 
weight in both strains (table 3). Similar dry weight/wet weight ratio in all groups (0.2 1 -0.22) 





At baseline, no differences in catecholamines and PRA levels were found between groups, 
whereas BNP levels were lower in MWF in comparison to other strains (table 4) . After 
ischemia/reperfusion, PRA was significantly lower in MWF than in Wistar rats. PRA after 
ischemia/reperfusion in MWF was significantly correlated with infarct size (r2=0.3 I 5; p=0.03), 
but not with renal function parameters. Regarding PRA, SHR did not differ from Wistar, nor 
could a correlation with infarct size be demonstrated. 
Noradrenaline and adrenaline levels after ischemia/reperfusion were similarly increased in all 
strains in comparison to respective baseline values, with the highest values of noradrenaline 
in SHR. Circulating dopamine levels were not different at baseline between groups and no 
response to ischemia/reperfusion was observed (data not shown) .  
BNP levels after ischemia reperfusion were similar in all strains. No correlation with infarct size 
was observed. BNP levels were neither correlated with catecholamines nor with PRA, neither 
at baseline nor after ischemia/reperfusion. 
Discussion 
In the present study we investigated the role of adverse cardiac remodeling as predisposition 
for increased sensitivity to cardiac ischemia in an animal model (MWF) of spontaneous 
progressive renal dysfunction. We showed increased sensitivity to ischemia in MWF rats, which 
could not be attributed to hypertension or adverse cardiac remodelling. These findings are 
in accordance with the literature [9], and suggest alternative mechanisms to play a role in 
increased heart ischemic sensitivity in renal dysfunction. 
Increased sensitivity to ischemia 
Sensitivity to cardiac ischemia was investigated by the amount of irreversible damaged tissue 
after acute ischemia/reperfusion .Area at risk appeared to consist of 39-49% of the left ventricle. 
The observed differences in area at risk between the groups may be attributed to strain-related 
differences in coronary anatomy since rats are not known to present with coronary collaterals. 
The relationship between area at risk and infarct area is found linear at the range of 25-75% 
risk area [2 1 ], justifying expression of infarct size per risk area as a measure of cardiac damage. 
Accordingly, the significant increase of infarct size in MWF represents increased sensitivity to 
acute cardiac ischemia reperfusion damage in rats with renal dysfunction. 
Underlying mechanisms 
Cardiac related 
It has been shown that changes in cardiac function and structure can lead to increased ischemic 
sensitivity [ I 0- 1 5]. Except for a mild increase in left ventricular systolic pressure, no significant 
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Table 4. Neurohumoral levels in plasma of the experimental groups at baseline and a�er ischemia reper­
fusion; Data are presented as median (25-7 5 quartile); PRA; plasma renin activity; BNP; brain natriuretic 




PRA (ngAngl/ml/min) 6.6 (5.6-9. 1 )  8. 1 (6.6- 1 1 .8) 5.0 (4.0-7.0) 
Noradrenaline (pg/ml) 4 1 1 (3 1 2-657) 479 ( 1 84-597) 445 (237-635) 
Adrenaline (pg/ml) 55.5 ( I 0.0- 1 08.0) 37.0 ( 1 0- 1 1 4) 1 6.0 ( I 0.0-5 1 .0) 
BNP (ng/ml) 3.3 (2.2-3.7) 3.6 (2.8-4.7) 1 .8 ( 1 .4-2.4) * 
Aft.er ischemialreperfusion 
PRA (ngAngl/ml/min) 40.0 (34.3-6 1 .8) 50.0 (38.0-59.0) 24.5 ( 1 9.2-36.4) * 
Noradrenaline (pg/ml) 822 (63 1 - 1 079) 849 (584- 1 5  I 0) 7 1 6  (482-838) 
Adrenaline (pg/ml) 367 ( 1 60-705) 732 (4 1 - 1 327) 399 ( 1 4 1 - 1 053) 
BNP (ng/ml) 2.8 (2.4-4. 1 )  4.8(2.8-5.9) 3.4 (3.0-4.8) 
functional cardiac parameters have been observed that could explain the increased cardiac 
sensitivity to acute ischemia/reperfusion in MWF. 
Myocytes: In MWF, cardiac hypertrophy was indicated from increased ventricular weight to 
body weight ratio. Left ventricular concentric hypertrophy by itself is associated with increased 
ischemic sensitivity [ 1 9] and was supported at cellular level by 29% increase in myocyte cross­
sectional area in MWF. However; higher blood pressure and a more pronounced increase in 
ventricular weight in SHR did not lead to higher sensitivity to ischemia.This indicates that high 
blood pressure-induced left ventricular myocyte hypertrophy may not be the causal factor for 
the increased acute ischemic susceptibility in proteinuric rats. Increased lung weight and right 
ventricular weight may suggest that pulmonary congestion and right ventricular dysfunction 
might have contributed [ 6,20]. 
Alternatively, metabolic changes could play a role in increased ischemia sensitivity in rats with 
renal dysfunction. Studies on uremic rats showed increased ischemic sensitivity [9], which 
could be prevented by infusion of insulin and glucose [ 1 5] .  Hearts are characterized by lower 
phosphocreatinin levels at normal creatinin and ATP levels [ I 3, 1 4] .  Finally, alterations in Ca­
handling [ 1 4,32], as well as altered phosphorilation of contractile proteins [33], shown to 
contribute to cardiac (diastolic) dysfunction, could have contributed. 
Vascu/ature: Pressure overload-induced hypertrophy is usually associated with decreased 
capillary density, as microvascular adaptation is lagging behind myocyte growth [34]. In addition, 
macrovascular (resistance sized arteries) deficiency [35] may contribute, as coronary reserve 
is found reduced [36-38]. In the present study. hearts of MWF did not display lower capillary 
density and capillary/myocyte ratio was even higher in MWF than in Wistar: This is in contrast 
to subtotally nephrectomized rats [39], in which increased cardiac ischemic sensitivity was 
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attributed to reduced capillary density [9]. Since cardiac perfusion is determined at resistance 
arteriolar level rather than at capillary level, and in our previous study in 25 weeks old MWF 
maximal coronary capacity was not reduced compared to control [ 40], structural vascular 
deficiency seems to be ruled out as underlying mechanism. 
However; functional vascular changes stil l may interfere with cardiac responses to ischemia [ 1 2] . 
Impaired endothelial function in aortic rings from MWF [20.40], but not from SH R or Wistar; 
supports functional vascular changes in MWF. A previous study from our group showed that 
in MWF, but not in SHR, endothelial function was impaired in coronary, but not mesenteric 
microvessels [ 1 3] .  Hence, impaired endothelial function in the coronary circulation, could 
provide an explanation for the increased sensitivity to ischemia in MWF. 
Connective tissue: Overall tissue density was not altered in MWF, indicating no increased 
oxygen diffusion distance through increased interstitial space. Also collagen content of the 
left ventricle, which could increase ventricular stiffness and hamper ventricular relaxation 
and cardiac perfusion, was not increased in MWF. In summary, since all aspects of adverse 
cardiac remodeling are either absent or less pronounced in MWF compared to SH R, the 
observed higher vulnerability to acute ischemic in MWF may not be explained by adverse 
cardiac remodeling. Moreover; the observation that cardiac remodeling in MWF does not 
match with studies in the 5/6 nephrectomy rat model [9] indicates that at different stages of 
renal dysfunction different mechanisms may play role in increased ischemic sensitivity.The lack 
of structural changes, however; does not exclude a role for functional alterations in vasculatures 
and/or myocytes. 
Neurohumoral related 
PRA, catecholamines and BNP have been measured to examine baseline neurohumoral 
activation as predisposition for increased cardiac ischemic sensitivity. BNP is mainly released 
from ventricular myocytes in reaction to stress or tension, and acts as an antagonist of the 
renin-angiotensin aldosterone and sympathetic nervous system to protect the body from 
volume overload [26]. Higher blood pressure, left ventricular hypertrophy, impaired coronary 
endothelial dependent relaxation [ 1 4] and increased circulating levels of cyclooxygenase 
products [28] may have contributed to this increased ventricular stress. 
Peripheral endothelial dysfunction, observed in MWF but not in SHR or Wistar; is associated 
with altered cyclooxygenase metabolism [40] . Similar to the impaired endothelial function 
in the coronary circulation, these changes in peripheral vessels may serve as a marker for 
ischemic vulnerability in MWF. 
Kidney related 
In MWF, renal dysfunction was evidenced by increased urinary protein excretion and focal 
glomerulosclerosis, without differences in creatinine clearance, which represents either a less 
severe renal dysfunction than in uremic rats or a different type of renal dysfunction [4 1 ] . 
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Even MWF rats twice as old as in  the present study with advanced proteinuria and focal 
glomerulosclerosis, did not show reduced creatinine clearance [ 40]. Although in the present 
study the renal dysfunction was the primary factor to i nvestigate, regarding its effect on sensitivity 
to ischemia, no correlation was found between renal parameters and infarct size.The relatively 
m ild renal dysfunction may exclude a number of factors that have an impact on outcome in  
more advanced renal fai lure, such as metabol ic acidosis, hyperkalemia, hyperparathyroidism 
and alterations i n  calcium homeostasis [9]. 
Finally. the consistent reduction in  hematocrit levels in  MWF and in  subtotally nephrectomised 
rats [9], but not in SHR, is well known in chronic kidney d isease [42,43]. Reduced hematocrit 
and lower number of red blood cells (data not shown) may account for impaired oxygenation 
during reperfusion, and hence l imitation of repair. In addition to a possible hemodi luting effect 
of fluid retention, erythropoietin resistance is well known in renal patients. Moreover; recently 
some of these factors, including inflammation, a prothrombotic mi l ieu, and anemia, are explicitly 
mentioned as "novel" risk factors in  cardiorenal d isease [ 44] 
Study limitations 
Because of the invasive character; baseline hemodynamics could not be measured in the 
same animals that underwent cardiac ischemia. Therefore, to examine cardiac and peripheral 
hemodynamics as pred isposition for increased ischemic vulnerabi l ity, measurements were 
performed in separate rats. Secondly, because of the cardio-depressive effects of the ischemia/ 
reperfusion protocol itself, cardiac function measurements after 24 h of reperfusion (although 
obtained) d id not provide reliable results, and were hence not included in the paper. 
Third ly, we measured neurohumoral factors in p lasma before and after ischemia reperfusion. 
The values after ischemia/reperfusion include effects of ischemia reperfusion as well as effects 
of the experimental procedure: chest surgery. 
Final ly, as blood sampl ing was not at the exact same time as uri ne collection, and measurements 
of creatin ine used d ifferent techniques for urine and plasma, comparison between experimental 
groups remain val id ,  but absolute data for creatinine clearance may deviate. 
Conclusion 
Aim of the present study was to investigate increased cardiac ischemic sensitivity in a model 
of spontaneous progressive renal disease, MWF rats, and the role of preexisting adverse 
cardiac remodel ing in this process. Our data indicate that MWF are more sensitive to cardiac 
ischemia. Comparing data from MWF and SHR, however; seems to exclude adverse card iac 
remodeli ng as underlying mechanism. Vascular endothel ial dysfunction, altered neurohumoral 
responsiveness and anemia may provide alternative explanations for the increased sensitivity 
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to ischemia/reperfusion damage seen in MWF hearts. 
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Abstract 
Primary chronic kidney disease is associated wrt:h high cardiovascular risk. However; the exact 
mechanisms behind this cardiorenal interaction remain  unclear.We investigated the interaction 
between heart and kidneys in novel animal model for cardiorenal interaction. Normal Wistar 
rats and Munich Wistar Fromter rats, spontaneously developing renal dysfunction, were 
subjected to experimental myocardial infarction to induce cardiac dysfunction (CD) and 
combined cardiorenal dysfunction (CRD), respectively (N = 5- 1 0) .Twelve weeks later; cardiac­
and renal parameters were evaluated. Cardiac, but not renal dysfunction was exaggerated in 
CRD.Accelerated cardiac dysfunction in CRD was indicated by decreased cardiac output (CD 
I 09 ± I O  vs. CRD 79 ± 8 ml/min), diastolic dysfunction (E/e') (CD 26 ± 2 vs. CRD 50 ± 5) 
and left ventricular overload (LVEDP CD I 0.8 ± 2.8 vs. CRD 2 1 .6 ± 1 .7 mm Hg). Congestion in 
CRD was confirmed by increased lung and atrial weights, as well as exaggerated right ventricular 
hypertrophy.Absence of accelerated renal dysfunction, measured by increased proteinuria, was 
supported by absence of addrt:ional focal glomerulosclerosis or further decl ine of renal blood 
flow in CRD. Only advanced peripheral endothel ial dysfunction, as found in CRD, appeared 
to correlate with both renal and cardiac dysfunction parameters. Thus, proteinuric rats with 
myocardial infarction showed accelerated cardiac but not renal dysfunction. As parameters 
mimic the cardiorenal syndrome, these rats may provide a clinically relevant model to study 
increased cardiovascular risk due to renal dysfunction. Peripheral endothelial dysfunction was 
the only parameter that correlated with both renal and cardiac dysfunction, which may indicate 
a mediating role in cardiorenal interaction. 
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Introduction 
Even mi ld renal dysfunction substantially increases cardiovascular risk [ 1 2, 20, 28] .  Moreover; 
many patients with heart failure suffer from concomitant renal dysfunction [ 1 9], ind icating a 
strong cardiorenal interaction.Although wel l recognized, the pathophysiology of this i nteraction 
is largely unclear. Patients characterized by a cond ition of primary chronic kidney d isease [36] 
are at an extremely high cardiovascular risk; I 0-20-fold i ncreased risk of cardiac death; the 2 
year mortal ity rate after myocardial infarction is increased up to 50%, compared to I O  year 
mortal ity in the general population of 25% [ 1 7] .  These findings have revived interest in the 
interrelation between heart and kidneys. To investigate the interaction between heart and 
kidneys in this h igh-risk group of patients, d ifferent animal models have been used so far [ 4 1 ] .  
Most studies include rats with either uni lateral [48] o r  5/6 nephrectomy [9, 55] t o  induce 
(a predisposition for) renal dysfunction, that were subjected to chronic experimental heart 
failure. Although studies have presented accelerated renal dysfunction [ 48], in neither study 
accelerated card iac dysfunction has been observed. Only one study reported worsening of 
cardiac dysfunction and exaggerated cardiac remodeling, but this could wel l be attributed 
to the larger infarcts in the cardiorenal group [ I OJ. As al l  models have their advantages and 
disadvantages, the acute character of the nephrectomy in the above models and the l ittle 
amount of renal tissue left for therapeutic intervention, provides a clear d isadvantage in the 
translation of the results to the human cardiorenal syndrome. We aimed to study cardiorenal 
interaction in an alternative animal model, better mimicking the cl in ical ly h igh-risk condition; rats 
that spontaneously develop slowly progressive renal dysfunction, subjected to experimental 
heart fai lure. Parameters of renal as wel l  as cardiac dysfunction were recorded and correlated 
to study interaction between heart and kidneys. As heart and kidneys are connected by 
vasculature, and endothelial function is reported to predict outcome in cardiac as wel l  as renal 
dysfunction, vascular endothel ial dysfunction was studied as potential mechanism underlying 
cardiorenal i nteraction. 
Methods 
Animals 
The study was performed in male Munich Wistar Fromter rats (MWF/ZtmHsd) and age­
matched Wistar rats (HsdCpb:WU), as their  genetic background (Harlan, The Netherlands/ 
USA). Animals were housed in groups under standard conditions at 1 2  h l ight/dark cycle at the 
animal faci l ities of the University of Groningen. All animals were fed standard diet (standard 
rat chow, Hope Farms, Woerden, The Netherlands) and received food and water ad l ib itum. 
All experiments were conducted in accordance with the NIK Guide for the Care and Use of 
Laboratory Animals and were approved by the Committee for Animal Experiments of the 
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University of Groningen. 
Experimental protocol 
At 1 2  weeks of age, all rats were placed in metabolic cages for measurements of water and 
food intake and 24 hour urine collection. Subsequently, under 2 .5% isoflurane anaesthesia 
blood samples (± 1 .5 ml) were withdrawn from the tail vein. Urine and plasma samples were 
processed and stored at -80°C for later analyses. Subgroups ofWistar and MWF rats (n = 5 
each) were sacrificed prematurely to obtain baseline measurements of cardiac function and 
to collect cardiac and renal tissue for further analysis. The remaining animals were allowed I 
week recovery before they were subjected to permanent coronary artery occlusion or sham 
surgery as described before [5 2]. Five rats of each group (ECHO apparatus became available 
half way through the study) underwent echocardiography at baseline and at 3 ,  7 and I 0- 1 I 
weeks after surgery to evaluate the time course of cardiac function. At the same time points, 
plasma and urine were collected from all rats (metabolic cages) to examine the time course of 
renal (dys)function.Twelve weeks after surgery, measurements of left ventricular function and 
cardiac and renal hemodynamics were obtained invasively.This time point was chosen because 
of anticipated endothelial dysfunction in CD an imals [ I 3 ] .  Blood samples were collected from 
the tail vein and processed for further analyses.The heart was dissected, weighted and cooled 
in ice-cold saline for diastolic arrest. A mid-ventricular slice was processed for histological 
analysis. The remaining tissue was separated in right ventricle, interventricular septum, viable­
and infarcted left ventricle, frozen in liquid nitrogen and stored at -80°C. 
Lung tissue was weighted. Kidneys were dissected, weighted and processed for histological 
analysis. 
The thoracic aorta was dissected and cut in r ings for in vitro endothelial function analysis [44], 
as well as structural analysis. 
Echocardiography 
Echocardiographical measurements were obtained with the use of a Vivid 7 (GE Healthcare) 
equipped with a I O  M Hz transducer. Under isoflurane anaesthesia (2 .5%), rats were placed on 
a heating pad to keep body temperature at 3 7°C. Images in  parasternal long-axis, short-axis 
and fourchamber apical view were obtained. The ejection fraction (EF) was calculated using 
the Teichholz method and cardiac output (CO) was estimated from the aortic flow profile and 
the diameter at valvular levels as follows: CO = aortic valve area times aortic velocity time 
integral times heart rate, as described before [ 45]. Mitra! i nflow measurement of early filling 
velocity (E) was obtained from an apical four-chamber view using pulsed Doppler with the 
sample placed at the tips of mitral leaflets.Tissue Doppler imaging measurement of mitral valve 
septal annular velocity (e') was also obtained from the four-chamber apical view. All calculated 
parameters have been presented as the mean of five consecutive beats to avoid beat-to-beat 
variation. As echocardiography could have been obtained only in subgroups, results should be 
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regarded as indication, rather than as group evaluation with statistical analysis. 
Blood and urine measurements 
After urine collection, blood samples were obtained under isoflurane anaesthesia. Measurements 
of plasma creatinine, electrolytes, haemoglobin, and haematocrit levels were performed with an 
iSTAT handheld analyser (ABBOTT) and appropriate cartridges (Creatin ine; EG7+). Standard 
blood count was performed in  whole b lood samples. For that, whole blood sampled from the 
tai l  vein was transported immediately to the hospital. Remaining blood was processed and 
plasma was stored at -80°C for later analyses. 
PRA was determined by Gammacoat RIA kit (Diasorin, M innesota, USA) according to the 
manufacturer's instructions and expressed as ngAngl/ml/h. BNP was measured with the use of 
BNP-45 EIA kit (Phoenix Pharmaceuticals, Inc) . Total urinary protein levels were determined 
using TCA precip itation measurement (Nephelometer analyzer 1 1 ,  Dade Behring, Marburg, 
Germany). All measurements were performed according to the manufacturer's instructions. 
Hemodynamics and cardiac function 
Under isoflurane anaesthesia, hemodynamics and cardiac performance were measured using 
a pressure transducer catheter (M icro-Tip 3French, Millar Instruments Inc., Houston, TX) 
inserted through the right carotid artery. The catheter was positioned in the aortic root and 
mean arterial blood pressure (MAP) and heart rate (HR) were measured. The catheter was 
advanced into the left ventricle, and left ventricular systol ic pressure (LVSP) and left ventricular 
end-diastolic pressure (LVEDP) were recorded. The maximal rates of increase and decrease 
in left ventricular pressure ( +dP/dtmax and -dP/dtmax) were determined as parameters of 
myocard ial contracti l ity and relaxation, respectively. Then, the catheter was withdrawn and 
immed iately positioned in the vena cava superior just above the heart, and central venous 
pressure (CVP) was measured and total peripheral resistance (TPR) was calculated as TPR = 
MAP - CVP/CO. The abdominal cavity was opened and a flow probe (Transonic, Ithaca, NY, 
USA) was positioned on the left renal artery [56]. After stabil ization, renal blood flow (RBF) 
was measured. Renal vascular resistance (RVR) was calculated as RVR = (MAP - CVP)/RBF. 
Histology 
A 1 .5 mm thick mid-ventricular sl ice was fixated in 2% phosphate buffered paraformaldehyde 
for at least 24 h, dehydrated, and embedded in paraffin for measurement of infarct size and 
morphometric analysis of cardiac structure. Deparaffinized 5 Im sections were either stained 
with Sirius Red and fast green to distinguish infarct from viable tissue and to visual ize interstitial 
col lagen; with Gomori's si lver staining in order to visual ize ind ividual myocytes; or with Lectin 
GSI to visual ize capi l laries. Methods as wel l  as the measurements of infarct size, myocyte size, 
capi l lary density and interstitial fibrosis are described in detai l  by van Kerckhoven et a l .  [ 49] . 
Infarct size was expressed as percentage of left ventricular circumference. 
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Kidneys were stained with PASS stain ing and scored on presence and degree of focal glomerular 
sclerosis as described before [ 44]. 
Aortic sections were stained with Vimoff stain ing. Aortic hypertrophy was obtained from 
medial thickness, corrected for lumen d iameter; as described before [8]. 
Cardiomyocyte function 
Force measurements were performed in single, mechanical ly isolated cardiomyocytes as 
described previously [27, 50] .  Briefly, tissue samples were defrosted in relaxing solution, 
mechanically disrupted and incubated in relaxing solution supplemented with 0.5% Triton 
X- 1 00 to remove all membrane structures. Single card iomyocytes were attached with sil icone 
adhesive between a force transducer and a motor. Sarcomere length of isolated cardiomyocytes 
was adjusted to 2.2 Im. Isometric force was measured in maximal ly activating calcium solution 
(pCa = - I O- log[Ca2+] = 4.5) and in relaxation solution (pCa 9 .0) to determine maximal force 
generating capacity (Fmax) and passive force (Fpas), and normalized for card iomyocyte cross­
sectional area. On transfer of the cardiomyocyte from relaxing to activating solution, isometric 
force started to develop. Once a steady state force level was reached, the cell was shortened 
within I ms to 80% of its original length to determine the basel ine of the force transducer. The 
distance between the basel ine and the steady force level is  the total force (Ftotal).The cel l  was 
re-stretched and returned to the relaxing solution, in which a second slack test, of I O  s duration 
was performed to determine passive force. Maximal force was obtained by subtracting passive 
force from the total force, i .e .  Fmax = Ftotal - Fpas. 
Endothel ial function 
Maximal endothel ium-dependent relaxation was measured in vitro in aortic rings obtained 
from subgroups of the experimental groups, as described before [ 44]. Briefly, thoracic aorta 
segments (approximately 2 mm) were cleaned of adherent tissue and mounted in an organ 
bath with Krebs solution (pH 7.5) contain ing (in mmol/L) :  NaCl ( 1 20.4) , KCI (5 .9), CaC12 (2.5), 
MgCl2 ( 1 .2), NaH2PO4 ( 1 .2) , glucose ( I 1 .5) ,  NaHCO3 (25 .0) , which was kept at 37°C and 
continuously bubbled with 95% 02 and 5% CO2.After equi l ibration, viabil ity of smooth muscle 
cel ls and endothel ium was tested using phenylephrine (PE; I 0-6 mol/L). After wash out and 
another 30 min of stabi l ization, endothelial function was measured as endothel ium-dependent 
relaxation to cumulative concentration of acetylchol ine (ACh; 3 9 I 0-8 - 3 9 I 0-4 mol/L) in 
the vessels precontracted by PE ( I 0-6 mol/L) . Area under the curve (AUC) was obtained as 
measure for endothelial function. Finally, sodium nitroprusside ( I 0-3mol/L) was added to the 
organ baths to obtain endothelium-independent relaxation. In order to examine the role of 
cyclo-oxygenase (COX) [44] , Ach-induced relaxation was studied in parallel in separate aortic 
rings in the presence of either I 0-6 M indomethacin or I 0-5 n imsul in, to inhibit COX I and 
COX2, or only COX2, respectively. 
Aortic sections were processed for analysis of endothelial nitric oxide synthase ( e-NOS) 
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expression using RT-PCR For that, total RNA was isolated using TRlzol reagent (lnvitrogen 
Corporation, Breda, The Netherlands) and converted to cDNA by QuantiTect Reverse 
Transcription (Qiagen,Venlo,The Netherlands). Gene expression was measured with Absolute 
QPCR SYBR Green ROX M ix (Abgene, Epsom, UK) in the presence of 7.5 ng cDNA and 200 
nM forward and reverse primers. qRT-PCR was conducted on the Biorad CFX384 (Biorad, 
Veenendaal, The Netherlands) . Initial denaturation and activation of the DNA polymerase at 
95°C for 3 min was followed by 35 cycles with denaturation for 1 5s at 95 °C and annealing and 
elongation for 30 s at 60°C, followed by a melt curve. 
Gene expression levels were corrected for ribosomal protein large (Rplp0). Primers used were 
endothelial NO synthase (eNOS) forward TCCTAACTTGCCTTGCATCC, eNOS reverse 
GGCAGCCAAACACCAAAGTC, Rplp0 forward CCTCATACCAGCGACGATTC, Rplp0 
reverse ATGTGGAGGAGTCTCACTTC . 
Statistical analysis 
Data are presented as mean ± standard error of the mean (SEM).  Data of rats with infarct < 20% 
of the left ventricle were excluded from analysis, as these small infarcts are hemodynamically 
fully compensated [37] . Analyses were performed using SPSS version 1 6. Parameters were 
compared using 2-way analysis of variances (ANOVA); effects of cardiac dysfunction as well 
as renal dysfunction were analyzed first separately, followed by analysis of interaction. This is 
presented in the figures using different symbols. In case data were not normally distributed, a 
nonparametric Kruskal-Wallis test followed by a Mann- Whitney U test with correction for 
multiple comparisons was used. Differences were considered significant at the level of 0.05 . 
Echocardiography could be obtained in only 3-5 rats per group, and hence results should be 
regarded as indication, rather than as group evaluation with statistical analysis. 
Results 
Control rats 
Twelve weeks old rats from both strains (MWF = RD; Wistar = control) were sacrificed to 
obtain baseline values, and general characteristics are presented in Table I . Food and water 
intake did not differ between RD rats and controls, nor did urine production. RD rats had a 
lower body weight than age-matched control. Lung weight and heart weight corrected for 
body weight were significantly increased in RD. At 1 2  weeks of age, renal dysfunction was 
confirmed by increased urinary protein excretion (UPE) and focal glomerulosclerosis (FGS) in 
RD, but no increase in plasma creatinine levels was observed. RD rats had slightly higher blood 
pressures, reflected in a 29% increase in left ventricular myocyte cross-sectional area (NS), 
with normal heart rate and normal left (LVEDP) and right (CVP) cardiac filling pressures. Renal 
blood flow, however; was strongly reduced in RD due to elevated renal vascular resistance 
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Table I. Characterization of control (Wistar) and RD (MWF) rats at 1 2  weeks of age 
.• 
Control RID 
N 5 5 
BW (g) 386 ± 7 249 ± 14 a 
Food intake (g/24h) 1 5  ± 4 19 ± I 
Water i ntake (ml/24h) 24 ± 3 26 ± 2 
Urine production (g/24h) 1 5  ± 2 1 1  ± I 
HW/BW (mg/g) 3.2 ± 0.2 4.5 ± 0.5 a 
Lung/BW (mg/g) 3 .3 ± 0.0 4.8 ± 0.2 a 
RKW/BW (mg/g) 3.7 ± 0. 1 3.7 ± 0. 1 
UPE (mg/24h) 28 ± 5 76 ± 1 9  a 
FGS (AU) 0.4 ± 0.4 1 .6 ± 0.4 a 
Plasma creatinine (mg/I) 3 1  ± I 25 ± 4 
MAP (mmHg) 89 ± 4 102 ± 3 a 
LVSP (mmHg) 1 17 ± 5 1 3 1 ± 3 a 
LVEDP ( mm Hg) 5 .3 ± 2.4 6.2 ± 1 .9 
HR (beats/min) 359 ± 1 8  364 ± 14 
CVP (mmHg) 1 .2 ± 1 .9 2. 1 ± 1 .7 
RBF/KW (ml/min/g) 6.0 ± 1 .6 2.6 ± 0.6 a 
Hct (%) 47.6 ± 0.4 44.2 ± 0.3 a 
HW: heart weight, B W: body weight, RKW: right kidney weight, UPE: urinary protein excretion, FGS: focal 
glomerulosc/erosis, MAP: mean arterial pressure, LVSP: left ventricular systolic pressure, LVEDP: left ventricular 
enddiasto/ic pressure, HR: heart rate, CVP: central venous pressure, RBF: renal blood flow, Hct hematocrit ; 
a: Significant difference between control and RD 
(47 ± 1 2  vs. 1 7  ± 4 mmHg/ml/min, in RD and control ,  respectively). Hematocrit was significantly 
lower in RD rats. Apart from a slightly increased myocyte size, histological analysis showed no 
signs of adverse left ventricular remodeling in RD; myocyte cross-sectional area 535 ± 7 1  
versus 4 1 4 ± 48 lm2; interstitial fibrosis: 5.0 ± 0.9 versus 5.9 ± 0.5%; capillary densrty: 2,89 1 ± 
337 versus 2, 1 56 ± 1 4 1  #/mm2; number of capillaries per cardiomyocyte 1 .92 ± 0.28 versus 
1 . 1 4  ± 0. 1 9 , in RD versus control, respectively. 
Myocardial infarction 
Cardiac dysfunction was induced by experimental myocardial infarction (Ml). This procedure 
resulted in 22% mortality, which occurred mainly within the first 24 h after surgery. Overall 
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Table 2. General characteristics of the experimental groups at 25 weeks of age 
Greup 
J 
Conu.eJ CID RI!> I @RD 
N 1 0  6 9 1 0  
BW (g) 482 ± 1 1  466 ± 1 4  340 ± 9 b 342 ± 8 b 
Food intake (g/24h) I I  ± 2 1 3  ± 3 1 3  ± I I I ± I 
Water i ntake (ml/24h) 2 1  ± I 26 ± 5 22 ± I 22 ± I 
Urine production (g/24h) 1 5  ± 2 1 8  ± 3 1 3  ± I 1 4 ± I 
Hct (%) 47.9 ± 0.6 1 8.7 ± 1 .0 45.0 ± 0.8 b 45.7 ±0.7 b 
Plasma [Na] (mmol/1) 1 37 ± I 1 38 ± I 1 37 ± 0 1 36 ± I 
Plasma [K] ( mmol/1) 4.4 ± 0.2 4.7 ± 0.2 4.5 ± 0. 1 4.7 ± 0. 1 
Plasma [Cl] (mmol/1) 1 02 ±  I 1 03 ± I 1 05 ± I 1 04 ± 0 
Urine [Na} (mmol/1) 92 ± 1 7  1 23 ± 36  1 47 ± 1 1  b 1 59 ± 22 b 
Urine [K] (mmol/1) 1 1 5 ± 1 5  1 25 ± 23 1 53 ± 9 b 1 52 ± 2 1  b 
Urine [Cl] (mmol/I) I O I ± 20 1 36 ± 40 1 76 ± 1 3  b 1 84 ± 25 
R�/BW (mg/g) 3.7 ± 0. 1 3.3 ± 0. 1 a 3.3 ± 0. 1 b 3. 1 ± 0. 1 b 
FGS (AU) 2.4 ± 0.6 3.6 ± 1 .2 22.4 ± 2. 1 b 1 2. 1  ± 1 .4 b 
8 W: body weight, Hct hematocrit, RKW: right kidney weight, FGS: focal glomerulosclerosis, CD: cardiac disease, 
RD: renal disease, CRD: cardiorenal disease; a: Significant effect of cardiac dysfunction b: Significant effect of 
renal dysfunction 
infarct size was not different in both groups (33 ± 5% in CD and 34 ± 4% in CRD), neither 
after exclusion of 3 rats with infarcts<20% (34 ± 5% in CD and 38 ± 3% in CRD). 
Characteristics of experimental groups at 25 weeks are presented in Table 2. Strain-related 
characteristics as seen at 1 2  weeks (Table I )  remained present in sham groups at 25 weeks. 
Whereas plasma concentrations of electrolytes did not differ between groups, concentrations 
in urine were significantly higher in rats with RD. Ml had no effect on electrolyte concentrations 
in urine. 
Renal effects 
Time course of UPE is shown in figure I .As anticipated, RD rats showed progressive proteinuria 
with age, which was absent in controls and CD rats. When renal dysfunction was combined 
with cardiac dysfunction in CRD, besides an initial decrease, proteinuria progressed at the same 
rate as in RD. 
The initial decrease occurred in both Ml groups, CD and CRD, at the same percentage. In 
RD, FGS increased with age from 1 .6 ± 0.4 AU at 1 2  weeks to 22.4 ± 2. 1 AU at 25 weeks, 
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Figure I. Time course of urinary protein excretion in the experimental groups. Control (n = I 0), CD cardiac 
disease (n = 6), RD renal disease (n = 6), CRD cardiorenal disease (n = I 0). 
+ Significant effect of renal dysfunction 
concomitant cardiac dysfunction. In fact, there was a h ighly s ign ificant, positive correlation 
between UPE and FGS (r2 = 0.64, p<0.00 I ) . RBF was s ignificantly lower in RD and was not 
affected by Ml in either strain (Table 3). RVR was significantly h igher in RD rats than in controls 
(52.8 ± 1 3. 1  and 1 3 .2 ± 1 .9 mmHg/ml/min, respectively), but not significantly affected by M l  
(CRD 39 .5 ± 6.9 mmHg/ml/min; C D  1 3 .5 ± 1 .3 mmHg/ml/min). This hemodynamic renal 
parameter RVR was s ignificantly, negatively correlated with both structural (FGS; r2 = 0.473, 
p<0.00 I )  and functional (UPE; r2 = 0.328, p = 0.002) renal parameters. Creatinine clearance 
was s imi lar in al l groups (control 8.2 ± 0.9; CD 7.3 ± 0.2; RD I 0.0 ± 1 .3 and CRD 9. 1 ± 1 . 1  
ml/min/kg) and decreased approximately 25% with aging irrespective of absence/presence of 
Ml .  No significant correlations of creatinine clearance with other renal parameters were found. 
Cardiac effects 
Effects on cardiac function 
Time course of card iac dysfunction is presented in Figure 2A and B. The EF (Figure 2A) was 
85% in s ham rats and remained stable over time. At 3 weeks, EF was severely depressed in  
both groups with Ml ,  and remained at th is  level for the rest of the study. CO (Figure 2B) 
showed s imi lar and stable values in  sham rats of both strains.Three weeks after Ml, CO was 
strongly depressed and remained low in CRD, but was partly restored in CD. Cardiac function 
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Table 3. Systemic and cardiac hemodynamics measured at 25 weeks of age 
- -
· Group Cantrel c� ,: R: 
N 10 6 9 
HR (beats/min) 33 1 ± 14 336 ± 35 360 ± 28 
MAP (mmHg) 94 ± 3 88 ± 4 107 ± 4 b 
LVSP (mmHg) 128 ± 4  1 23 ± 8 134 ± 3 
+dp/dt (mmHg/s) 909 1 ± 299 7463 ± 375 a 8993 ± 3 18 
-dp/dt (mmHg) 7463 ± 375 6009 ± 432 a 6 199 ± 5 13 
RBF/KW (ml/min.g) 7. 1 ± 0.8 6.7 ± 0.4 2.8 ± 0 .7 b 
Cf{O) 
10 
4 16 ± 38 
84 ± 5 a 
108 ± 2 a c 
8452 ± 455 a 
4377 ± 299 a c 
2.7 ± 0.5 b 
CD: cardiac disease, RD: renal disease, CRD: cardiorenal disease, HR- heart rote, MAP: mean arterial pressure, 
LVSP: le� ventricular systolic pressure, ±dP/dt positive/negative first derivative of pressure signal, RBF/KW: renal 
blood �ow/kidney weight; a: Significant effect of cardiac dysfunction; b: Significant effect of renal dysfunction; c: 
Significant effect of combined cardiorenal dysfunction 
and hemodynamics parameters measured 1 2  weeks after surgery, are presented i n  Table 3. 
Heart rate was s imi lar in control rats, rats with CD and rats wrt:h RD, but h igher (p = 0.06) 
in rats wrt:h CRD. RD rats had h igher MAP than control, which was significantly reduced after 
Ml .  Ml reduced left ventricular systol ic pressure by 4% in  CD, but by 20% in CRD. Whereas 
Ml induced reduction of left ventricular systol ic function ( +dP/dt), was not exaggerated in 
CRD compared to CD, diastol ic dysfunction, presented as a reduction of relaxation 
velocity (-dP/dt) as wel l  as increase in tissue Doppler parameter (E/e'), was sign ificantly more 
pronounced in CRD (Figure 2C). Moreover, heart weight-body weight ratio, as wel l  as lung 
weight-body weight ratio was significantly h igher in the CRD rats (Figure 3). Parameters of 
congestion, upstream from the injured left ventricle were analyzed and presented in Figure 
3. LVEDP was increased by 80% in CD, but almost by 200% in CRD, indicating elevated left 
ventricular preload. Simi larly, left atrial weight increased 3 times more in CRD than in CD. 
Twice as h igh right atrial weight only in CRD rats suggests that congestion was not restricted 
to the damaged left s ide of the heart. In addition, central venous pressure appeared h ighest in 
the CRD rats, although no significant differences could be obtained between the experimental 
groups. 
Effects on myofilament function 
Myofi lament function of isolated skinned fibers from the viable left ventricular free wall is 
presented in Figure 4. Whereas active force was s imi lar in  all groups, passive force increased 
after Ml .  This i ncrease was found statistically s ign ificant in CRD, but not in CD. 
Effects on cardiac structure 
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Figure 2.  Cardiac function parameters obtained by echocardiography. E/e' early ft/ling velocity (E) to  mitra/ valve 
septa/ annular velocity (e) ratio. Control (n = 5), CD: cardiac disease (n = 3), RD: renal disease (n = 5), CRD: 
cardiorenal disease (n = 4) 
those of 1 2  weeks old rats (Figure 5). M l  significantly reduced capi l lary density to the same 
extent in CD and CRD. Simi larly, interstitial col lagen and myocyte size were increased due 
to Ml, but without differences between CRD and CD. Furthermore, no d ifferences between 
the groups are found for number of capi l laries per myocyte (range 1 .8-2.3). Myocyte size in 
the right ventricle was significantly and exponentially (p<0.00 I )  increased in  rats with CRD 
(Figure 5), and was significantly and positively correlated with congestion parameters, such as 
LVEDP, atrial weight and lung weight Hence, right ventricular myocyte size may better explain 
the increased heart weight body weight ratio (r2 = 0.4 1 8; p<0.00 I )  in rats with CRD than left 
ventricular myocyte size (r2 = 0.002; p = 0.797) . 
Circulatory effects 
Effects on blood 
Before Ml ,  plasma ren in activity (PRA) was sign ificantly lower in RD compared to control rats; 
4.4 ± 0.5 versus 8.0 ± 0.8 ngAngl/ml/h. M l  induced a significant increase in PRA only in CRD 
rats (altered PRA from before- to 7 weeks post-Ml :  CRD +6.2 ± 1 .6; CD -2. 1 ± 2.5 ; RD - 1 .2 
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Figure 3. Parameters of congestive heart failure. Control (n = I 0), CD: cardiac disease (n = 6), RD: renal disease 
(n = 9), CRD: cardiorenal disease (n = I 0). LVEDP: le� ventricular enddiastolic pressure, CVP: central venous 
pressure. + Significant effect of renal dysfunction; # Significant effect of combined cardiorena/ dysfunction 
40 
N N-E E 30 z 6 
::. 
C1I 
C1I (.) 4 e 20 
.E -





(\ cJ> �'O (j�'O ��
o\ 
<jO
'(\ <j'O �'O (j�'O 
Figure 4. Active and passive force development in isolated myofibri/s. Control (n = 5), CD: cardiac disease (n 
= 5), RD: renal disease (n = 5), CRD: cardiorenal disease (n = 5). *Significant effect of cardiac dysfunction 
± 1 .2; control -2.5 ± 1 .0 ngAng 1/ml/h). This increased PRA was significantly correlated with 
LVEDP (r2 = 0.46 1 ,  p<0.00 I ) , lung weight (r2 = 0.5 1 5 , p<0.00 I )  and right ventricular myocyte 
size (r2 = 0. 1 75, p = 0.042), but not with renal parameters, such as proteinuria, creatinine and 
renal blood flow. Before Ml, there was no difference in BNP levels between groups. Ml induced 
highest increase of BNP in CRD rats (altered BNP from before to 7 weeks post-Ml: CRD 1 . 1  
± 0.2; RD 0.3 ± 0.4; CD 0.5 ± 0.2; control 0.6 ± 0.2 ng/ml). BNP values 7 weeks post-Ml were 
positively correlated with lung (r2 = 0. 1 84, p = 0.0 1 4) and atrial weights (r2 = 0.2 1 5 , p=0.008 
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Figure 5. Le� and right ventricular remodeling presented as interstitial collagen, capillary density and myocyte 
hypertrophy. Control (n = I 0), CD: cardiac disease (n = 5), RD: renal disease (n = 9), CRD: cardiorenal disease 
(n = I 0). *Significant effect of cardiac dysfunction; #Significant effect of combined cardiorena/ dysfunction 
and r2 = 0. 1 38, p = 0.040 for left- and right atrium, respectively) , but not with renal parameters. 
Ml in CD did not affect hematocrit, nor number of red blood cells (Table 4). However, number 
of white blood cells was significantly reduced after M l .  In RD, lower hematocrit levels shown 
at 1 2  weeks of age, were also observed at 25 weeks, and matched with lower numbers of red 
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blood cells (Table 4). Number of white blood cells was pronouncedly reduced in RD. In CRD, 
Ml did not affect hematocrit, number of red blood cells, or number of white blood cells. Platelet 
numbers were similar in all groups. 
Vascular effects 
There were no differences between groups with regard to aortic media/lumen ratio at 1 2  
weeks after M l  ( control 0.23 ± 0.03; CD 0.23 ± 0.04; RD 0.25 ± 0.2: CRD 0.28 ± 0.02) .There 
was a slight increase in total peripheral resistance in CD rats from 0.7 1 ± 0.07 to 0.95 ± 0. 1 0  
mmHg min/ml, and in CRD from 0.8 1 ± 0.07 to 1 .04 ± 0. 1 8  mmHg min/ml. A significant 
correlation was found between TPR and left ventricular congestion parameters, LVEDP and left 
atrial weight (r2 = 0.328, p = 0.026; r2 = 0.355, p = 0.0 1 6, resp.), but not with pulmonary and 
right ventricular congestion parameters, nor with renal parameters .  In aortic rings, endothelium­
independent relaxation, obtained by response to sodium nitroprusside, was reduced by 23% 
(NS) in CD and RD and by 5 3% in CRD rats (p<0 .05) . Moreover, endothelium-independent 
relaxation was significantly correlated with congestion parameters LVEDP, left atrial weight 
and lung weight, but not with any of the renal parameters .  Endothelium-dependent relaxation, 
obtained by the response to acetylcholine, is presented in figure 6A. RD caused a significant 
reduction in endothelium-dependent relaxation (AUC control 99.0 ± 1 4 .8 AU; RD: 54.6 ± I 1 .9 
AU) ,  which was maintained after correction for endothelium-independent relaxation. CD did 
not significantly impair endothelium-dependent relaxation (AUC 93 .0 ± 37.8 AU) . Although 
not statistically significant, an additional effect might be seen in the vessels from CRD rats (AUC 
32.8 ± 9.4 AU) . Interestingly. endothelium-dependent relaxation was significantly correlated 
with both renal dysfunction parameters as well as left ventricular overload parameters (figure 
7), but not with systemic hemodynamic parameters, such as TPR, MAP and CVP. Endothelial 
NO-synthase expression was slightly increased in aortas of rats with renal dysfunction, but 
without additional effects of Ml ( eNOS/Rplp0 in control 0.82 ± 0. 1 5 ; CD 0.75 ± 0.27; RD I .  I I 
± 0.20; CRD I . 1 8  ± 0. 1 7). 
Effects of COX inhibition on Ach-induced relaxation is presented in figure 6B. In  control as well 
as RD, COX2 inhibition by nimsulide enhanced the Ach-induced relaxation, whereas COX I 
and COX2 inhibition by indomethacin had no effect, indicating a COX I mediated vasodilation 
compensated by COX2 mediated vasoconstriction .  Ml had similar effects in CD as well as 
CRD; no effect of nimsulide, but increased vasorelaxation on indomethacin. 
Discussion 
Even mild renal dysfunction substantially increases the risk of cardiovascular morbidity or 
mortality, and many patients with heart failure suffer from concomitant renal dysfunction, 
supporting a strong interaction between heart and kidneys. Primary chronic kidney disease 
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Table 4. Effects on hematocrit (Hct), number of red- (RBC) and white (WBC) blood cells, and platelets 
<sroup CD RD Control CRD 
N 10 6 9 1 0  
Hct (%) 47.8 ± 0.6 48.7 ± 1 .0 45.0 ± 0.8 b 45.7 ± 0.7 b 
RBC (#. I O  12/1) 9.4 ± 0. 1 9.4 ± 0. 1 7.9 ± 0.2 b 7.8 ± 0. 1 b 
WBC (#. I O  12/1) 10.7 ± 0.8 8.7 ± 0.6 a 2.2 ± 0.2 b 2.3 ± 0. 1 b 
Platelets (#. I O  1 2/1) 739 ± 68 852 ± 49 887 ± 44 832 ± 40 
CD: cardiac disease, RD: renal disease, CRD: cardiorenal disease, # number; a: Signiftcant effect of cardiac 
dysfunction; b: Significant effect of renal dysfunction 
is associated with extremely high cardiovascular risk [36] .  The interaction between heart and 
kidneys in this relatively high-risk group of patients was studied in an animal model mimicking 
the clinical condition; rats that spontaneously develop progressive renal dysfunction, subjected 
to experimentally induced heart failure. The main findings were: ( I )  cardiac, but not renal 
dysfunction was exaggerated in combined cardiorenal dysfunction; (2) cardiac dysfunction was 
characterized by systolic and diastolic dysfunction with cardiopulmonary congestion and right 
ventricle hypertrophy; (3) adverse left ventricular remodeling and myofi lament dysfunction 
could not explain the deteriorated cardiac function in cardiorenal disease; (4) vascular 
endothelial dysfunction may provide a link between renal and cardiac dysfunction. 
Rat model for cardiorenal disease 
As anticipated from literature [35],  renal dysfunction in 1 2  weeks old RD rats was confirmed 
by functional, structural and hemodynamic changes, represented by increased U PE and FGS 
and reduced renal blood f low, respectively. Furthermore, hematocrit levels were reduced, 
which is in agreement with previous findings in rats [ I ] ,  as well as in patients with chronic renal 
disease [23,  46], and notified as a "novel" risk factor in cardiorenal disease [47]. RD coincided 
with mildly increased MAP and normal CVP [24]. Combining this model with experimental 
myocardial infarction, a well-established model of cardiac dysfunction [37, 38] ,  may therefore 
provide a suitable animal model to study chronic renal dysfunction as predisposition for high 
cardiovascular risk. 
Renal dysfunction in cardiorenal disease 
There was no effect of cardiac dysfunction on progression of renal dysfunction as evidenced by 
functional (UPE) , hemodynamic (RVR) and structural (FGS) parameters. Apart from the initial 
decrease, the progression of UPE in CRD was similar to that in RD. Since this initial decrease 
occurred to the same extent in CD and CRD rats, it might be attributed to reduction in MAP 
shortly after Ml. The absence of progressive proteinuria is in contrast to results reported in 
rats after unilateral nephrectomy and Ml [48], but in accordance with the commonly used 
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Figure 6. Parameters of endothelial function. A Concentration-dependent relaxation to acetylcholine in 
phenyleprine-precontracted aortic rings. B Effect of COX inhibition on maximal Achinduced relaxation. Control 
(n = 6), CD: cardiac disease (n = 4), RD: renal disease (n = 6), CRD: cardiorenal disease (n = 5). INDO 
indomethacin, NIM nimesulide; +Significant effect of renal dysfunction 
cardiorenal model of rats with subtotal nephrectomy and Ml [55 ,  56]. Renal dysfunction in RD 
and CRD resulted in increased FGS in comparison to control and CD; however; it was lower in 
CRD than in CD. When taking the strong correlation between UPE and FGS, it seems that this 
difference may have also occurred in the early post-Ml phase. RVR was severely increased in RD 
compared to control, but without additional increase in CRD.AII these functional, hemodynamic 
and structural parameters of renal dysfunction were significantly inter-correlated, supporting 
mutual interaction of renal parameters and substantiating the observation of absence of 
progressive renal dysfunction due to concomitant cardiac dysfunction. In contrast, creatinine 
clearance, as an estimate of glomerular filtration rate, was reduced over time, but not different 
between experimental groups. This would support recent suggestions that proteinuria and 
reduced glomerular fi ltration rate may represent different types of renal dysfunction, rather 
than being a measure of increased severity [SJ. Finally, no correlations were found between 
renal parameters and cardiac parameters, indicating absence of a direct relationship in the 
present study. Although not accelerated by concomitant cardiac dysfunction, renal function 
still was declining over time in CRD. It is generally acknowledged that worsening of renal 
function can lead to worsening of cardiac function and outcome in patients, as reviewed by 
Damman and coworkers [6] . However; to our knowledge there are no clinical studies available 
investigating the opposite relation: comparing worsening of renal function in patients with or 
without concomitant cardiac dysfunction. 
Cardiac dysfunction in cardiorenal disease 
Calculated CO provided a first indication of more severe cardiac dysfunction in rats with 
primary renal dysfunction. Accelerated cardiac dysfunction in CRD, as indicated by lower CO, 
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Figure 7. Statistically significant correlations betvveen endothelial function and renal as well as cardiac 
parameters 
and fai lure. Comparing our results to avai lable literature reveals that accelerated cardiac 
dysfunction was not observed in uni lateral nephrectomy + Ml [48] or in 5/6 nephrectomy 
+ Ml [56], whereas rats with temporal L-N NA infusion, in addition to 5/6 nephrectomy, did 
show signs of more severe cardiac dysfunction [ I ] . However; one recent study is showing 
aggravation of cardiac remodel ing with concomitant renal dysfunction [ I OJ. U nfortunately, this 
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study did not include rats with only 5/6 nephrectomy or sham Ml rats. Moreover; control rats 
did not show cardiac dysfunction after M l  as measured by EF or LVEDD, and changes in cardiac 
function and remodeling could well be attributed to the larger infarct sizes in the cardiorenal 
group [ I OJ . Since the congestion in systolic heart failure is related to renal dysfunction and 
increased mortality [7], many studies focused on systolic dysfunction. However; in a substantial 
proportion of cardiorenal disease patients, cardiac dysfunction is characterized by diastolic 
rather than systolic dysfunction; heart failure with preserved ejection fraction [29, 3 2] .  Data 
from the present study indicate that rats with CRD may display diastolic heart failure indicated 
by stronger reduction in cardiac output at similar ejection fraction, increased E/e' ratio and signs 
of congestion. This was accompanied by right ventricular overload, indicative for pulmonary 
hypertension, as commonly observed in cardiorenal diseased patients [26] . In a recent study, 
it was argued that diastolic dysfunction only develops into congestive diastolic heart failure 
because of underlying renal insufficiency [5 I ], which underscores the relevance of our model. 
Underlying mechanisms 
Adverse cardiac remodeling 
In 1 2  weeks old MWF, a cardiac phenotype was indicated from higher heart weight-body 
weight ratios associated with increased left ventricular systolic pressure at normal enddiastolic 
pressure.Three months of CRD resulted in pronouncedly increased cardiac weight, suggesting 
adverse cardiac remodeling [ 4 3] .  However; besides a minor; and possibly blood pressure­
related left ventricular myocyte hypertrophy, adverse remodeling of the left ventricle was not 
observed either at 1 2  or at 25 weeks. Thus, adverse left ventricular remodeling neither was 
a predisposition to develop accelerated cardiac dysfunction in CRD, nor could be associated 
with the exaggerated cardiac dysfunction in CRD, once established. This is in accordance with 
results in rats with 5/6 nephrectomy + Ml [34, 56] ,  but in contrast to a recent study of Dikow 
et al. [ I OJ . In this latter study, however; effects on remodeling were only observed in the border 
zone of the scar and not in the remote areas, and hence would match with our results obtained 
in remote areas . In the present study, increased pulmonary weight suggested pulmonary 
congestion and right ventricular overload.This was evidenced by a significant increase in right 
ventricular myocyte size, indicating right ventricular concentric hypertrophy, and could be 
associated with the activated renin angiotensin system in CRD. A higher correlation between 
total ventricular weight and right-, compared to left ventricular myocyte size, supports an 
important contribution of the right ventricle to increased heart weight in CRD. Moreover; right 
ventricle overload might have also contributed to the dysfunction of LV [4] . 
Myofi/ament function 
Cardiac diastolic dysfunction could be caused by various mechanisms [ I I ], including altered 
function of contractile proteins within the cardiomyocyte. Whereas active force was similar 
in all groups, passive force was significantly increased in CRD. Correlation with impaired left 
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ventricular relaxation indicated intrinsic diastolic dysfunction rather than fibrosis related stiffness 
of the left ventricle. High cardiomyocyte stiffness has been reported in diastolic dysfunction 
patients and correlated significantly with LVEDP [2]. 
Anemia 
Irrespective of concomitant cardiac dysfunction, MWF showed anemia, indicated by lower 
hematocrit as well as number of red blood cells. Since white blood cell number is even 
more pronouncedly decreased, anemia may result from general bone marrow dysfunction 
rather than from hemodi lution or erythrocyte-specific mechanisms, such as erythropoietin­
resistance [23].This is supported by results of a pi lot study of culturing bone marrow-derived 
endothelium progenitor cells [33] , showing less than I 0% yield in MWF compared to Wistar. 
All aspects, including anemia [23, 25] , erythropoietin-resistance [39], reduced numbe�/and or 
function of endothelium progenitor cells [3, 1 6, 40], general bone marrow dysfunction [2 1 ,  22], 
are commonly described in renal dysfunction. However, as no additional effects were observed 
in CRD rats compared to CD and RD rats, this does not provide an explanation for the 
accelerated cardiac dysfunction in primary renal dysfunction. 
Vascular function 
Endothel ial dependent relaxation measured in aortic rings served as a biomarker for 
endothelial dysfunction in more distant vascular beds. Ml has been associated with reduced 
endothel ium-dependent relaxation in aortic rings [ 1 3, 5 3]. Moreover, impaired endothelium­
dependent relaxation in aortic r ings in MWF [44] could be associated with endothelial 
dysfunction in coronary, but not in mesenteric arteries [ 1 5]. There is growing evidence of 
the role of endothelium in regulation of cardiac diastolic function [54]. It is believed that 
low availability of NO produced by endothelial NO synthase leads to decrease in diastol ic 
function, cardiac hypertrophy and fibrosis, whereas enhancement of this enzyme attenuates 
these changes. Endothelium derived NO has been shown to have positive effects not only on 
diastol ic, but also on systol ic function [ 1 8]. Moreover. the endothelial dysfunction might limit the 
cardioprotective effect of erythropoietin [ 4 2]. Therefore, exaggerated endothelial dysfunction 
in CRD might have contributed to further impairment of cardiac dysfunction in these rats. 
However, as eNOS expression in the present study was similar in RD and CRD and even 
slightly higher compared to control and CD, impaired eNOS would not explain the endothelial 
dysfunction in CRD. Similarly, Ml induced altered COX-activity was comparable in CD and 
CRD and hence may not have contributed to endothelial dysfunction in CRD. Unfortunately, 
to our knowledge no data are available about endothelial function in renal arteries in MWF. 
Interestingly, aortic endothelial function was the only parameter that significantly correlated 
with renal as well as cardiac parameters, suggesting a mediating role for the vasculature. This 
suggested role may be supported by the finding that endothelial function predicts individual 
susceptibility to renal damage in 5/6 nephrectomy [ 1 4, 30, 3 I ]. 
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Study l imitations 
Although the present study may throw new light on the interaction between heart and kidneys 
in cardiorenal disease, it may have some limitations as well: the MWF rat strain used in this 
study is an inbred model based on proteinuria, which could have caused other unknown 
genotypical/ phenotypical changes as well; we cannot fully exclude primary pulmonary disease 
in this strain. Moreover; as most inbred Wistar-origin models, MWF rats had substantially lower 
body weights at the same age than outbred Wistar. Although a clear explanation is to our 
knowledge not known, it may trouble either/not correcting for body weight Furthermore, 
although proteinuria, focal glomerulosclerosis, mild hypertension and reduced renal blood 
flow are well known in the MWF's, reduced GFR as often seen in cardiorenal patients was 
not present in the MWF. Finally, the first indication for exaggerated cardiac dysfunction came 
from echocardiographical measurements only performed in a subgroup of rats, which clearly 
hampers proper statistical analysis . 
Conclusion 
In conclusion, experimental Ml did not exaggerate renal dysfunction in the proteinuric MWF 
rat However; cardiac dysfunction was exaggerated by this primary renal dysfunction. The 
accelerated cardiac dysfunction could be characterized by elevated left ventricular preload, as 
well as pulmonary congestion, right ventricular overload and right ventricular hypertrophy.This 
animal model may provide an important step to understand the complex clinical condition of 
cardiorenal disease . Finally the study provides evidence that vascular endothelial dysfunction 
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Abstract 
Introduction. Myocardial perfusion gating techn iques offer possib i l ity of measurement of left 
ventricular end systol ic (ESV) and end diastol ic volume (EDV) and left ventricular ejection 
fraction (LVEF) in cl in ical and pre-clin ical trials. The aim of this study was to evaluate left 
ventricular volumes (LVV) and LVEF with 1 3N-N H3 in comparison with the reference 1 8F-FDG 
in different rat models. 
Methods: I n  th is study 1 8  male Wistar rats, 1 2  control rats and 6 rats with myocardial i nfarction 
(Ml) were imaged with micro-PET. The rats were scanned with gated 1 3N-NH3 and 1 8F-FDG 
sequentially for the assessment of LW and LVEF A val idated 3-dimensional segmentation 
algorithm was used to calculate LW and LVEF. 
Results: Mean LVEF measured with 1 3N-NH3 was 45 .6±8.9 and 75.3±9.4%, mean ESV was 
0.40±0. 1 2  and 0. 1 4±0. 1 I ml and mean EDV was 0.53± 1 6  and 0.75±0. 1 8  ml for Ml and 
control rats respectively. Moderate to good correlations were observed between values of 
1 3N-NH3 and 1 8F-FDG for calculation of ESV (r = 0.80, P<0.000 I ,  SEE = 0. 1 0), EDV (r = 0.63, 
P=0.005, SEE = 0. 1 4) and LVEF (r =0.84, P<0.000 I ,  SEE = 9.5) . LVEF  measured with 1 3N-NH3 
was significantly lower in Ml rats in comparison to measurement with 1 8F-FDG (45 .6 ± 8.9 vs 
54.9 ± 9 .3 %; p = 0.04). 
Conclusion: Correlations were moderate to good for the assessment of ESV, EDV and LVEF 
between gated 1 3N-NH3 and 1 8F-FDG. LVEF was underestimated with gated 1 3N-NH3 i n  rats 
with myocardial infarction. I n  healthy rats LV volumes and LVEF can be measured reproducible 
with both approaches. 
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Introduction 
Animal models are widely used in  studies on heart d isease and novel treatment therapies. 
However; the poss ibi l ities of non-invasive assessment of cardiac function in small an imals is sti l l  
l imrted. Positron emission tomography (PIT) has been proven to b e  a n  useful and accurate 
tool for detection of stunning, ischemia and for measuring perfusion [ I ] . I n  add ition, PET can 
be used to visual ize cardiac perfusion and metabolism and the calculation of left ventricular 
volumes (LW) and ejection fraction (LVEF) by the appl ication of cardiac gating techn iques and 
specific PET tracers [2,3] . A combined measurement of d ifferent parameters is a powerful 
way to monitor card iac function and perfusion in a non-invasive way. This may be helpful to 
evaluate the effectiveness of various treatment strategies in small animal models of cardiac 
dysfunction. Previously, these measurements had to be made sequentially with use of d ifferent 
tracers, characterized by their own specific properties. PET measurements performed with 
1 3 N-NH3 are currently predominantly used as an accurate non-invasive diagnostic techn ique 
for quantification of myocard ial perfusion in the cl inical setting [ 4]. Simultaneous measurement 
of myocardial perfusion, LW and LVEF wrth 1 3N-NH3 using a combination of dynamic and 
ECG-gated acquisrtion protocols has been reported earlier in human studies, but not in animal 
studies [5,6]. Even though cl inical results are very promising, cardiac nuclear imaging i n  smal l 
animals remains chal lenging due to the small size of the animal and consequent smal l heart 
volume. 
1 8F-FDG has proven itself to be a rel iable tracer for the assessment of LW and LVEF  and 
myocard ial viabi l ity, in rats as wel l  as in humans [ 1 ,2,5,7] and is therefore the preferred method 
for these measurements. However a gated 1 3 N-NH3 PET measurement in small animals has not 
been evaluated so far.The aim of this study was to evaluate gated 1 3N-NH3 for the assessment 
and reproducib i l ity of LW and LVEF measurements in rats in comparison with the reference 
method gated 1 8F-FDG PET using micro-PET. 
Materials and methods 
Animals 
The study was performed in 1 8  male Wistar rats (Harlan, The Netherlands). Animals were 
housed in groups under standard conditions at 1 2h l ight/dark cycle until they reached 1 2  
weeks of age. Al l  animals received standard diet and water ad l ibrtum during the study. At 1 2  
weeks of age rats were subjected to myocard ial infarction (Ml) (n = 6) by coronary artery 
l igation as described before [8]. Twelve controls were included. Approximately I I weeks after 
Ml surgery, the rats were subjected to m icro-PIT scanning (PIT) to study LV volumes and 
LVEF.The rats were scanned using the radiotracers 1 3N-NH3 and 
1 8F-FDG sequential ly within 
a s ingle anaesthetic period. Wrthin two weeks PET studies were repeated in 9 control rats to 
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study reproducibility of the measurements. 
Myocardial infarction size was evaluated in the paraffin sections stained with Sirius Red/ Fast 
Green and expressed as the mean of the inner and outer percentage of scar tissue to the 
inner and outer circumference of the left ventricle. All animal experiments were performed by 
licensed i nvestigators in compliance with the Law on Animal Experiments ofThe Netherlands. 
The protocol was approved by the Committee on Animal Ethics of the University of Groningen. 
Data Acquisition 
All rats were scanned while under 1.5% isoflurane anaesthesia and maintained in a fixed supine 
position. A heating pad was used to maintain a constant body temperature. PET tracers were 
intravenously injected into the penile vein. 1 3N-NH
3 
was injected first, followed by 1 8F-FDG 
with a time interval of 4 5  minutes.The radiotracers were administered as a 0.4 - 0. 6 ml bolus, 
with an average dose of 4 8.8 ± 13 .8 MBq for 1 3N-NH
3 
and 5 1.0 ± 13 .0 MBq for 1 8F-FDG.The 
camera ( micro-PET Focus 2 2 0; Siemens/Concorde) was started simultaneously with injection 
of 1 3N-NH
3
.To enable the subtraction of residual background activity from the 1 3N-NH3 study, 
the 1 8F-FDG acquisition protocol was started 5 minutes before the actual 1 8F-FDG injection. 
The interval between the start of the 1 3N-N H3 and 
1 8F-FDG acquisition was I hour. A separate 
transmission scan was acquired for attenuation correction. Different list-mode protocols 
were used. A  2 0  minutes list-mode acquisition protocol was used for 1 3N-N H
3 
imaging and a 
9 5  minutes list-mode acquisition protocol was used for 1 8F-F DG imaging. During the whole 
protocol cardiac excitation was recorded and stored using the BioVet system. Three ECG 
electrode leads were placed on both for-legs and left hind-leg. 
Data Processing 
PET data was reframed into a gated sequence of 8 bins.The data were reconstructed per bin 
using an iterative reconstruction algorithm (4 iterations, 16 subsets, 2 -dimensional ordered­
subsets expectation maximization). Datasets were fully corrected for random coincidences 
and scatter. Images were processed using software programmed in MATLAB and in C 
programming language to obtain end-systol ic volume (ESV), end-diastolic volume (EDV) and 
LVEF values. F irst re-angulation of the original PET images was performed resulting in typical 
vertical- and horizontal long axis and short axis views. A validated 3 -dimensional segmentation 
algorithm was then used to identify the endocardial contours to calculate LV volumes [I] .  
Examples of re-angulated 1 3N-NH3 and 
1 8F-F DG images obtained from a control and a Ml  
animal are shown in  figure I . 
Statistical analysis 
Analyses were performed using standard statistical software (GraphPad Prism, Excel). ESV, EDV 
and LVEF values as measured with micro-PET are shown as mean ± SD. A paired two-sided 
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Student t test was used to compare results obtained from the two radiotracers. Correlations 
between 1 8F-FDG and 1 3N-NH3 were performed using Pearson correlation coefficients. 
Agreement between 1 8F-FDG and 1 3N-NH3 values was evaluated using Bland-Altman analyses 
[9]. 
The validity of 1 3N-NH3 LV function measurements was analysed by determining precision, 
accuracy and bias.The limits of agreement were set at ± 2 SD. 
Results 
There were no significant differences in body weight (364 ± 94 vs. 423 ± 72 g for control and 
Ml rats respectively) or heart rates (354 ± 22 vs. 349 ± 49 beats per minute for control and Ml 
rats respectively) during PET imaging between groups. Mean M l  size in M l  group was 37 ± 1 2%. 
Good reproducibil ity was observed for ESV, EDV and LVEF when control rats were scanned 
on different days for gated 1 3N-NH3 as well as 
1 8F-FDG PET (table I ) . 
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Table I. Reproducibility of LV volumes and LVEF measurements with gated ' 3N-NH 3 and 
1 8F-FDG micro-PET 
test re-test SAD p 
II 
t3N-NH3 
ESV (ml) 0. 1 2  ± 0.05 0. 1 1  ± 0,03 0.2 1 0.94 
EDV (ml) 0.47 ± 0.07 0.49 ± 0. 1 2  0.59 0.32 
lVEF (%) 75.4 ± 7.8 78.8 ± 6.0 4 1  0.29 
18F-FDG 
ESV (ml) 0.07 ± 0.02 0.08 ± 0.03 0. 1 2  0.32 
EDV (ml) 0.4 1 ± 0.09 0.39 ± 0.22 0.48 0.74 
LVEF (%) 8 1 .5 ± 3.5 75. 1 ± 5. 1 45 0.24 








The mean values of LW and LVEF are presented in table 2.There were no significant differences 
observed between values obtained with gated 1 3N-NH3 and 
1 8F-FDG PET in the control group, 
or in the group as a whole for ESV, EDV or LVEF. Both the control and the Ml group showed 
a lower LVEF when compared to 1 8F-FDG. This difference was significant in the Ml group (P = 
0.04). EDV and ESV values were higher; but not significantly, in both groups when compared 
with 1 8F-FDG measurements. When comparing the values obtained with different tracers, 
significant correlations were observed between values of gated 1 3N-NH3 and 
1 8F-FDG PET for 
ESV (r = 0.80, SEE = 0. 10 ,  P < 0.000 I ), EDV (r = 0.63, SEE = 0. 1 4  , P = 0.0048) and LVEF (r 
= 0.84, SEE = 9.5, P < 0.000 I )  (figure 2). 
The agreement analysis between measurements is presented in figure 3. Small mean differences 
of 0.04 ml for and 3% for LVEF (95% confidence intervals -0.3 1 - 0.23 ml for LW and - 15 - 2 1  
% for LVEF) were found (table 3). Both mean values of ESV and EDV were higher with when 
measured with 1 3N-NH3 in comparison to 
1 8F-FDG PET, whereas mean LVEF was lower when 
obtained from 1 3N-NH3 images.When determining the strength of the relation we found that 
it was moderate to good for EDV (r = 0.63) , ESV (r = 0.80) and LVEF (r = 0.84) . Agreement 
proportions of 67 % were achieved within 0. 1 ml for ESV, 83% within 0.2 ml for EDV and 72% 
within I 0% for LVEF. 
Discussion 
In this study we showed that LV function measurements (ESV, EDV and LVEF) can be obtained 
with gated 1 3N-NH3 micro-PET images in rats, both healthy and rats with an induced myocardial 
infarction. In the total group of rats a moderate agreement for ESV and EDV and good 
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Table 2. Overview of LV volumes and LVEF obtained with gated 13N-NH
3 
and 18F-FDG micro-PET. 





Control 0. 1 4± 0. 1 1  0. 1 2  ± 0.Q7 0.45 1 2  
Ml 0.40 ± 0. 1 2  0.32 ± 0. 1 4  0. 1 7  6 
Total 0.23 ± 0. 1 7  0. 1 9  ± 0. 1 4  0. 1 2  1 8  
EDV (ml) 
Control 0.53 ± 0. 1 6  0.49 ± 0. 1 6  0.38 1 2  
Ml 0.75 ± 0. 1 8  0.70 ± 0.24 0.58 6 
Total 0.60 ± 0. 1 9  0.56 ± 0.2 1 0.28 1 8  
lVEF (%) 
Control 75.3 ± 9.4 74.9 ± 1 0.2 0.88 1 2  
Ml 45.6 ± 8.9 54.9 ± 9.3 0.04 6 
Total 65.4 ± 1 7.0 68.3 ± 1 3.7 0.20 1 8  
ESV: end-systolic volume; EDV: end-diastolic volume; LVEF: left. ventricular ejection fraction 
agreement for LVEF was observed when comparing the two gated-based imaging methods. 
Both ESV and EDV obtained from 1 3N-NH3 images were sl ightly h igher, but not significant as 
compared to 1 8F-FDG-derived values. There was an underestimation of LVEF with I 3N-NH3 
when compared to I 8F-FDG observed, which was significant, in the Ml group. 
Direct comparison of gated 1 8F-FDG with 1 3N-NH3 has not been studied before i n  a small 
an imal model. The effect of the algorithm used on I 3N-NH3 derived images to calculate 
EDV, ESV and LVEF and the d ifferences in properties of the tracers itself may resutt i n  small 
d ifferences of parameters estimation. Analysis of gated PET images was performed with a 
previously validated 3-dimensional segmentation algorithm for identification of endocardial 
contours, enabling calculation of LV-volume [ I ]. This software program was val idated in mice 
that underwent I 8F-FDG in comparison with the reference method M RI, assigned as the most 
optimal reference method.This val idated software program was therefore used in the current 
rat study. The underestimation of LVEF by gated 1 3N-NH3 could be caused by partial volume 
effect and moderate uptake (count rate) of 1 3N-NH3 compared with 
1 8F-FDG.The I 3N positron 
has a longer range ( 1 .4 mm) compared with the 1 8F positron ( I mm).Another possible influence 
was the interval of one hour between 1 8F-FDG and 1 3N-NH3 acquisition. Anaesthetics could 
also have influenced the results, due to difference in heart rate variabi l ity [ I OJ. Rats with a 
myocardial infarction showed a lower LVEF, due to a h igher ESV. Contour detection may be 
d ifficult in myocardial regions without perfusion.The contour may be drawn to widely.This wil l  
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Figure 2. Correlations between ESV (A), EDV (B) and LVEF (C) determined with gated 1 3N-NH
3 
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Table 3. Predictive performance of13N-NH
3 
for LV volumes and LVEF measurements. 
PrecisiOn Ac-curacr Bias 
- - - -- --
MeaA Min/Max R Mean ± 2 S@ 
"" ' 
ESV (ml) 0.05 0. 1 
1 8F-FDG 0. 1 9  ± 0. 1 4  0.05 - 0.57 
13N-NH3 0.23± 0. 1 7  0.06 - 0.58 0.80 50 67 -0.04 -0.23/0. 1 6  
EDV (ml) 0. 1 0.2 
1 8F-FDG 0.56 ± 0.2 1 0. 1 2 - 0.98 
1 3N-NH3 0.60 ± 0. 1 9  0.36 - 1 .04 0.63 44 83 -0.04 -0.38/0.29 
LVEF (%) 5 1 0  
1 8F-FDG 68.3 ± 1 3.7 42.0 - 86.8 
1 3N-NH3 65.4 ± 1 7.0 36.8 - 85.5 0.84 so 72 3 - 1 5/2 1 
* Percentage within specified range of gated 18F-FDG 
result in h igher ESV Dedicated software programs wi l l  be needed to estimate the contour of 
regions with absent perfusion in the myocard ial wal l .  Even though 1 3N-NH
3 
images rendered 
a lower LVEF and h igher ESV and EDV, 1 3N-N H
3 
enables determination of ESV, EDV and LVEF 
with a satisfying accuracy when l imits of agreement were set at 0. I ml (ESV) 0.2 ml (EDV) 
and I 0% (LVEF) . These l imits of agreement were identified after evaluation of intra-ind ividual 
d ifferences in  9 control animals. 
Previous studies in  humans with gated 1 3N-N H
3 
for the measurement LV function showed also 
higher values for EDV and ESV when compared to their reference method [5,6]. Khorsand et. 
al., found excel lent agreement between values obtained with 1 8F-FDG and 1 3N-NH
3 
in patients 
with coronary artery d isease (CAD) However, they did not include healthy controls i n  their 
study [SJ . 
Evaluation of LV function and volumes provide important prognostic information in CAD 
[ 4, I I ] . Combined measurement of cardiac function and perfusion in tomographic imaging 
wi l l  be a powerful  method to monitor in a non invasively way the progress of the underlying 
disease and effect of treatments. In c l in ical practice, 1 3N-NH
3 
is an established method for 
the quantitative imaging of myocard ial blood flow at rest and during pharmacologic stress to 
measure coronary flow reserve for the evaluation the significance of CAD[ 4, 1 2] as wel l  as for 
the detection of microvascular disease [ 1 3] .  
1 8F-FDG has been proven to be a reliable tracer for the quantification of LV-function [ 1 ,2, 1 4, 1 5] 
and was therefore used as the reference method in this study. 1 8F-FDG derived values for 
EDV, ESV and LVEF were compared with values derived from the golden standard M RI and 





volumes compared to FOG imaging however; which suggests that there is considerably more 
overestimation of volumes by NH3 compared to MRI ,  as was evaluated in our previous study 
[ I ] .  
Small-animal PET scanners are becoming increasingly popular tools for biomedical research. 
The ability to sequentia l ly monitor the same animal over time, assess biochemical processes 
in vivo, and demonstrate the effect of a new drug or the expression of membrane receptors 
[ 1 7] has brought the once-limited field of micro-PET and micro-SPECT [ 1 8] to the forefront 
of molecular medicine imaging. Our results indicate that micro-PET can be used to assess the 
function and geometry of left ventricle in both healthy rats and rats after myocardial infarction, 
which could possible lead to better monitoring of the progression of heart failure and the 
efficacy of multiple treatment strategies. 
Study limitations 
To mimic the clinical environment rats with and without myocardial infarctions were used to 
obtain functional values over a wide range. A potential pitfall in this setting is the delineation of 
the LV contours extended infarcted myocardial areas, which is more difficult and may lead to 
incorrect estimation of the LV volumes. Our program was able to estimate the contour of the 
LV properly in infarcted rats and systematic errors were reduced this way. 
Conclusion 
ECG-gated 1 3N-NH3 micro-PET correlates with gated 
1 8F-FDG for the assessment of LW and 
LVEF in rats. Whereas LV volumes and LVEF in healthy rats can be measured reproducible 
with both approaches, LVEF in Ml model was slightly underestimated with gated 1 3N-NH
3 
micro-PET.The small systematic bias and the limits of agreement are reasonable small enough 
to justify the conclusion that these methods can be used interchangeably. Dynamic ECG-gated 
1 3N-NH3 PET may provide a novel non-invasive method to monitor parameters of cardiac 
function over time in healthy and heart failure animal models. 
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Purpose. Card iac dysfunction leads to decreased organ perfusion. We aimed to measure 
cardiac and renal perfusion simultaneously with the use of 1 3N-NH
3 
micro-PIT in different 
rat models. 
Procedures. Ten male Wistar rats underwent sham surgery (n=S) or coronary artery l igation 
to induce myocardial infarction (Ml, n=S). Eleven weeks later 1 3N-NH
3 
micro-PET scan was 
performed to study the card iac and renal perfusion. 
Results. Card iac perfusion was sign ificantly reduced in Ml group and correlated with ejection 
fraction and Ml size (r=0.89; p<0.00 I and r=-0.86; p<0.00 I respectively). Renal perfusion 
showed a notional 1 7% reduction in Ml group when compared to sham (3 .44 ± 0.40 vs 4. 1 2  ± 
0.48 ml/g/min resp.; NS) .There was a trend towards greater reduction of perfusion in cortical 
than medul lar region. Cortex perfusion was negatively correlated with histological changes. 
Conclusion. 1 3N-NH3 micro-PIT may be a potential tool for evaluation of card iac and renal 
functional and perfusion changes in presence of card iac dysfunction in rat models. 
1 00 
Imaging of cardiac and renal perfusion with nN-NH3 micro-PET 
Introduction 
Renal dysfunction is one of the most common co-morbidities in heart failure (HF) population. 
The co-existence of these entities results in worse prognosis [ I ] . These observations revived 
interest in the pathophysiological interrelationship between heart and kidney. Although the 
exact mechanisms remain unclear; there are multiple factors known that play a role in this 
interaction [2]. One of the pivotal mechanisms underlying this inter-organ relationship  are the 
hemodynamic changes - reduced cardiac output leading to reduced renal blood f low (RBF). 
Reduced RBF has been shown to be the main determinant of renal function [3], which is a 
strong prognostic factor in H F  population [ I ]. Not only is the total renal perfusion reduced in 
the presence of cardiac dysfunction, but also the differences in regional cortical and medullar 
blood f low have been observed [ 4]. Moreover; different mechanisms underlie the regulation of 
blood flow in cortical and medullar regions [5] .  As a result, many vasoactive regulatory factors 
yield different effects on cortical and medullar blood flow. Since many of these factors, such as 
noradrenaline, angiotensin 1 1 ,  nitric oxide, are known to play role in cardiorenal syndrome and 
are being targeted by common treatment strategies, studies on regional renal perfusion in the 
presence of cardiac dysfunction might help understand better the pathophysiology behind this 
syndrome and improve the treatment strategies.Therefore a noninvasive, preclinical method for 
the evaluation of cardiac and renal kidney perfusion is needed. Positron emission tomography 
(PET) offers a promising, quantitative and minimally invasive alternative for measurements of 
organ perfusion. PET scans with 1 3N-NH3 have been used to evaluate cardiac perfusion [6, 7] as 
well as renal perfusion in humans [8] and big mammals [9, I OJ. Since most of the experimental 
research on cardiorenal interaction is performed in rodents [ I I ], we aimed to use the 1 3 N-NH3 
micro-PET to investigate the cardiac and renal perfusion in a healthy rat and in a rat model 
based on myocardial i nfarction. 
Materials and methods 
Animals 
The study was performed in I O  male Wistar rats (Harlan, The Netherlands). Animals were 
housed in groups under standard conditions at 1 2h light/dark cycle until they reached 1 2  weeks 
of age. All animals received standard diet and water ad libitum during the study. At 1 2  weeks 
of age rats were subjected to myocardial infarction (Ml) (n=S) by coronary artery ligation or 
sham surgery (n=S) as described before [ 1 2]. Approximately I I weeks after the surgery, the 
rats were subjected to micro-PET scann ing. One week after the PET scanning, the animals 
were sacrificed and heart and kidney tissue has been collected for further histological analysis. 
All animal experiments were performed by licensed investigators in compliance with the Law 
on Animal Experiments ofThe Netherlands.The protocol was approved by the Committee on 
I O I  
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Animal Ethics of the University of Groningen. 
Echocardiography 
Echocardiographical measurements were obtained with the use of a Vivid 7 (GE Healthcare) 
equipped with a I 0-MHz transducer. Under isoflurane anaesthesia rats were placed on a 
heating pad to maintain body temperature.The ejection fraction (EF) was calculated using the 
Teichholz method from the short axis images obtained at mid-papillary level.The measurement 
have been performed on 5 consecutive heart beats and presented as the mean of these values 
to avoid beat-to-beat variation. 
Micro-PET data Acquisition 
All rats were scanned while under 1 .5% isoflurane anaesthesia and maintained in a fixed supine 
position. A heating pad was used to maintain a constant body temperature. 1 3 N-ammonia 
( ' 3N-NH3) was injected intravenously into the penile vein .The radiotracer was admin istered as 
a 0.4 - 0.6 ml bolus, with an average dose of 55 ,2 ± 5,0 MBq.The camera (micro-PET Focus 
220; Siemens/Concorde, TN, USA) was started simultaneously with injection of the tracer. 
Thereafter; a microCT scan was performed using a microCAT II system (Siemens Preclin ical 
Solutions, Knoxville .TN, USA) using the same fixed bed with maintained stereotactic position. 
M icro-PET images were corrected for scatter and reconstructed applying an interactive 
reconstruction algorithm (OSEM 2D). 
Micro-PET data processing 
A I O  minutes list-mode acquisition protocol was used for 1 3N-NH3 imaging. PET data was 
reconstructed into 22 frames with a total of I O  min ( I 2x5sec, 8x30sec, 2x 1 50sec). Blood 
flow maps were analyzed manually by ROI analysis using lnveon Research Workplace software 
(Siemens; USA).The ROls for cardiac perfusion evaluation were drawn on images in transverse 
plane on all images were heart was visible and i ncluded also infarcted areas (figure I ).The ROls 
for renal perfusion evaluation were drawn on each kidney on 5 consecutive slides in coronal 
plane representing the middle section of the kidney. Firstly, the first IO frames (5-60 seconds) 
were summed and the ROI for cortex region has been drawn ( excluding the medulla and 
col lecting system; figure 2A) . Subsequently all frames were summed and the ROI for medullary 
region has been drawn ( excluding col lecting system and previously drawn cortical region, 
figure 2B) . Finally, ROls were pooled to assess the mean RBF. Due to the partial tissue trapping 
of 1 3N-NH3, a two-compartment kinetic model has been used as described before [ I  OJ. The 
arterial input function was determined from a ROI placed in the left ventricle of the heart. 
All scans have been analysed by two independent researchers blinded for the groups. The 
mean values of these analyses are reported. 
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Histology 
After collection kidneys were longitudinal bisected, fixed in formaldehyde solution and 
subsequently embedded in paraffin. Sections of 4 µm were stained with periodic acid Schiff 
(PAS) and scored on presence and degree of focal glomerular sclerosis as described before. 
FGS score was expressed in arbitrary units (AU) as described before [ 1 3]. The sections were 
evaluated by the examiner who was blinded for the groups. 
The heart was dissected, cooled in ice-cold saline for diastolic arrest.A midventricular s l ice was 
embedded in paraffin and subsequently stained with Sirius Red/ Fast Green. The infarct size 
was expressed as the mean of the inner and outer percentage of scar tissue to the inner and 
outer circumference of the left ventricle as described before [ 14]. 
Figure I. Analysis of cardiac perfusion. A: sham group; B: Ml group 
Figure 2. Analysis of regional renal blood �ow. The placement of ROls for perfusion analysis. A: selection of 




All data is presented as mean ± SEM.A Mann-Whitney U test was used to compare the results 
between the groups. Differences were considered significant at the level of 0.05. 
All analyses were performed with the use of PASW software version 1 8. 
Results 
At the moment of termination, mean body weight was simi lar in both groups (458 ± 1 9  vs. 
459 ± 20 g for Ml and sham group respectively). The mean LVEF was 55.8 ± 4. 1 % and 77.8 
± 1 .0% for Ml and sham respectively (p = 0.008). The mean infarct size was 32 ± 8 % in the 
Ml group (p=0.008 vs. sham) .There was a strong correlation between LVEF and Ml size in the 
whole study group (r = -0.89; p<0.00 I ) . 
Cardiac perfusion measured with 1 3N-NH3 micro-PET was significantly reduced in Ml group 
in comparison with the sham group (6.32 ±0.96 vs. 1 1 .55±0.6 1 respectively) . There was 
significant correlation between perfusion obtained with micro-PET scan and both LVEF (r = 
0.89; p < 0.00 I )  and Ml size (r = -0.86; p < 0.00 I ) . 
Renal global and regional perfusion measurements with 1 3N-NH3 micro-PET showed no 
statistically significant differences between the left and right kidney in any of the groups (table I ) . 
Mean renal perfusion was decreased by 1 7% in Ml group in comparison to sham, however the 
difference was not significant (p=0.42). Similar pattern has been seen with regard to regional 
perfusion - both cortex and medulla perfusion values were lower in Ml group, however not 
significantly. When compared to values obtained from the sham group, the reduction of the 
regional perfusion in Ml group seemed to be greater in cortex than in medulla (22% vs. 9% 
respectively), resulting in increased ratio between medul la and cortex perfusion (0.68 ± 0.04 
vs. 0.57 ± 0.05), however this increase did not reach statistical significance. There was no 
significant correlation between this ratio and any of the cardiac parameters. 
The mean renal perfusion showed positive correlation with cardiac perfusion (r = 0.65; p = 
0.042) (figure 3A), but not with LVEF. There was significant correlation between cortical and 
cardiac perfusion (r = 0.73; p = 0.0 1 6) (figure 3B) and a trend towards correlation with LVEF 
(r = 0.62; p = 0.058) and M l  size (r = -0.60; p = 0.070).There were no significant correlations 
or trends found for medullar perfusion with any of the cardiac parameters. The histological 
analysis showed increased focal glomerulosclerosis in Ml group (5.4 ± 1 .6 AU vs 1 .0 ± 0.4 AU 
for Ml and sham, respectively; p = 0.0 1 6) (figure 4).There was a negative correlation between 
FGS and both total renal and cortical perfusion (r = -0.67, p = 0.035; r = -0.66, p = 0.036 resp.) 
(figure 3C and 3D) .  
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Table I. Regional and total kidney perfusion measurements. Data expressed in m/lg/min and presented as 
mean ± SEM. 
Ml group (n=S) Sham group (n=S) 
Total kidney perfusion - mean 3.44 ± 0.40 4.1 2 ± 0.48 
Left kidney 3.4 1 ± 0.42 4.06 ± 0.5 1 
Right kidney 3.46 ± 0.39 4.1 7 ± 0.46 
Right/left kidney ratio 1 .02 ±0.02 I .OS ± 0.06 
Cortex perfusion - mean 3.85 ± 0.37 4.92 ± 0.59 
Left cortex 3.80 ± 0.39 4.88 ± 0.63 
Right cortex 3.89 ± 0.36 4.97 ± 0.57 
Right/left cortex ratio 1 .03 ± 0.03 1 .03 ± 0.06 
Total medulla perfusion - mean 2.65 ± 0.36 2.90± 0.52 
Left medulla 2.64 ± 0.35 2.98 ± 0.58 
Right medulla 2.66 ± 0.38 2.82 ± 0.47 
Right/left medulla ratio 1 .00 ± 0.03 1 .00 ± 0.09 
Discussion 
In the present study, we used 1 3N-NH3 micro-PET to evaluate the cardiac and renal perfusion 
in healthy rats and rats with myocardial infarction. We showed that experimental cardiac 
dysfunction leads to reduced cardiac perfusion and we found a trend towards reduction in 
renal perfusion. The latter reduction seemed to be higher in the cortical than medullar region 
of the kidney. Cardiac perfusion was significantly correlated with renal and cortical, but not with 
medullar perfusion. Interestingly, there was a negative correlation between cortical perfusion 
and the severity of histological changes in this region. 
Myocardial infarction leads often to reduction in cardiac function and subsequently reduced 
peripheral organ perfusion. In our study, experimental Ml led to decrease in cardiac perfusion. 
Measured cardiac perfusion was strongly correlated with infarct size and LVEF. There was a 
trend towards lowering of renal perfusion in animals with experimentally induced cardiac 
dysfunction; however the difference did not meet the statistical significance. The lack of 
significance might have resulted from small experimental groups and some variation in the 
induced infarct size - it has been shown that smal l infarcts do not lead to substantial reduction 
in cardiac function and cardiac output therefore the renal perfusion might not be significantly 
affected. 
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Figure 3. Correlations between total renal and cardiac perfusion (A), cortical and cardiac perfusion (B); total 
renal perfusion and focal glomerulosderosis (C); cortical perfusion and focal glomerulosc/erosis (D).AU; arbitrary 
units. 
Figure 4. The representative photographs of cortex region. A: sham group; B: Ml group; white arrow indicating 
normal glomeruli, black arrow - sclerotic glomeruli. 
1 06 
Imaging of cardiac and renal perfusion with ' 3N-NH3 micro-PIT 
has also been shown, that the cortical blood flow is markedly diminished, whereas medul lary 
blood flow appears to be preserved [ 4]. We were able to show this trend in present analysis. 
Although the differences were not significant, the cortical blood flow was reduced by 22% in 
comparison to 9% reduction in  medul lar perfusion. Significant correlation between cardiac 
and cortical but not medul lar perfusion found in our study supports the observations of 
d ifferent regulation mechanisms of regional renal blood flow [5] .  Whereas in the medullar 
region vasodilation occurs to preserve the blood flow [ 1 5], the activated ren in-angiotensin­
system leads to vasoconstriction in the cortical region[ 1 6] . Increased angiotensin I I  levels lead to 
glomerular hyperperfusion and i ncreased fi ltration fraction and preservation of kidney function. 
However; on long term angiotensin I I  causes glomerular matrix accumulation and progression of 
glomerulosclerosis. Activation of regulatory systems and preferential vasoconstriction of renal 
cortical vessels may also contribute to the i ncreased sodium and retention and subsequently 
increased venous pressures and edema formation[ 1 6] .  This leads to higher pressures in the 
kidney and hypoxia, which may cause further histological changes and decrease of kidney 
function [ 1 7]. In the present study we showed increased glomerulosclerosis in Ml group and a 
significant correlation between severity of glomerulosclerosis and cortical perfusion. Again, th is 
correlation was not found for the medul lar perfusion which provides additional evidence for 
d ifferent regulatory mechanisms. 
In  the present study, we used the 1 3N-NH
3 
micro-PET for cardiac and renal perfusion 
measurement in  rats. The advantage of this approach is the possibi l ity of simultaneous 
measurement of perfusion of two organs. Recently, we have shown that ECG-gated 1 3N-NH
3 
micro-PET can be also used for estimation of cardiac volumes and function, which extends the 
possibi l ities of this method [ I 8]. PET imaging furthermore al lows repetitive imaging due to its 
non-invasive character: Whereas cardiac perfusion measurements have been described before 
in l iterature [6, 7], regional renal perfusion measurements remain sti l l  chal lenging. There have 
been d iscrepancies reported between various methods [ 1 9] and even the measurements with 
radioactive microspheres have been shown to have its l imitations in RBF determination [ 1 9]. 
The technique we used might offer a promising, quantitative and minimal ly invasive alternative 
for measurements of regional RBF [20]. 
The accuracy of the RBF measurements with the use of PET depends on the tracer: We used 
the protocol with 1 3N-NH
3, which has been described before and val idated by comparison 
to microspheres study [ I OJ. Renal retention of 1 3N and its relative long half- l ife compared 
with i so-water al lows extended image acquisition periods. Also the shorter range of the 1 3N 
positron compared with iso-water is attractive.This leads to better quality of acquired images. 
Because of the tracer kinetics, this method requires a two-compartment model. Since 1 3N-NH
3 
is rapidly metabolized, it has been argued that the values of arterial input should be corrected 
for 1 3N-metabol ites in blood. Analysis by Chen showed that there is only l ittle contamination, 
which leads to l imited underestimation of the results and therefore the correction is not 
necessary [ I OJ. 
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Due of the complicated structure of the kidney, systematic errors due to finite spatial resolution 
and partial-volume effects might occur. This might lead to underestimation of cortical flow and 
thus the ability to show subtle differences in regional blood flow might be limited. It cannot 
be also excluded that with in the cortical ROls an unknown part of medullar region has been 
included and vice-versa.Although the maximal size of ROls did correspond with the size of the 
cortex region found in histological studies and the PET flow maps provided relatively sharp 
boundaries of cortical region, the accuracy of the ROls location should be i nterpreted with 
some caution.  
Our study is limited by the small size of experimental groups. There was some variation in 
infarct size between animals in Ml group, which in some animals might have resulted only in  
a slight reduction of cardiac function and therefore l imited effects on renal perfusion. We did 
not perform the simultaneous microsphere blood flow measurements to compare the results; 
however the used protocol has been described and val idated in literature before. 
Conclusion 
M icro-PET with the use of 1 3N-NH3 might serve as an useful non-invasive tool for measurement 
of cardiac and regional renal perfusion in small animal models. The possibility to evaluate 
regional renal perfusion in rodents might help to understand the changes occurring in kidney 
in the presence of cardiac dysfunction.The use of 1 3N-NH3 allows simultaneous assessment of 
cardiac and renal perfusion in rodents. This all may contribute to better understanding of the 
cardiorenal syndrome. 
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Abstract 
Background. The renin-angiotensin-aldosterone system (RAAS) plays a key role in the 
progression of heart failure (HF) and concomitant kidney dysfunction. Despite the use of RAAS 
blockade, sustained activation of RAAS has been suggested to link with adverse outcome.We 
aimed to investigate the prognostic value of active plasma renin concentration (APRC) and 
prorenin in patients with HF treated with RAAS-blocking agents and its relationship with 
kidney function parameters. 
Methods. One hundred clinically stable patients with HF, treated with RAAS-blocking agents, 
were studied. Renal function parameters including effective renal plasma flow and glomerular 
filtration rate were measured invasively. The combined end point consisted of all-cause 
mortality, heart transplantation, and admission to hospital for HF. 
Results. Mean age was 5 8  ± 1 2  years, and 7 6% were men. Mean left ventricular ejection 
fraction was 2 8  ± 9, and median APRC levels were 2 4 .3  ng/ml per hour. Active plasma renin 
concentration was most strongly associated with mean arterial pressure (r = 0.60, P <0.00 I ). In 
multivariate linear regression analysis, age, mean arterial pressure, angiotensin II concentration, 
and use of aldosterone antagonists were significantly related with APRC (adjusted R2=0.5 3). 
Patients in the highest quartile of APRC had a worse prognosis. In multivariate analysis, APRC 
remained associated with worse prognosis: HR 2 .87 (95% Cl 1. 1 4 -7.2 0), P = 0.02 5 .  Prorenin 
did not show prognostic value.The prognostic value of APRC was strongest in patients with 
decreased kidney function. 
Conclusions. Our data indicate that APRC is a strong prognostic factor in patients with HF in 
the presence of RAAS inhibition, especially in patients with kidney dysfunction. 
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Introduction 
Heart failure (HF) is a complex syndrome associated with substantial mortality [ I ]. Decreased 
perfusion activates multiple compensatory mechanisms, of which the renin-angiotensin­
aldosterone system (RAAS) is widely acknowledged to be of special importance [2].Activation 
of the RAAS cascade leads to increased blood pressure and water and salt retention, which 
upholds perfusion. Although initially aimed to preserve cardiovascular homeostasis, long-term 
activation of the RAAS eventually has an adverse effect on cardiac structure and function 
leading to progressive remodeling and ultimately worsening HF. 
Many patients with H F  have compromised kidney function, which is associated with a worse 
prognosis [3,4]. Decrease in cardiac output and/or increased venous pressure in H F  result in 
decreased renal blood flow, which has been shown to be the most important determinant 
of renal function in patients with HF [5,6]. Present therapies of H F  cannot fully prevent the 
development of progressive HF and further deterioration of the renal function. Strategies 
to block the RAAS, for instance with ACE inhibitors (ACEi), angiotensin II receptor blockers 
(ARBs), and aldosterone receptor antagonists (ARAs) , have been proven to reduce H F  
centered morbidity and mortality [7- 1 OJ. However, as a result o f  lack o f  negative feedback, 
RAAS-blocking agents increase plasma renin concentration and plasma renin activity (PRA). 
Although initially deemed unharmful, sustained increased levels of PRA have been found to be 
a strong and independent prognostic factor in patients with HF [ I I ,  1 2]. Little is known about 
the prognostic value of active renin concentration in the presence of RAAS inhibition [ I 3] . 
Therefore, efficacy of RAAS blockade, single or dual or triple, and its effect on neurohormonal 
status are subject to study, both in HF without and with concomitant renal disease. 
Recently, it has been shown that prorenin not only serves as a renin precursor but also has its 
own function. It has been suggested that it acts by generating angiotensin I (Angl), as well as 
independently of Angl generation [ 1 4] .  Taking into account much higher prorenin levels than 
renin levels, further investigation of the relation between renin and prorenin could be of special 
interest to better understand the pathophysiologic role of RAAS in H F  [ 1 5]. 
The aim of the current study was to evaluate the prognostic value of active plasma renin 
concentration (APRC) in a group of patients with chronic HF being treated with RAAS­
blocking agents. Second, we tried to determine to what extent this value is dependent on 
prorenin concentrations and whether prorenin has individual prognostic value or adds to 
prognostic value of APRC in this population. Finally, we tried to determine the interrelationship 
of increased levels of APRC with other parameters of indices of renal impairment on clinical 





The main study design has been published elsewhere [ 1 6]. In short, outpatients with HF, � 1 8  
years old, with left ventricular ejection fraction (LVEF) <45%, and clinically stable were asked 
to participate. All patients used RAAS inhibitors (ACEi, ARBs, ARAs, or a combination), and 
all medication had to be stable for at least I month. Exclusion criteria were a myocardial 
infarction within the last 3 months, cardiac surgery or angioplasty within the last 3 months or 
scheduled to undergo these procedures, unstable angina pectoris, primary renal disease, prior 
organ transplantation, or chronic use of renal function-compromising medication. Baseline 
measurements included weight, height, blood pressure (mean arterial pressure [MAP] was 
calculated as follows: [2 x diastolic blood pressure + I x systolic blood pressure ]/3), and 
assessment of New York Heart Association function class.All patients underwent measurements 
of renal function. Glomerular fi ltration rate (GFR),  effective renal plasma flow (ERPF), and 
extracellular volume were measured by the clearances of 1 25 1-iothalamate and 1 3 1 1-hippuran 
as described earlier [ 1 7]. The filtration fraction (FF) was calculated as the ratio of GFR and 
ERPF and expressed as percentage.The study protocol was approved by the institutional ethics 
committee. All patients gave written consent. 
Active plasma renin concentration, angiotensin I I  (Angil) ,  and prorenin concentrations were 
measured as markers for RAAS activity. Active plasma renin concentration was measured by 
quantifying Angl generation in the presence of excess exogenous angiotensinogen, obtained 
from nephrectomized sheep as described before in detail, 1 8, 1 9  and expressed as ngAngl/ 
ml per hour. The detection limit was 0. 1 ngAngl/mL per hour. Angiotensin II was measured 
by a specific radioimmunoassay after extraction from plasma by reversible adsorption to 
octadecylsilyl silica (Sep-Pak;Waters, Milford, MA) as described before [20]. Using this method, 
the cross-reactivity with both Angl and Ang ( 1 -7) was low (<0.2%) . Prorenin was measured 
with Human Prorenin ELISA kit ( Innovative Research, Novi, Ml) with prorenin-depleted human 
plasma and prorenin-depleted human plasma spiked with recombinant human prorenin from 
human embryonic kidney cell culture used as standards. The detection limit was 0.0 I ng/ml. 
Analyses were performed in a routine setting according to the guidelines of the manufacturer. 
N-terminal pro-brain natriuretic peptide (NT-proBN P) was determined by 
electrochemiluminescence assay (Roche Diagnostics, Mannheim, Germany). 
High-sensitive C-reactive protein was measured by nephelometry with a threshold of 0. 1 5 6 
mg/L (BNI I  N, Dade Bahring, Marburg, Germany). C-reactive protein levels below the detection 
level were scored as 0. 1 5 6 mg/L. 
Urinary albumin excretion rate (in milligrams per 24 hours) was determined as a parameter 
of structural kidney damage and measured by nephelometry (Dade Behring Diagnostics, 
Marburg, Germany). 
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Follow-up 
Patients' follow-up started after renal function measurements had taken place. The primary 
(combined) end point consisted of all-cause mortality, heart transplantation, or admission to 
hospital for HF. 
Relation between APRC and GFR 
To evaluate the relation between APRC levels and kidney function on prognosis, the study 
population was divided into APRC groups above or below the median with preserved renal 
function (�60 mUmin/ 1 .73 m2) or impaired renal function (<60 mUmin/ 1 .73 m2), creating 4 
subgroups. 
Statistical analysis 
Data of variables are presented as mean ± SD when normally distributed, medians with 
interquartile ranges when non-normally distributed, and frequencies and percentages for 
categorical variables. In the linear regression analysis, non-normally distributed data were log 
transformed. Multivariate linear regression analysis, including all univariate associated variables, 
was used to determine the contribution of different variables to APRC . P = 0 . 1 0  was used 
for removal of nonsignificant variables. Cox proportional hazards regression analysis was 
used to evaluate the association with baseline parameters and the occurrence of end points. 
Continuous variables were divided by their SD to allow comparison of relative contributions 
of different variables. Statistical analyses were performed using SPSS version 1 6.0 (SPSS Inc, 
Chicago, IL) .  
The authors are solely responsible for the design and conduct of this study, all study analyses, 
the drafting and editing of the manuscript, and its final content. 
Results 
The study population consisted mostly of male patients (76.5%) with a mean age of 5 8  ± 1 2  
years. All patients received RAAS inhibition (88% ACEi, 1 4% ARBs, and 36% ARAs) and most 
were treated with beta-blockers (84%) and diuretics (70%). Mean LVEF was 28% ± 9%, and 
mean G FR was 75 ± 27 mUmin/ 1 .73 m2. Median APRC levels were 24.3 ng/ml per hour.We 
classified patients according to quartiles of APRC (table I ). Patients in the highest quartile were 
more often female and had higher levels of prorenin, Angil, increased creatinine levels, lower 
values of GFR and ERPF, and more severe H F  as represented by lower LVEF, lower MAP, and 
higher NT-proBNP levels.They were also more often treated with diuretics and ARAs .There 
was no difference between the groups in use of ACEi or ARBs, neither in percentage nor in 
dose. 
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n 1 00 
Age (years) 58 ± 1 2  
Male sex ( n, %) 76 (76) 
LVEF (%) 28 ± 9  
NYHA class, % 
I 1 4  
I I 46 
I l l 30 
IV 1 0  
Hemoglobin levels 14, 1 ± 1 ,4 
(g/dl) 
Sodium (mmol/L) 136 ± 3 
ECV (Ukg BW) 0.26±0.05 
Blood pressure 
SBP (mmHg) 1 20 ± 2 1  
DBP (mmHg) 69 ± 12  
MAP (mmHg) 86 ± 1 4  
Renal function 
Serum creatinine 1 12 ± 34 
(mmol/dl) 
GFR (ml/ 75 ± 27 
min/ I .73m2) 
ERPF (ml/ 275 ± 88 
min/ 1 .73m2) 
FF (%) 27 ± 5 
UAE (mg/day) 5,70 
(3,45- 1 I , I 0) 
Neurohormones 
NT-proBNP 6 1 2  
(pg/ml) (269- 1 784) 
APRC (ng/ml/h) 24,3 
(5,6-7 1 ,9) 
1 1 8 
J 
25 
63 ± 1 0  
2 1  (84) 





1 4,4 ± I . I  
1 37 ± 4 
0.26±0.04 
1 36 ± 1 9  
77 ± 1 0  
97 ± 1 1  
I 05 ± 23 
84 ± 26 
288 ± 87 





, , . 
2,6 ( 1 ,5 3,9) 
AP-RC quartite 
l 3 4: 
25 25 25 
58 ± 12  55 ± 1 1  56± 12  
1 9  (76) 19 (76) 17 (68) 
27 ± 9 27 ± 8 25 ± 1 1  
1 2  20 0 
68 40 24 
1 6  28 56 
4 1 2  20 
1 3,9 ± 1 ,5 14, 1 ± 1 ,2 1 3,8 ± 1 ,7 
1 36 ± 2 136 ± 3 1 34 ± 3 
0.28±0.05 0.25±0.04 0.25±0.05 
1 24 ± 1 5  1 1 4 ± 1 8  1 04 ± 1 6  
7 1  ± 1 2  67 ± 9 60 ± 10  
89 ± 12  83 ± 1 1  75 ± 1 0  
9 9  ± 23 1 19 ± 38 126 ± 43 
83 ± 20 74 ± 30 60 ± 25 
303 ± 77 27 1 ±  1 00 239 ± 75 
28 ± 4 27 ± 5 25 ± 7  
6, 1 5  4,05 6,0 
(2,86- 1 2,25) (3,0- 12,95) (3,9- 1 1 , I )  
520 49 1 1004 
(259- 1 355) (2 1 0-2007) (362-2076) 
1 0,9 42, 1 1 2 1 ,2 
(9,3 1 4,5) (35,8 49,4) (94,7- 1 57,3) 
P-.vatue 
0.0 15 
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Table I continued 
Variables iotaJ APtlC ql.@Ftire :P-valoe 
population � 2. 3 
Angiotensin I I  9,9 5,5 (3, 1 -9,8) 7,8 1 1 ,3 13,7 <0.00 1 
(pmol/1) (4,7- 1 5, 1 )  (4,2- 1 1 ,3) (9,6- 1 9, 1 ) ( 1 0,0- 1 9,9) 
Prorenin (ng/ml) 2, 17  1,36 2,20 2,2 1 3 ,02 <0.00 1 
( 1 ,30-3,89) (0,90-2, I 0) ( I ,  1 2  3,6 1 )  ( 1 ,64--4,02) (2,04-4,6 1 )  
hsCRP ( mg/I) 2,5 1 ,9 1 ,9 2,6 3,6 0. 1 2 1  
( 1 ,0- 4,3) (0,8-3,8) (0,8-5,5) ( 1 ,4-3,9) (0,9-5,5) 
Treatment n (%) 
ACEi 88 (88) 22 (88) 23 (92) 22 (88) 2 1  (84) 0.584 
ARBs 14 ( 14) 4 ( 16) 2 (8) 4 ( 16) 4 ( 16) 0.798 
ACEi + ARB 2 (2) I (4) 0 (0) I (4) 0 (0) 0 .525 
Beta-blockers 85 (85) 23 (92) 18 (72) 2 1  (84) 23 (92) 0.709 
Diuretics 69 (69) 13 (52) 13 (52) 1 8  (72) 25 ( 1 00) <0.00 1 
Aldosterone 36 (36) I (4) 6 (24) 12 (48) 17 (68) <0.00 1 
antagonists 
LVEF: Left ventricular ejection fraction; NYHA: New York Heart Association; ECV: extracellular volume; SBP: 
systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; GFR: glomerular (titration 
rate; FF (titration fraction; UAE: urinary albumin excretion; BNP: brain natriuretic peptide;APRC: active plasma 
renin concentration; ACEi: angiotensin converting enzyme inhibitors; ARBs: angiotensin receptor blockers; hsCRP: 
high-sensitive C-reactive protein. P value for trend. 
Relationship of cardiorenal hemodynamic and functional parameters with APRC and 
prorenin 
Active plasma renin concentration was most strongly associated with MAP (r = -0.60, P <0.00 I ) . 
Age, renal hemodynamic (ERPF, FF), renal functional (GFR) ,  and cardiac (LVEF) parameters 
were also significantly related to APRC. With respect to RAAS-related parameters, prorenin 
and Angil concentrations were significantly related to APRC. With respect to treatment, only 
d iuretics and ARAs showed a relationship  with APRC. I n  multivariate l inear regression analysis 
(table 2), age, MAP, Angi l concentration, and use of ARAs remained significantly related with 
APRC (adjusted R2 = 0.53) . 
Because of high colinearity between renal function parameters (r = 0.90, r = 0.73 for GFR vs 
ERPF and creatin ine, respectively), only GFR and FF were included in the multivariate model. 
Prorenin was significantly related to G FR, MAP,APRC,Angl l concentration, and use of ARAs and 
diuretics. In contrast to APRC, there was only a modest borderl ine nonsignificant association 
with ERPF (P = 0.054), FF (P = 0.054), and plasma NT-proBNP (P = 0.05) and no association 
with age (P = 0.580), creatinine (P = 0.08), or LVEF (P = 0.228). In multivariate analysis, only 
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Table 2. Multivariate regression analysis for APRC 
Variable B SE Beta p,-value 
-
Age -0.026 0.0 1 1 -0.200 0.0 1 6 
GFR -0.0 1 0  0.005 -0. 1 7 1  0.065 
MAP -0.044 0.009 -0.393 <0.00 1 
Angiotensin I I  0.326 0. 1 30 0. 1 93 0.0 1 4  
Aldosterone antagonists 0.730 0.282 0.229 0.0 1 1 
Adjusted R2 0.530 <0.00 1 
NT-proBNP, APRC, and use of d iuretics remained significant predictors of prorenin (adjusted 
R2 = 0.26) . 
Outcome related to APRC and prorenin 
During a 3-year follow-up, I I patients died, 5 underwent heart transplantation, and 1 2  were 
admitted to the hospital for congestive heart failure. Patients with the highest APRC had a 
worse prognosis in comparison with other groups (60% reached end point in quartile 4 in 
comparison with 20%, 1 2%, and 1 2% in quartiles I ,  2, and 3, respectively; P = 0.00 I )  (figure I ) . 
In a predefined multivariate Cox regression analysis, including age, gender; hemoglobin 
levels, parameters of renal and cardiac function, and treatment, only APRC, NT-proBNP, and 
hemoglobin levels remained significantly related to worse outcome (HR 2.87 [95% Cl 1 . 1 4-
7.20], P = 0.025 ; H R  3.37 [95% Cl 1 .47-7.7 1 ], P = 0.004; and H R  1 .88 [95% Cl 1 . 1 0-3.2 1 ], P 
= 0.022, respectively). Prorenin did not contribute significantly to prognosis in the multivariate 
analysis. 
Active plasma renin concentration outcome association by GFR strata 
As shown in table 3, patients with decreased kidney function and high APRC levels were of 
highest risk for poor c l inical outcome. Considering subgroups with preserved kidney function, 
high levels of APRC did not change this risk. In contrast, in patients with decreased kidney 
function, high APRC levels were associated with worse prognosis with an H R  of 3.54 (95% 
Cl 1 .02- 1 2.36, P = 0.047). After adjustment for cardiac parameters (MAP, LVEF, and NT-pro­
BNP) ,  the point estimate of the H R  remained numerically comparable; however; APRC lost 
its statistical significance: H R  3. 1 0  (95% Cl 0.82- 1 1 .76, P = 0.096). When subgroups with high 
APRC levels were taken into account, the presence of kidney dysfunction significantly increased 
the risk for worse outcome: H R  I 1 .66 (95% Cl 3.34-40.7 1 ,  P < 0.00 I )  and 5.92 (95% Cl 1 .58-
22.2 1 ,  P = 0.008) before and after adjustment, respectively. Kaplan-Meier survival curves are 
shown in figure 2. 
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Figure I .  Survival analysis according to quartiles APRC. APRC Q I ,  Q2, Q3, Q4 indicate quartile I , 2, 3, and 4, 
respectively. HT x, heart transplantation. 
Finally, we also calculated the interaction term between APRC and GFR levels using both 
variables dichotomized according to the strategy mentioned above, and we found a trend 
toward interaction (P = 0. 1 09) .  
Discussion 
In the present analysis, we confirm that APRC is a strong prognostic factor in patients with H F  
treated wrth RAAS blocking agents. For the first time, we show that APRC i s  of prognostic value 
especially in H F  patients wrt:h impaired kidney function. Even after adjustment for various kidney 
function parameters, which were measured invasively using state-of-the-art techniques, APRC 
remained a significant predictor of outcome. Next to APRC, NT-proBNP and hemoglobin 
levels were also of predictive value. Increased levels of active renin have previously been shown 
predictors of mortality in patients with H F  [ 1 3 ,2 1 ]. Several explanations can be proposed for 
the observed prognostic value of high levels of APRC in HF. First, h igh APRC may reflect the 
severity of the cardiac disease [22] and/or kidney dysfunction [ 4]. However, in our population 
even after adjusting for various cardiac and renal parameters, APRC remained a significant 
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Table 3. APRC outcome association by GFR strata 
L - - Ulilildiusted Adjusted for a.r-diac function * 
HR (95% Cl) p H R  (95% Cl) p 
Subgroup I I I 
(n==42) 
Subgroup 2 0.77 (0. 19-3.09) 0.7 14 0.68 (0. 1 6-2.97) 0.6 10 
(n==29) 
Subgroup 3 2.54 (0.64- 10. 1 5) 0. 188 1.30 (0.3 1 -5.48) 0.720 
(n- 10) 
Subgroup 4 9.00 (3.44-23.53) <0.00 1 4.03 ( I .25- 1 3.00) 0.020 
(n=2 I )  
Subgroup I :  GFR";?.60 mL/min/ I . 73m2, APRC<24.3 ng/mL/h; Subgroup 2: GFR";?.60 mL/min/ / . 73m2, 
APRC";?.24.3 nglmL/h; Subgroup 3: GFR<60 mL/min/ I . 73m2, APRC <24.3 nglmL/h; Subgroup 4: GFR <60 
mL/min/ I. 7 3 m2, APRC ";?.24.3 nglmL/h. * Adjusted for MAP, LVEF, and NT-proBNP. 
predictor of outcome, so that direct effects via APRC may explain its prognostic significance. 
Another possible explanation may be that higher APRC levels reflect more intensive RAAS 
inhibition. Interestingly, use of captopril eliminated the prognostic value of PRA on I -year 
mortality in the SAVE trial [23]. However; this is i n  contrast to reports of the survival benefit of 
RAAS inhibition, especial ly in patients with the most neurohormonal response [7-9]. We also 
did not find significant differences in use of ACE inhibitors or ARBs nor in ACEi/ARBs dose 
between patients with different APRC levels. 
Active plasma renin concentration levels were significantly related to age, MAP, and Angil 
concentration and the use of aldosterone antagonists, which confirms reports from the 
literature [ 1 3 ,24]. We did observe differences in the use of ARAs between patients with 
different APRC levels. Patients using aldosterone antagonist had higher APRC levels than those 
who did not use this treatment. However; survival analysis of the subgroup of patients using 
aldosterone antagonists showed that also in this group APRC levels were of prognostic value, 
with the lowest survival in the patients with highest levels of APRC (data not shown) . 
There were also differences in diuretics use between groups of patients in our study. Diuretics 
have been shown to increase ren in secretion, mostly because of extracellular volume 
contraction and electrolyte disturbances that are being sensed by the macula densa apparatus 
[25]. Although we did not observe any differences i n  extracellular volume, there was a trend 
toward lower sodium concentration with increasing APRC, so we cannot fully exclude the 
effect of diuretics on APRC levels. 
Our population was characterized by a substantial number of H F  patients with decreased 
renal function and renal perfusion. We are the first to show that high APRC levels have strong 
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Figure 2. Kaplan-Meier curves according to baseline APRC levels and GFR 
may also reflect decreased renal perfusion [SJ and, in HF, renal blood f low decrease is especially 
pronounced in cortical regions [26], the region responsible for active renin secretion [27] this 
may be of eminent importance. 
What factors underlie the association of increased APRC and worse outcome? Renin and 
prorenin can bind to the recently cloned prorenin/renin receptor and cause the development 
of fibrosis and damage without Angll formation [ 1 4, 1 5] .  Experimental studies have shown 
that smooth muscle cell-specific overexpression of the prorenin/renin leads to systemic 
hypertension. Reversely, strategies aimed to block the prorenin/renin receptor using the handling 
region peptide could ameliorate hypertensive renal damage [28]. Whether renin and prorenin 
exert maladaptive signaling in H F  is still subject to study, and we cannot exclude this effect in 
our study.As expected, we observed a correlation between APRC and prorenin concentration. 
However, after adjustment for multiple variables, prorenin did not show prognostic value in our 
population, which questions diagnostic use of prorenin. 
Another possibility to consider is the ACE escape phenomenon. It has been shown that 
because of the existence of alternative pathways, Angil formation is not completely blocked 
upon ACE inhibition [29-3 1 ] . Moreover, the use of ARAs on top of ACE inhibition induces 
further activation of RAAS system and leads to increased levels of active renin and to increased 
Angll formation. We were able to confirm those findings in our population; patients with 
highest APRC levels were more often using ARAs and had also highest Angil levels. 
Furthermore, activation of the sympathetic nervous system (SNS), reported in HF, leads to 
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increased secretion of renin [32,33]. Blockade of SNS with beta-blockers reduces APRC in 
HF, also in presence of ACEi [34,35]. We cannot fully exclude the hypothesis that association 
of APRC with the outcome is related to SNS activation in our patients; however; that there 
was no significant differences in beta· blockers use between groups of patients with different 
APRC and that prescription of those drugs does not influence the prognostic value of renin 
[2 1 ]  make this hypothesis unl ikely. 
Clinical implications 
Blocking RAAS activity with ACEi and/or ARBs became a common practice in the last 2 decades. 
This treatment has resulted in reduced mortal ity in this group of patients [7]. However; it has 
previously been shown [ I 3] and confirmed in the current study that increased APRC levels 
correlate with worse outcome, also in the presence of RAAS blockade. The prognostic value 
of the APRC was strongest in the group of patients with impaired kidney function.This suggests 
that a treatment strategy including drugs blocking renin might be more beneficial in this group 
of patients. Direct renin inhibitors showed to have favorable effects on neurohormonal status 
in patients with HF [36] and thus may be a promising treatment in patients with HF, especially 
in the presence of kidney dysfunction. However; we have to await mortal ity trials for definite 
proof 
Study limitations 
Our study is limited by its small sample size. Another l imitation of this study is its observational 
nature. We were not able to explore cause-effect relationship of prognostic value of high 
APRC levels. In addition, there were some differences with regard to aldosterone blockers and 
diuretics use. Patients with higher levels of APRC were more often using this kind of treatment. 
Although we corrected for this difference, we might not be able to show their true influence 
in multivariate analysis. 
Conclusions 
In conclusion, increased APRC is a strong predictor of outcome in patients with HF using 
RAAS-blocking agents. Heart failure patients with decreased kidney function and a h igh APRC 
are at the highest risk for adverse cl inical outcome . Our data suggest that renin regulation and 
possibly renin inhibition may be of particular importance in this group of patients. Further 
studies are needed to answer whether additional therapy aimed at sustained RAAS activation 
could be beneficial in patients with HF and impaired renal function. 
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Heart failure is a clinical syndrome with high morbidity and mortality rates [ I ]. The effects of 
treatment and thus clinical outcome in heart failure patients are very often compromised by 
the existing co-morbidities, among which one of the most common is renal failure. Its presence 
significantly influences the treatment and prognosis in heart fai lure patients [2].Therefore, this 
co-existence of heart and kidney dysfunction, often referred to as "cardiorenal syndrome", 
has received much attention in the last years [3,4]. Multiple mechanisms have been proposed 
as the underlying mechanisms of this heart-kidney interaction, among which hemodynamic 
changes, neurohormonal activation, inflammation and endothelial dysfunction seem to play 
a central role. However; the exact pathophysiology of the cardiorenal syndrome remains 
unclear. This thesis aimed to improve the understanding of this important clinical condrtion 
by introduction of a new animal model and imaging techniques for experimental studies and 
further investigation of the effects of common treatment strategies in the clinical setting. 
The cardiorenal interaction has been and is currently being investigated in multiple clinical trials 
involving different treatment strategies [5 ,6,7]. However; because of the observational character 
of most of the studies, an in-depth investigation of the pathophysiology of the heart-kidney 
relationship is not ful ly possible. Therefore, a better understanding of this clinical condrtion 
requires well-designed animal studies performed in a dedicated animal model. 
In PART I we explored the possibi lities of animal studies on the cardiorenal interaction. In 
chapter 2 we have reviewed different animal models that have been so far used in stud ies 
on card iorenal interaction. These animal models are based on the use of rodents, since this 
approach has the advantages of relatively low costs, availability, and housing conditions.Although, 
they all represent, to some extent, clinical characteristics of the cardiorenal syndrome, still 
the translation towards the clinical situation is limited. Therefore, a new and better model 
is needed. Such a model should meet multiple requirements as mentioned in chapter 2, 
including progressive deterioration of both organs, hemodynamic changes affecting both 
heart and kidney and activation of various compensating neurohormonal systems, and finally 
confirmation by histological changes as observed in patients with the cardiorenal syndrome. 
The recent developments in molecular biology techniques have increased the number of 
possibilities in creating new models for various diseases. This approach may also lead to the 
development of a new model for the cardiorenal syndrome. However; it has to be addressed 
that both heart and kidney failure are heterogeneous disorders resulting from multiple clinical 
conditions involving various pathophysiological pathways. Therefore, we may as well not be 
able to develop one model entirely mimicking the c linical characteristics of the cardiorenal 
syndrome. The alternative may be the use of different models, depending on the postulated 
research question. A more or less integrated analysis of the results obtained from multiple 
studies making use of various models may help us to understand the complexity of the heart­
kidney interactions. 
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I n  our experimental studies on the card iorenal interaction, presented in  chapter 3 and 4, 
we used a novel animal model for the cardiorenal interaction. We have chosen a Munich­
Wistar-Fromter (MWF) rat, a strain characterized by spontaneous and gradual development 
of renal dysfunction, resulting in increased proteinuria and glomerulosclerosis [8,9].The gradual 
deterioration of the kidney function mimics the time-course of renal fai lure observed in  
humans. In  chapter 3 we have investigated the cardiac sensitivity to acute ischemia/reperfusion 
damage in MWF rats in comparison to healthy Wistar rats and hypertensive SHR. It has been 
suggested in l iterature that cardiac ischemic tolerance in the presence of renal dysfunction 
is reduced [ I OJ, which may explain worse outcome of these patients. It is bel ieved that next 
to factors associated with the kidney and circulation, also cardiac factors contribute to this 
reduced card iac ischemic tolerance [ I I ,  1 2] .  We showed increased sensitivity to i schemia in 
MWF rats, which could not be attributed to hypertension or adverse cardiac remodel l ing. Our 
findings are in accordance with the recent findings by Dikow and col leagues in an alternative 
model [ I 3], and suggest alternative mechanisms to play a role in increased heart i schemic 
sensitivity in renal dysfunction.These mechanisms could include endothelial dysfunction, altered 
neurohumoral responsiveness and/or anemia and should be further stud ied in various animal 
models. 
In chapter 4 we have stud ied the time-course of changes in both cardiac- and renal function in 
our model after introducing a myocardial infarction. We showed that experimental myocardial 
infarction d id not exaggerate renal function, however; the deterioration of card iac function 
was accelerated by the presence of renal dysfunction. Renal dysfunction in our model was 
confirmed by increased proteinuria and histological changes. Interestingly, creatinine clearance 
was not different from values observed in other groups.This seems to support the hypothesis 
that proteinuria and reduced glomerular fi ltration rate represent d ifferent types of renal 
dysfunction [ 1 4] .  Again, this underscores the heterogeneous character of renal failure ,  which 
should be considered when analyzing the data from experimental stud ies. I nterestingly, with 
regard to cardiac function, we have observed not only systolic, but also prominent d iastol ic 
dysfunction.This is in agreement with cl inical observations in patients with renal dysfunction [ 1 5] .  
Moreover; recently i t  has been suggested that d iastol ic dysfunction develops into congestive 
diastolic heart failure because of underlying renal insufficiency [ 1 6]. We suggest that this model 
could serve as a tool for further investigation of this interesting and cl inically important aspect 
of the cardiorenal interaction. Our study showed that in this model endothelial dysfunction 
is an important mediator in the card iorenal interaction.There is growing evidence of the role 
of endothelium in regulation of cardiac systol ic and diastolic function [ 1 7, 1 8] ,  as well as renal 
perfusion in heart failure patients [ 1 9] .  Endothel ial function also plays a crucial role in the 
actions of erythropoietin [20,2 1 ] . Since the correction of anemia improves both cardiac and 
renal function in heart fai lure [22], endothelial dysfunction might be an important contributor 
in the heart/kidney interaction. Future research is needed in order to evaluate the exact role 
of endothel ial dysfunction in the pathophysiology of the card iorenal syndrome, its relevance in 
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the clinical setting and potentially beneficial treatment strategies. 
The animal studies on the card iorenal interaction require not only a relevant animal model, 
but also tools to investigate various aspects of the heart-kidney connection. Especially the 
proper quantification of hemodynamic changes and organ perfusion remain a challenge. The 
currently used techniques are not suitable for repetitive measurements due to their invasive 
character. In PART II we have studied positron emission tomography (PET) with the use of 
1 3 N-N H3 as a method of evaluation of the cardiorenal axis, which can be used in experimental 
studies. I ntroduction of PET al lowed quantitative and non-invasive measurements of multiple 
organs function and perfusion. PET scanning with 1 3 N-NH 3 has been used in the evaluation 
of cardiac and renal perfusion in humans [23,24]. Promising results have been obtained also 
for simultaneous measurements of myocardial perfusion, left ventricle volumes (LW) and 
ejection fraction (LVEF) with the use of 1 3N-NH3 PET [25]. In chapter 5 we showed that this 
technique allows measurement of both LW and LVEF simultaneously in healthy rats and rats 
after myocardial infarction and results obtained with this approach are comparable with the 
measurements with the golden standard, 1 8F-FDG micro-PET. Moreover. we showed that it might 
be used for repetitive measurements, which allows monitoring of the changes in measured 
parameters over time. This approach thus offers a tool for monitoring the progression of 
d isease and the efficacy of pharmaceutical and non-pharmaceutical interventions. 
The hemodynamic changes in heart failure resulting from decreased cardiac output lead 
to reduction of organ perfusion, including the kidneys [26]. It has been hypothesized that 
restoration of cardiac function would lead to an improvement in renal perfusion, and thus renal 
function [27]. However; the tool for repetitive measurements of regional renal perfusion in small 
animals is still missing, and therefore the research possibilities regarding th is aspect of cardiorenal 
interaction are l imited. In chapter 6 we described a pi lot study with healthy rats and rats with 
myocardial infarction, in which we studied the use of 1 3N-NH3 micro-PET for simultaneous 
assessment of both cardiac and renal regional perfusion.We showed that experimental cardiac 
dysfunction leads to reduced cardiac perfusion and we found a trend towards a reduction in 
renal perfusion. The latter was more pronounced in the cortical regions, supporting findings 
from literature [28,29]. Interestingly, these changes correlated with histological changes. As 
expected , measured cardiac perfusion was strongly correlated with infarct size and LVEF. Our 
results suggest that micro-PET with the use of 1 3N-NH 3 might serve as an useful non-invasive 
tool for simultaneous measurement of cardiac and regional renal perfusion in small animal 
models. This technique might be used in studies on renal perfusion in the presence of cardiac 
dysfunction. In addition, it may provide more insight into mechanisms activated by d ifferent 
treatment strategies. Implementation of this technique in experimental studies could also help 
in comparing results from the animal studies on cardiorenal interaction with the clinical setting, 
this would underscore the similarities and d ifferences between these studies and therefore 
could lead to easier translation and better understanding of the cardiorenal syndrome. 
One of the most important cardiorenal connectors is the renin-angiotensin-aldosterone system 
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(RAAS) [3,4]. We further explored the role of the RAAS in heart failure patients in PART I l l .  
Since the pharmacological blockade of  the RAAS resulted in  improved prognosis [30,3 I ], it has 
become one of the cornerstones of the therapy in heart failure patients. However, long-term 
RAAS blockade disables regulatory mechanisms of the kidney and can lead to further decrease 
in renal blood flow and GFR Moreover; RAAS-blocking agents increase the plasma levels of 
prorenin and ren in. In chapter 7 we studied whether this increase m ight be of prognostic 
value. We have studied a relatively smal l group of heart failure patients being treated with ACE 
inhibitors. We showed that renin is indeed a strong prognostic factor in this patient population. 
This is in agreement with previous data from l iterature [32]. Interestingly, the prognostic value 
of renin was especially pronounced in  the group of patients with reduced kidney function. 
Even after adjustment for various kidney function parameters, renin remained a significant 
predictor of outcome. I nterestingly, prorenin did not show prognostic value in our study. The 
association between increased renin levels and worse outcome might be a reflection of ACE 
escape mechanisms, reported before in l iterature [33]. Another possib i l ity is the action exerted 
by renin independently of angiotensin formation. This hypothesis is supported by the recent 
findings on prorenin/renin receptor [34,35]. Our results suggest that beneficial effects could 
be achieved by blocking the RAAS at the level of renin ,  especially in patients with decreased 
renal function. This can be achieved by the use of direct renin inhibitors. They have already 
been shown to have favorable effects on neurohormonal status in patients with HF [36] and 
are currently studied in multiple trials, such as ATMOSPHERE, ALTITUD E  and ARIANA-CH F  
[6,7]. Whether these agents could serve a s  a n  additional treatment in  heart failure patients 
needs further clarification and we need to await the results from ongoing trials to be able to 
answer this question. 
Future perspectives 
In this thesis we have addressed multiple aspects of experimental and cl in ical stud ies on the 
card iorenal interaction, which should be further investigated. 
We used an animal model for stud ies on combined heart- and kidney fai lure. Our studies 
suggest an important role of endothel ial dysfunction in the cardiorenal interaction. Although it 
has already been known that endothel ial dysfunction is present in the heart fai lure population 
and is associated with renal dysfunction, our results suggest that it may play an important 
mediating role i n  development of heart/renal fai lure in the presence of the disorder of one of 
the organs. Future studies on endothelial dysfunction and its interaction with other card iorenal 
connectors as wel l  as on possible treatment strategies are therefore required. 
Our studies on imaging of the card iorenal axis with 1 3N-NH3 micro-PET show that this method 
offers an attractive alternative to invasive measurements used so far. We demonstrated that 
with the use of this technique, quantitative, repetitive measurements of left ventricle function 
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and volumes can be obtained. Our pilot study results also suggest that regional kidney perfusion 
as wel l  as myocardial perfusion may be obtained non-invasively with this technique.The latter 
has to be confirmed in larger studies. This could lead to a significant improvement of our 
understanding of the different cardiorenal interactions in heart failure patients. 
The important role of the RAAS in the cardiorenal interaction has been addressed multiple 
times. RAAS blockade has become one of the cornerstones of heart failure treatment and 
resulted in reduced mortality. However; it also leads to and increase in renin levels, which we 
showed to correlate with worse outcome, especially in the group of patients with impaired 
kidney function. This suggest that more beneficial effects could be obtained in this group of 
patients with the use of direct renin blockers. Currently ongoing and future clinical trials with 
these agents should give the answer whether they can be a sign ificant improvement in  the 
therapy. 
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Hartfalen is een klinisch syndroom dat geassocieerd is met een hoge morbiditeit en mortaliteit. 
De effecten van de behandeling en dus de klinische uitkomst bij patienten met hartfalen zijn 
vaak beperkt door de aanwezigheid van andere aandoeningen, waarvan nierfalen een van de 
meest voorkomende is. Nierfalen heeft grote invloed op de behandeling en de prognose bij 
hartfalen patienten. Daarom heeft deze co-existentie van hart- en nierdysfunctie, ook wel het 
"cardiorenaal syndroom" genoemd, veel aandacht gekregen in de afgelopen jaren. Meerdere 
onderliggende mechanismen lijken een rol te spelen in dit gezamenlijk falen van hart en nier: 
Hemodynamische veranderingen, neurohormonale activatie, ontsteking en endotheeldysfunctie 
lijken de meest prominente rol te spelen. Echter, de onderliggende pathofysiologie van het 
cardiorenaal syndroom is onduidelijk. Dit proefschrift is erop gericht om de kennis van en 
begripsvorming over de cardiorenale interactie in het kader van hartfalen te vergroten door 
de introductie van een nieuw diermodel en beeldvormende technieken voor experimentele 
studies en aanvullend onderzoek in patienten met hartfalen naar de effecten van de vaak 
gebruikte behandelstrategieen. 
De cardiorenale interactie werd en wordt momenteel onderzocht in meerdere klinische studies 
waarbij onder andere gekeken wordt naar verschillende therapeutische strategieen. Echter, 
als gevolg van het observationele karakter van de meeste van deze studies is mechanistisch 
onderzoek naar de pathofysiologie van de hart-nier-relatie niet goed mogelijk. Een beter 
begrip van het cardiorenaal syndroom zou verkregen moeten warden in goed opgezette, 
gecontroleerde experimenten in het juiste diermodel. 
In DEEL I hebben we de mogelijkheden voor dierexperimenten op het gebied van de 
cardiorenale interactie onderzocht. In hoofdstuk 2 zijn de verschillende diermodellen die tot nu 
toe gebruikt zijn gebruikt in studies, met als onderwerp de cardiorenale interactie, besproken 
in hun pathofysiologische context. Als diermodel werd in het merendeel van de gevallen 
gebruik gemaakt van een knaagdiermodel wat het voordeel heeft van relatief lage kosten, 
ruime beschikbaarheid en controleerbare huisvestingcondities . Hoewel deze diermodellen 
enigszins de klinische kenmerken van het cardiorenaal syndroom laat zien blijft de vertaling 
van de bevindingen naar de klinische praktijk moeizaam en beperkt. Daarom is er dringend 
behoefte aan nieuwe en betere modellen. Een dergelijk model moet kenmerken bevatten 
zoals beschreven in hoofdstuk 2. Hierbij moet men denken aan een progressieve verslechtering 
van de functie van beide organen, hemodynamische veranderingen die zowel het hart als de 
nieren be·1nvloeden, activatie van de verschillende neurohormonale systemen en histologische 
veranderingen zoals waargenomen bij patienten met het cardiorenaal syndroom. Door de 
recente stormachtige ontwikkelingen van nieuwe moleculair biologische technieken zijn de 
mogelijkheden van translationeel onderzoek enorm vergroot. Dit kan ook leiden tot de 
ontwikkeling van een nieuw model voor het cardiorenaal syndroom. Echter, hart- als nierfalen 
zijn heterogene syndromen en zijn het gevolg van verschillende klinische aandoeningen. Daarom 
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is het bijzonder moei l ijk om een model te ontwikkelen die al le kl in ische kenmerken van het 
card iorenaal syndroom in zich heeft. Een alternatief is om h iervoor verschi l lende model len in  
te zetten, d ie gerelateerd zijn aan een specifieke onderzoeksvraag. Een ge'integreerde analyse 
van de resultaten van verschi l lende model len zou ons dan mogelijk verder kunnen helpen om 
de complexiteit van de interactie tussen hart en n ier beter te leren begrijpen. 
In  de experimentele studies in  hoofdstuk 3 en 4, hebben we gebruik gemaakt van een nieuw 
d iermodel voor de cardiorenale interactie. Er is hier gekozen voor de Munich-Wistar-Fromter 
(MWF) rat, een stam die wordt gekenmerkt door de spontane ontwikkel ing van renale 
dysfunctie, wat leidt tot een verhoogde prote'inurie en glomerulosclerose. De geleidel ijke 
verslechtering van de n ierfunctie l ijkt op het beloop van n ierfalen zoals d it ook wordt gezien 
bij patienten met nierfalen. In hoofdstuk 3 hebben we de cardiale gevoel igheid voor acute 
ischemie / reperfusie schade i n  MWF ratten onderzocht en vergeleken met gezonde en 
spontane hypertensieve ratten.  In  de l iteratuur is beschreven dat de ischemische tolerantie 
verminderd is in aanwezigheid van nierdysfunctie wat de slechtere prognose van deze patienten 
zou kunnen verklaren. Er wordt aangenomen dat naast de factoren, die geassocieerd zijn 
met de nieren en circulatie, ook cardiale factoren bijdragen aan een verminderde card iale 
ischemische tolerantie. We toonden een verhoogde gevoel igheid voor ischemie aan in  MWF 
ratten d ie niet verklaart kon warden door de aanwezigheid van hypertensie of card iale 
remodellering. Onze bevindingen zijn in  overeenstemming met recente bevindingen van 
Dikow in een ander model en suggereren de aanwezigheid van alternatieve paden. Deze 
paden kunnen endotheeldysfunctie, veranderde neurohumorale gevoel igheid en/of anemie 
zijn. Deze mechanismen moeten verder onderzocht worden in  verschil lende diermodel len .  
In  hoofdstuk 4 hebben we de veranderingen in  hart-en nierfunctie na een hartinfarct 
onderzocht. We zagen dat een experimenteel hartinfarct de nierfunctie niet be'invloedt, 
maar dat de verslechtering van de hartfunctie wel werd versneld door de aanwezigheid 
van een verminderde n ierfunctie. De n ierdysfunctie in d it model werd bevestigd door de 
aanwezigheid van prote·inurie en histologische veranderingen. lnteressant in ons experiment 
was de bevinding dat creatin ineklaring n iet verschi l lend was tussen de verschi l lende groepen. 
Dit l ijkt onze hypothese te ondersteunen dat prote·inurie en een verminderde glomerulaire 
fi ltratiesnelheid verschi l lende entiteiten van nierdysfunctie zijn .  Verder; bevestigt dit nogmaals 
het heterogene karakter van nierfalen. D it heterogene karakter moet in ogenschouw worden 
genomen bij de interpretatie van gegevens verkregen uit experimenteel onderzoek. Een 
opval lende bevinding was verder dat de card iale dysfunctie niet al leen de systol ische, maar 
ook de diastolische dysfunctie betrof. D it is in overeenstemming met kl in ische observaties bij 
patienten met een verminderde nierfunctie. Recent is gesuggereerd dat d iastol ische dysfunctie 
kan leiden tot d iastol isch hartfalen door onderl iggende nierfalen. Ons d ierexperimenteel 
model zou een instrument kunnen zijn in verder onderzoek naar dit interessante en kl in isch 
belangrijk aspect in de cardiorenale interactie. In ons model was de endotheeldysfunctie 
een van de belangrijkste determinanten van de card iorenale interactie. Er zijn  steeds meer 
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aanwijzingen dat het endotheel daarnaast een rol speelt in de regulatie van, speelt ook een 
rol in de regulatie de systolische en diastolische hartfunctie zowel in de regulatie van renale 
perfusie bij patienten met hartfalen. Endotheelfunctie speelt verder ook een cruciale rol in de 
werking van het hormoon erytropoetine dat een specifieke stimulerende werking heeft op 
de vorming van rode bloedcellen. Omdat een verhoging van het aantal rode bloedcellen bij 
patienten met te weinig rode bloedcellen zowel de hart- als nierfunctie bij hartfalen verbetert, 
is het te verwachten dat het endotheel een belangrijke rol speelt in de driehoek hart, nier 
en anemie, ook wel het cardiorenale anemie syndroom genoemd. Verder onderzoek is nodig 
om de precieze rol van endotheel dysfunctie in de pathofysiologie van het cardiorenale 
anemie syndroom, de relevantie ervan in de klinische setting en de potentiele therapeutische 
strategieen te onderzoeken. 
Dierexperimenten naar de cardiorenale interactie vereisen niet alleen een adequaat model, 
maar ook specifieke meetinstrumenten om de verschillende aspecten van de interactie 
tussen hart en nier te kunnen onderzoeken. Vooral de kwantificatie van hemodynamische 
veranderingen en perfusie van de beide organen zijn een uitdaging. Vanwege hun invasieve 
karakter zijn de op dit moment gebruikte technieken niet geschikt voor het uitvoeren van 
herhaalde metingen. 
In DEEL II bestudeerden we in een dierexperimenteel model de mogelijkheden van 
positronemissietomografie (PET) met 1 3N-NH
3 
voor de afbeelding en evaluatie van de 
cardiorenale as .. Met PET is het mogelijk om van meerdere organen tegelijkertijd kwantitatieve 
en niet-invasief orgaanfunctie en orgaanperfusie te meten . PET-scanning met 1 3N-NH
3 
is bij 
mensen al succesvol gebruikt voor de evaluatie van cardiale en renale perfusie. Goede resultaten 
met 1 3N-NH3 PET zijn ook verkregen tijdens gelijktijdige metingen van myocard perfusie, linker 
ventrikel volumes (LW) en ejectiefractie (LVEF). In hoofdstuk 5 hebben we aangetoond dat 
deze techniek gebruikt kan worden voor metingen van zowel LW als LVEF bij gezonde ratten 
en ratten met myocardinfarct. De resultaten zijn vergelijkbaar met de metingen met de gouden 
standaard, 1 8F-FDG micro-PET. We hebben ook aangetoond dat deze techniek gebruikt kan 
warden voor herhaalde metingen. Dit maakt de monitoring van veranderingen in de gemeten 
parameters in de tijd mogelijk. Deze aanpak biedt dus een instrument voor onderzoek naar de 
progressie van de ziekte en de werking van farmaceutische en niet-farmaceutische interventies. 
De hemodynamische veranderingen bij hartfalen als gevolg van een verminderde cardiale 
output leiden tot een vermindering van de perfusie van de organen, inclusief de nieren. Het 
is verondersteld dat het herstel van de hartfunctie zou leiden tot een verbetering van de 
renale perfusie, en dus de nierfunctie. Een meetinstrument waarmee we regionale renale 
perfusieveranderingen van organen in de tijd kunnen meten in kleine dieren ontbreekt op dit 
moment. Om die reden zijn de mogelijkheden voor dit type onderzoek met betrekking tot de 
cardiorenale interactie beperkt. 
In hoofdstuk 6 beschrijven we een pilot-studie met gezonde ratten en ratten met een hartinfarct, 
waarin we de waarde van 1 3N-NH
3 
micro-PET onderzocht hebben voor een gelijktijdige 
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beoordel ing van zowel hart- als renale regionale perfusie. We l ieten zien dat experimentele 
card iale dysfunctie leidt tot een verminderde card iale perfusie en we zagen een trend in een 
vermindering van de renale perfusie . De laatste bevinding was meer uitgesproken in de corticale 
gebieden van de n ier; wat ondersteund wordt door bevindingen uit de l iteratuur. Een belangrijke 
bevinding was dat deze veranderingen correleerden met histologische veranderingen.  Zoals 
verwacht, was de gemeten card iale perfusie sterk gecorreleerd met de grootte van het infarct 
en de LVEF. Onze resultaten suggereren dat micro-PET met het gebruik van 1 3N-NH3 zou 
kunnen d ienen als een bruikbare niet-invasieve techniek voor gelijktijdige metingen van cardiale 
and regionale renale perfusie in kleine d iermodel len. Deze techniek kan inzicht geven hoe 
de perfusie van de nier veranderd bij het optreden hartfalen. Daarnaast kan deze techniek 
meer inzicht geven in de werkingsmechanismen en impact van verschi l lende medicamenteuen 
niet-medicamenteuze behandelingsstrategieen. Een vergel ijking met observaties uit de kl in ische 
praktijk l igt voor de hand.Translationele overeenkomsten en verschi l len zouden kunnen leiden 
tot een beter begrip van het cardiorenaal syndroom. 
Een van de belangrijkste cardiorenale connectors is het renine-angiotensine-aldosteron systeem 
(RAAS). We hebben de rol van het RAAS bij patienten met hartfalen verder onderzocht 
in DEEL I l l .  Omdat de farmacologische blokkade van het RAAS leidde tot een verbeterde 
prognose in patienten met hartfalen werd blokkade van het RAAS een van de hoekstenen van 
de therapie bij deze patienten. Echter; op de lange termijn ontregelt chronische RAAS blokkade 
de regulatie mechanismen van de nieren wat kan leiden tot verdere dal ing van de nierperfusie 
en GFR. Daarnaast verhogen RAAS-remmers de plasmaspiegels van prorenin en renine.  
In hoofdstuk 7 hebben we onderzocht of deze stijging een prognostische betekenis zou kunnen 
hebben. In een relatief kleine groep van patienten met hartfalen die behandeld worden met 
ACE-remmers toonden we aan dat renine een sterke prognostische factor op het optreden van 
aan het hart gerelateerde ongewenste gebeurtenissen. D it is in overeenstemming met eerdere 
data uit de l iteratuur. lnteressant is dat de prognostische waarde van renine vooral zichtbaar 
was in de groep patienten met een verminderde nierfunctie. Zelfs na correctie voor d iverse 
aan nierfunctie gerelateerde parameters, bleef renine een s ignificante voorspel ler van prognose. 
Opvallend is dat prorenine geen prognostische waarde had in onze studie. Het verband tussen 
verhoogde renine spiegels en een s lechtere kl in ische uitkomst zou een weerspiegel ing kunnen 
zijn van ACE escape mechanismen, een fenomeen welke al eerder beschreven is in de l iteratuur. 
Een andere mogelijkheid is dat de werking van renine onafhankel ijk is van angiotensinevorming. 
Deze hypothese wordt ondersteund door recente bevindingen over de prorenine / reni ne­
receptor. Onze resuttaten suggereren dat gunstige effecten vooral bij patienten met een 
verminderde nierfunctie zouden kunnen warden bereikt door het blokkeren van het RAAS op 
het niveau van ren ine. D it zou bijvoorbeeld kunnen warden bewerkstel l igd door het gebruik 
van d irecte renineremmers. Deze middelen hebben al eerder gunstige effecten laten zien op 
de neurohormonale status bij patienten met HF. Directe renine blokkers warden momenteel 
onderzocht in verschi l lende stud ies, zoals ATMOSPHERE, ALTITUDE en ARIANA-CH F. Of 
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deze middelen hun toepassing hebben bij patienten met gecombineerd hart en nierfalen is 
nog onbekend. 
Toekomstperspectieven 
In dit proefschrift is translationeel de cardiorenale interactie onderzocht. 
In het experimentele dee/ beschrijven we een nieuw diermodel van gecombineerd hart­
en nierfalen. Onze studies beschrijven een belangrijke rol voor endotheeldysfunctie in de 
cardiorenale interactie en er kan warden geconcludeerd dat endotheeldysfunctie waarschijnlijk 
een belangrijke rol speelt in de ontwikkeling van gecombineerd hart- en nierfalen.Toekomstige 
studies over endotheeldysfunctie, de interactie met andere cardiorenale connectors en over 
mogelijke therapeutische strategieen zijn dan ook noodzakel ij k. 
De studies over beeldvorming van de cardiorenale as met 1 3N-NH3 m icro-PET laten zien 
dat deze methode een aantrekkelijk alternatief voor invasieve metingen zou kunnen zijn. 
We hebben aangetoond dat met deze techniek kwantitatieve herhaalde metingen van de 
linker ventrikelfunctie en volume mogelijk zijn. Onze pilot-studie suggereerde dat met behulp 
van deze techniek regionale nierperfusie en myocardperfusie niet-invasief gemeten kunnen 
warden. De klinische relevantie dient te warden uitgezocht in grotere studies. Dit kan leiden 
tot een substantiele verbetering van ons inzicht in de verschillende cardiorenale interacties bij 
patienten met hartfalen. 
De rol van het RAAS in de cardiorenale interactie is al meerdere keren onderzocht. RAAS 
blokkade is een van de hoekstenen van de hartfalen behandel ing, wat onder andere heeft 
geresulteerd in een verminderde mortaliteit. Echter, blokkade van het RAAS leidt ook tot 
een toename van de renine spiegels. Wij hebben aangetoond dat deze hoge renine spiegels 
correleren met slechtere prognose, vooral in de groep patienten met een verstoorde 
nierfunctie. Dit suggereert dat in het bijzonder deze groep patienten baat zouden kunnen 
hebben bij het gebruik van directe renine blokkers. Studies welke op dit moment warden 
uitgevoerd en toekomstige klinische studies met deze geneesmiddelen zullen antwoorden 








Niewydolnose serca to choroba charakteryzujqca s1� wysokq zachorowalnoscici i 
smiertelnoscici. Efektywnose leczenia pacjent6w z niewydolnoscici serca jest cz�sto ograniczona 
poprzez wsp6fwyst�pujqce choroby, sposr6d kt6rych jednci z najcz�sciej wyst�pujcicych jest 
niewydolnose nerek. Poniewaz wsp6fwyst�powanie niewydolnosci serca i nerek, nazywane 
"zesprnem secowo-nerkowym (kardionefrologicznym)" wiq2e si� z gorszym rokowaniem, sta}o 
si� ono przedmiotem wielu badan naukowych w ostatnich latach. Uwaza si�, iz u podstaw tego 
zesporu lezci liczne mechanizmy regulacyjne, sposr6d kt6rych centralnci rol� odgrywajci zmiany 
hemodynamiczne, aktywacja ukfad6w nerwowo-hormonalnych, zapalenie i niewydolnose 
sr6dbfonka.Jednakze, dok}adne powiq2ania patofizjologiczne sa wciq2 nieznane. Celem n in iejszej 
pracy byfo po��bienie wiedzy na temat tego istotnego kl inicznie zesporu chorobowego 
poprzez badania z zastosowaniem nowego modelu zwierz�cego, nowych technik obrazowania 
oraz anal iz� wpfywu stosowania popularnych lek6w na rokowanie pacjent6w z n iewydolnoscici 
serca. 
Zesp& sercowo-nerkowy jest analizowany w wielu prowadzonych obecnie badaniach 
klinicznych z zastosowaniem r6znych modeli terapeutycznych. Jednak obserwacyjny charakter 
tych badan nie pozwala na dokladnci anal iz� patofizjologicznych powiq2an pomi�dzy sercem i 
nerkami.Ten eel mozna osicigncie poprzez badania eksperymentalne z zastosowaniem zwierzcit 
laboratoryjnych. Cz�se I dotyczy takich wfasnie badan . W rozdziale 2 przeanalizowalismy 
i podsumowalismy rozne modele zwierz�ce, zastosowane dotychczas w badaniach 
kardionefrologicznych . Pomimo iz wszystkie te modele posiadajci w pewnym stopniu cechy 
zesporu chorobowego obserwowanego u pacjent6w, wyniki uzyskane w tych badaniach 
n ie zawsze mogci bye zastosowane w praktyce klinicznej. Z tego powodu potrzebny jest 
nowy model zwierz�cy do badan eksperymentalnych. W rozdziale 2 przedstawilismy cechy, 
jakimi powinn ien si� on charakteryzowae, takie jak stopniowy rozw6j niewydolnosci obu 
narzcid6w, zmiany hemodynamiczne i aktywacja r6znych neurohormonalnych mechanizm6w 
regulacyjnych, jak r6wniez zmiany histologiczne obserwowane w populacji pacjent6w. Jednym 
ze sposob6w uzyskania takiego modelu moze bye zastosowanie ostatnich osiqgni�e biologii 
molekularnej Nalezy jednak pami�tae, ze zar6wno niewydolnose serca jak i nerek to zesprny 
chorobowe, kt6re sci wynikiem roznych chor6b pierwotnych i aktywacji l icznych mechanizm6w 
patofizjologicznych. Z tego powodu stworzenie jednego modelu zwierz�cego, kt6ry w pelni 
by}by odzwierciedleniem obserwacji klinicznych moze okazae si� n iemozliwe. Alternatywci 
moze bye zastosowanie r6znych modeli ,  w zaleznosci od badanego zagadnienia. Jednoczesna 
analiza wynik6w takich badan moze pom6c w lepszym zrozumieniu powiq2an mi�dzy sercem 
i nerkami. 
W rozdziale 3 i 4 prezentujemy wyn iki badan eksperymentalnych, w kt6rych zastosowalismy 
nowy model zwierz�cy oparty na szczurach szczepu Wistam Munich Fromter (MWF) . 
Zwierz�ta te charakteryzujci si� stopniowym rozwojem n iewydolnosci nerek prowadzcicym do 
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bialkomoczu i szkl iwienia k-l'�buszk6w nerkowych .  W rozdziale 3 badalismy wrazliwosc mi�snia 
sercowego na zmiany niedokrwienne w naszym modelu w por6wnaniu do innych modeli -
zdrowych szczur6wWistar i szczur6w z nadcisnieniem t�tniczym (SHR) .  Dotychczasowe badania 
sugerujci, ii: niewydolnosc nerek prowadzi do zwi�kszonej wrazl iwosci m i�snia sercowego na 
zmiany n iedokrwienne, jakkolwiek czynniki zwiq2ane z samym mi�sniem sercowym r6wniez 
odgrywajq znaczqcq role. W naszych badaniach wykazalismy. ii: zmiany histologiczne w mi�sniu 
sercowym, czy tez nadcisn ienie t�tnicze nie wyjasniajq w wystarczajcicym stopniu zmniejszonej 
tolerancji miokardium na zmiany niedokrwienne. Nasze wyniki potwierdzajq wczesniejsze 
doniesienia i sugerujq, ii: inne n iz dotychczas uwazano czynniki odgrywajq rol� w powyzszym 
proces1e .  
W rozdziale 4 opisane sq badania nad zmianami w wydolnosci serca i nerek nast�pujqce 
po drugotrwatym niedokrwieniu mi�snia sercowego, czyli zawale serca. W badaniach tych 
wykazal ismy. ii: w naszym modelu niewydolnosc serca po zawale serca nie miara znaczqcego 
wptywu na funkcj� nerek, jednak wsprnistnienie niewydolnosci nerek i serca przyspieszyfo 
rozw6j tej drugiej. Dysfunkcja nerek w naszym badaniu charakteryzowara si� obecnosciq 
bia&omoczu i zmian histologicznych, jednakze kl i rens kreatyniny nie by-I' obnizony. co 
potwierdza r6:znorodnosc obraz6w kl inicznych obserwowanych w niewydolnosci nerek 
jes l i  chodzi O niewydolnosc serca, to w naszych badaniach wykazal ismy obecnosc zar6wno 
niewydolnosci skurczowej jak i rozkurczowej serca, co odzwierciedla obserwacje kl in iczne. Co 
ciekawe, niekt6rzy autorzy sugerujq, ii: wsp&istnenie n iewydolnosci nerek jest niezb�dnym 
warunkiem do rozwoju rozkurczowej niewydolnosci serca. Zastosowany przez nas model 
moze bye przydatny w dalszych badaniach nad tym aspektem zesporu kardionefrologicznego. 
Nasze wyniki sugerujq, ii: waznym elementem w patofizjologii powiq2an pomi�dzy sercem i 
nerkami jest ( dys)funkcja sr6dbfonka. Ostatnie badania wskazujq na waznci rol� sr6db-l'onka 
w regulacji funkcji serca, zar6wno skurczowej jak i rozkurczowej, a takze perfuzj i nerek u 
pacjent6w z niewydolnosciq serca. Zachowana funkcja sr6db-l'onka jest istotna takze dla 
prawidfowego dziarania erytropoetyny, co dodatkowo podkresla jej istotnq rol� w zespole 
kardionefrologicznym, poniewaz leczenie n iedokrwistosci u pacjent6w z niewydolnoscici serca 
poprawia funkcj� serca i nerek Dlatego tez dalsze badania powinny skoncentrowac si� na 
ustaleniu dokradnej roli (dys)funkcj i  sr6db-l'onka w relacji pomi�dzy sercem a nerkami, co maze 
doprowadzic do wprowadzenia nowych strategii terapeutycznych. 
Badania eksperymentalne nad zespo-l'em sercowo-nerkowym wymagajq nie tylko zastosowania 
odpowiedniego modelu zwierz�cego, ale r6wniez technik pozwalajcicych na pomiary 
i losciowe i jakosciowe zmian patofizjologicznych zachodzqcych w trakcie tych badan. Obecnie 
najwi�kszym wyzwaniem pozostajq dokradne pomiary zmian hemodynamicznych i zmian 
w ukrwieniu r6:znych narzqd6w. Ze wzgl�du na ich inwazyjny charakter; techniki stosowane 
obecnie n ie mogci bye uzywane do wielokrotnych pomiar6w. W cz�sci II zanalizowalismy 
mozl iwosci zastosowania pozytronowej tomografi i emisyjnej (positron emission tomography. 
PET) z zastosowaniem 1 3N-N H3 w badaniach eksperymentalnych. Wprowadzenie PET 
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pozwol i./o na n ieinwazyjne pomiary zarc5wno funkcji jak i ukrwienia wielu narzqdow. PET z 
uzyciem 1 3N-N H3 jako znacznika jest uzywany do pomiarc5w perfuzj i miokardium i nerek u 
ludzi. Obiecujqce wyniki dafy takze badania nad jednoczesnym pomiarem perfuzj i miokardium, 
geometrii i funkcji serca. W rozdziale 5 pokazal ismy, iz zastosowanie tej techniki pozwala na 
jednoczesne pomiary geometrii i funkcji serca szczurc5w, zarc5wno zdrowych jak i szczurc5w z 
niewydolnosciq serca. Wyniki uzyskane przy pomocy tej metody byfy porc5wnywalne z tymi 
uzyskanymi za pomocq metody uznanej za z+oty standard, czyl i skanc5w z uzyciem 1 8F-FDG jako 
znacznika. Dodatkowo, pokazal ismy iz metoda ta pozwala na wielokrotne pomiary u jednego 
osobn ika, co ma kluczowe znaczenie dla pokazania ewentualnych zmian badanych parametrc5w 
w czasie. Dzi�ki temu mozliwe staje si� monitorowanie zmian chorobowych jak i efektc5w 
zastosowania rc5znych terapi i  w badaniach eksperymentalnych. 
Zmiany hemodynamiczne obserwowane w n iewydolnosci serca Sq efektem zmniejszonego 
rzutu serca i prowadzq do zmniejszonej perfuzji narzqdow obwodowych, w tym nerek. Uwaza si�, 
iz poprawa funkcji serca maze doprowadzic do zwi�kszenia ukrwienia nerek, a w  konsekwencji 
do poprawy ich funkcj i .  Jednakze obecnie brakuje narz�dzi eksperymentalnych pozwalajqcych 
na wielokrotne pomiary ukrwienia nerek, przez co badania nad tym zjawiskiem Sq ograniczone. 
W rodziale 6 opisujemy wst�pne badania, w ktc5rych anal izowal ismy zastosowanie PET z 1 3N­
NH3 jako znacznikiem do jednoczesnych pomiarc5w ukrwienia mi�snia sercowego i nerek. W 
badaniach tych zaobserowal ismy zmniejszone ukrwienie mi�snia sercowego i trend w kierunku 
zmniejszonej perfuzj i nerek u zwierzqt z niewydolnosciq serca. Zmniejszenie ukrwienia nerek 
by./o gtc5wnie obserwowalne w regionach korowych, zgodnie z doniesieniami z innych badan. 
Co ciekawe, zmiany te byfy skorelowane z zaobserowanymi zmianami strukturalnymi .  Zgodnie 
z oczekiwaniami, ukrwienie mi�snia sercowego by+o s i ln ie powiq2ane z wielkosciq obszaru 
obj�tego niedokrwieniem jak i z funkcjq skurczowq serca. Nasze wyniki sugerujq, iz technika 
ta maze bye przydatnym narz�dziem do oceny ukrwienia obu narzqdow. Jej zastosowanie 
w badaniach eksperymentalnych maze pomc5c w zrozumieniu zmian zachodzqcych w 
niewydolnosci serca, pozwol i  porc5wnac wyniki uzyskiwane w badaniach nad zwierz�tami z 
wynikami z badan kl in icznych, a co za tym idzie pomoze w lepszym zrozumieniu patofizjologi i  
zesporu kardionefrologicznego. 
Jednym z najwazniejszych elementc5w w patofizjologi i wzajemnych prnqczen pomi�dzy 
sercem a nerkami jest ukfad renina-angiotensyna-aldosteron (renin-angiotensin-aldosterone 
system; RMS). W cz�sci I l l prezentujemy wyniki anal izy roli RAAS w opisywanym zespole. 
Farmakologiczna blokada RAAS doprowadzifa do poprawy rokowania u pacjentc5w, przez co 
sta+a si� ona jednq z podstawowych strategi i terapeutycznych w niewydolnosci serca. Jednakze 
drugotrwa+e blokowanie RAAS prowadzi do dysfunkcji mechanizmc5w regulacyjnych nerki, a 
co za tym idzie zmniejszenia ich funkcj i .  Ponadto, ze wzgl�du na p�tle sprz�zenia zwrotnego, 
prowadzi ona do wzostu poziomc5w proreniny i reniny we krwi .W rozdziale 7 zanalizowal ismy 
czy ten wzrost moze miec wpfyw na rokowanie pacjenc5w. Badanie zosta+o przerpowadzone 
w relatywnie ma+ej grupie pacjenc5w leczonych inhibitorami konwertazy angiotensyny (ACE) .  
Z naszej anal izy wynika, i z  faktycznie wysokie poziomy reniny sq  czynnikiem decydujqcym o 
1 50 
Streszczenie 
rokowaniu, co potwierdza doniesienia z innych badan. Ponadto, zaleznosc ta byta najsilniej 
wyrazona w grupie pacjent6w z obnizonq funkcjq nerek. Nie stwierdzilismy przy tym podobnego 
wpfywu podwyzszonych poziom6w proreniny na rokowanie w tej grupie pacjent6w. Zwiq2ek 
reniny z gorszym rokowaniem pacjent6w mo:ze wynikac z opisanego wczesniej "mechanizmu 
ucieczki", lub tez z dzialania reniny poprzez receptor dla reniny i proreniny. Nasze wyniki 
sugerujq, :ze blokada RAAS na poziomie reniny moze przyniesc dodatkowe korzysci, zwlaszcza 
w grupie pacjent6w ze wsprnistniejqcq niewydolnosciq nerek. Mo:zna to osiqgnqc poprzez 
stosowanie bezposrednich inhibrtor6w reniny. lch korzystny wpfyw na status neurohormonalny 
u pacjent6w z niewydolnosciq serca zostat opisany w literaturze i jest obecnie analizowany 
w wielu badaniach klinicznych, takich jak ATMOSPHERE, ALTITUDE czy tez ARIANA-CHF. 
Badania te powinny wyjasnic czy leki te mogq posruzyc jako dodatkowa terapia u pacjent6w z 
niewydolnosciq serca. 
Przyszfe badania 
W niniejszej publikacji opisane Sq eksperymentalne i kliniczne badania nad r6:znymi aspektami 
zale:znosci pomiE:dzy funkcjq serca i nerek. Wyniki tych analiz zachE:cajq do dalszych badan w 
przysztosci . 
Nasze eksperymentalne badania z zastosowaniem zwierzE:cego modelu sugerujq waznq 
rolE: dysfunkcji sr6dbtonka w badanym przez nas zespole kardionefrologicznym. Pomimo, 
iz wsp61istnienie dysfunkcji sr6dbtonka u pacjent6w z niewydolnosciq serca i jej zwiq2ek z 
funkcjq nerek byra juz opisana wczesniej, nasze wyniki sugerujq jej znacznie wazniejszq 
rolE: w patofizjologii zesporu sercowo-nerkowego niz pierwotnie uwazano. NiezbE:dne sq 
dalsze badania nad tym aspektem badanej przez nas jednostki chorobowej, gdyz mogq one 
doprowadzic do modyfikacji strategii terapeutycznych. 
Nasze badania nad pozytronowq tomografiq emisyjnq z zastosowaniem 1 3N-NH3 jako znacznika 
pokazafy, :ze technika ta moze sruzyc jako alternatywa dla tych stosowanych obecnie. DziE:ki 
jej uzyciu mozliwe Sq wielokrotne, ilosciowe pomiary funkcji i geometrii serca, jak rowniez 
nieinwazyjna ocena ukrwienia nerek i miE:snia sercowego. Potwierdzenie naszych wynik6w w 
wiE:kszych badaniach pozwoli na rozpowszechnienie u:zycia tej techniki, co mo:ze doprowadzic 
do lepszego zrozumienia zmian patofizjologicznych zachodzqcych w niewydolnosci serca. 
Znaczqca rola RAAS w patofizjologii zesporu sercowo-nerkowego byra udowodniona 
wielokrotnie, przez co blokada tego ukradu stala siE: podstawq terapii pacjent6w z niewydolnosciq 
serca. DziE:ki temu rokowanie tych pacjent6w ulegto znacznej poprawie. Jednakze jak 
wykazalismy, drugotrwala blokada tego ukradu prowadzi do wzrostu poziom6w reniny, 
kt6ry to wzrost ma negatywny wpfyw na rokowanie. Zaleznosc ta sugeruje, iz zastosowanie 
bezposrednich inhibitor6w reniny moze bye wyjqtkowo korzystne w tej grupie pacjent6w. 
Badania kliniczne, zar6wno te prowadzone obecnie jak i przyszte, powinny odpowiedziec na 
pytanie czy zastosowanie tych lek6w moze faktycznie przyniesc dodatkowe korzysci. 
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Vier jaar geleden ben ik naar Groningen gekomen om onderzoek op het gebied van het 
cardiorenaal syndroom te verrichten. Maar onderzoek doe je niet alleen.Veel mensen hebben 
aan het tot stand komen van dit proefschrift bijgedragen. Het is niet mogelijk om iedereen hier 
te noemen, maar ik wil in het bijzonder een aantal van hen bedanken. 
Allereerst mijn promotoren: prof. dr. Hans L. H illege en prof. dr. Wiek H. van Gilst. Beste 
Hans, zonder jou had dit proefschrift niet tot stand kunnen komen. Je steun en vertrouwen 
heb ik enorm gewaardeerd. Als ik advies nodig had, stand je deur altijd voor mij open en 
meestal konden we samen een oplossing vinden, en dat betrof niet alleen wetenschappelijke 
problemen. Je optimisme en inspiratie hebben me gemotiveerd om door te gaan met het 
onderzoek, ondanks alle moeilijke tijden. Daarvoor mijn grate dankl 
Beste Wiek, ik wil je bedanken voor het vertrouwen om mij dit onderzoek te laten verrichten. 
lk herinner me ons eerste gesprek nog goed, toen ik in Groningen was tijdens de ISCOMS in 
2007. lk had toen nog geen idee dat ik zo lang in deze stad zou bl ijven wonen en werken. lk heb 
altijd genoten van onze discussies over mijn project en onderzoek maar ook over het leven, en 
dankzij jouw kennis en ervaring heb ik mezelf verder kunnen ontwikkelen. 
Als tweede wil ik mijn copromotor dr. Rudolf A. de Boer bedanken. Beste Rudolf, jouw 
enthousiasme, positieve stemming en humor hebben mij erg geholpen tijdens het afronden 
van dit proefschrift. Bedankt voor je begeleiding tijdens mijn onderzoeksperiode en je hulp en 
geduld tijdens de "never-ending submission" van ons renine stuk. 
De leden van de leescommisie, prof. dr. A.H.J. Danser; prof. dr. G .J .  Navis en prof. A.A. Voors wil 
ik bedanken voor het kritisch doorlezen van mijn proefschrift. Professor Danser wil ik daarnaast 
bedanken voor zijn bijdrage aan de analyse van de neurohormonale veranderingen in mijn 
dierexperimenten, professor Navis voor haar bijdrage aan mijn review over diermodellen en 
professorVoors voor zijn opmerkingen tijdens de cardiorenale besprekingen. 
Prof. dr. Dirk Jan van Veldhuisen, beste Dirk Jan, ik wil je bedanken voor je heldere en kritische 
blik en relevante opmerkingen op mijn artikelen. 
Dr. Regien G. Schoemaker; beste Regien, bedankt voor je steun en hulp vanaf het opzetten 
van de experimenten tot en met het schrijven van de experimentele manuscripten. Hoewel 
je bij de afrondingsfase van dit proefschrift minder betrokken was, hoop ik dat dit proefschrift 
ook aan jouw verwachtingen voldoet. 
U iteraard wil ik alle co-auteurs van mijn artikelen bedanken voor hun bijdrage aan dit 
proefschrift. In het bijzonder wil ik een paar van hen noemen. Dr. Hendrik Buikema wil ik 
bedanken voor zijn hulp met de analyses van de endotheelfunctie resultaten. Dr. Riemer Slart 
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wil ik bedanken voor zijn hu lp tijdens de analyses en het schrijven van mijn PET artikelen. Prof. 
dr: jolande van der Velden wil ik bedanken voor het u itvoeren van de metingen voor mijn 
experimentele stuk en hulp met de analyses van deze metingen. 
Een belangrijke rol in het hele promotietraject spelen natuurl ijk collega's. lk wil ju l l ie bedanken 
voor alle gezel l igheid tijdens en na het werk, al le congressen, barrels, cocktails u itjes, AIO­
weekendjes etc., waar ik met veel p lezier aan heb meegedaan. I rma, H isko, jardi ,  Wil lem-Peter, 
Liza, Meimei, Bo, Cheng, Li l i ,  Laura, Reinout, Hongjuan, Michael, Leonie,Atze, Frank, Lennaert, Niek, 
Vincent, Renee, Megan en Wardit - sommige van jul l ie zijn al klaar met het promotieonderzoek 
en bezig met andere d ingen, sommige zijn nag steeds bezig nieuwe d ingen uit te vinden, maar 
ik wens jul l ie al lemaal heel veel succes verder en hoop jul l ie tegen te komen in de toekomst! 
Oak col lega's van de Cardio Research: Kevin, Marcelle, Hessel, Rob, I smael, You Ian, Marthe, Ali , 
Anne, Suzan en Vincent - wil i k  bedanken voor de samenwerking, congressen en barrels en 
oak jul l ie wens ik succes met alles! 
Grote dankgaat oak uit naar de Al O's van andere afdelingen die iktijdens mijn onderzoekperiode 
heb ontmoet en waar ik mee heb gewerkt: I nge , Silvana, Pramod, Azazeh, Kiran, Peter, Diana, 
Maggie, Mahdi, Saritha, George, Bernadet, H iddo, lryna, Hjalmar, Roel ien, Nadir, Solmaz, Stefan,  
Else, Wendy, Reza en Golnar - good luck with everything in  the future! Daarnaast wi l i k  
oak Laura en Licette bedanken voor a l le  gezel l igheid tijdens de urenlange metingen in het 
isotopenlab. Succes verder met ju l l ie medische carrieres! 
Daarnaast wi l ik graag alle stafleden van de afdel ing experimentele cardiologie, Pim ,  Beatrijs, 
Herman, Alexander, I rene, Hasan en Maxi, hartelijk danken voor hun bijdrage aan mijn 
proefschrift door middel van interessante d iscussies, opmerkingen en suggesties. Carla, Ma�an, 
Daniel le, Brechtel ,  Hedde, Petra, Alma en Audrey wil ik graag bedanken voor alle hulp met 
het regelen van verschi l lende zaken en, wat bijna altijd onmogelijk leek, ruimte te vinden in de 
agenda's voor een afspraak met mijn supervisoren. 
Natuurl ijk  mogen alle hardwerkende mensen op het lab niet ontbreken - bedankt voor alle 
hulp tijdens mijn onderzoek. Si lke, I nge, janny, Martin, Bibiche, Bianca, Linda, Germaine, Maaike, 
Jan, Azuwerus, Bettine - zonder jul l ie was een groat deel van dit proefschrift niet mogelijk 
geweest. Veel dank ben ik verschuld igd aan de verpleegkund igen van de nierfunctiekamer -
Marjan, Roelie en Dirkina - bedankt voor ju l l ie hulp tijdens de nierfunctieonderzoeken en 
plannen van de agenda. Oak mensen van het CDL wil ik graag bedanken voor alle plezierige 
momenten en vrol ijkheid in het oude en nieuwe CDL. Yoran en Jurgen wi l ik bedanken voor 
de hulp met de analyses van de beeldvormings onderzoeken. 
Mijn paranimfen, Anne-Margreet de Jong en N icolas Schroten 
Beste Anne-Margreet, door al die jaren dat wij zij aan zij in onze kamer hebben gezeten zijn 
we niet al leen goede collega's geworden maar oak gewoon goede vrienden. Wij hebben veel 
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momenten van geluk en verdriet gedeeld. Hoewel wij op totaal andere projecten hebben 
gewerkt, konden we altijd een onderwerp vinden waarover uitgebreid ged iscussieerd moest 
warden, waarna we dan tot laat op het werk bleven om toch het werk doen. lk kan altijd op 
jouw steun rekenen en j ij hebt mij enorm geholpen, zowel tijdens het onderzoek als tijdens 
het afronden van het proefschrift. lk ben erg bl ij dat je mijn  paranimf wilt zijn en d it belangrijke 
moment met mij wi lt delen. 
Beste Nicolas, jest mi niezmiernie mi-1-o ze zgodzi-1-es s i� wspierac mnie w tym waznym dla mnie 
dniu. Ciesz� si�. :ze moglismy razem pracowac nad jednym tematem, choc zaruj� :ze tak ma-1-o 
by-1-o okazj i ,  by faktycznie pracowac wspolnie. Dzi�kuj� za wszelkq pomoc w trakcie doktoratu 
i za wszystkie rozmowy po polsku w czasie pracy. Zyczf:: Ci powodzenia w dalszej karierze, 
zar6wno tej naukowej jak i kl in icznej, i mam nadziej� Ci� cz�sciej spotykac niz tylko przy okazj i 
kongresow NWC! 
During my stay in Groningen I met a lot of great people who have contributed to my life there. 
I cannot mention them all here, but I would l ike to express my special thanks to some of them. 
To start with, my great Pol ish friends: Agata, Piotr, Marysia, Maciek, Hania, Jacek, Wojtek, Bartek, 
Justyna, Gosia, S-1-awek! Kochani ,  dzi�kuj� Warn bardzo za wszystkie wspolnie sp�dzone chwi le, 
wsparcie, pomoc, wszystkie momenty radosci i zabawy. Dzi�ki Warn wielokrotnie czu-1-em si� 
jak w domu i mia-1-em sit� walczyc z przeciwnosciami losu. Mam nadziej�. :ze mimo iz nasze 
drogi zyciowe prowadzq nas w r6:znych kierunkach, pozostaniemy w kontakcie i b�dziemy 
si� cz�sto widywac! Zycz� Warn wszystkim powodzenia! Ma-1-gosia J., Marta, Magda K., Adam, 
Jessica.Andreas, Gideon, l ld ik6, Samir, Magda Cz., Marcin, Gemma. Johnny, Sonja and many many 
others - I wish you all the best and good luck with making your dreams come true. Not to 
forget are my Pol ish friends, who have supported me from a distance. Matylda, Karol ina, Natal ia, 
Ania S., Przemek, Ania C., Bartosz, Paulina, Krzysztof, Zaklina, Jacek - dzi�kuj�! 
Het /even is zo mooi omdat het zo onvoorspelbaar is. Een jaar geleden kon ik n iet verwachten 
dat i k  ergens anders dan in Groningen zou wonen en werken. Maar het !even bl ijft me verrassen 
en nu ben ik in Den Haag bezig met een n ieuw hoofdstuk van mij n  leven. Allereerst wil ik dr: 
Marco Gotte en dr: Ben Delemarre bedanken voor het in  mij gestelde vertrouwen en de 
mogel ijkheid om mijn kl in ische ervaring op het gebied van de card iologie in  het HagaZiekenhuis 
uit te breiden. Daarnaast wil ik alle stafleden en collega's van de afdel ing cardiologie bedanken 
voor de steun in de laatste weken, toen ik mijn  werk met het afronden van m ijn proefschrift 
moest combineren. I would also l ike to thank all the friends I met in The Hague, who made my 
new start so enjoyable. Again it is not possible to mention them all , but my special thanks go to 
Agata, Pawe/' and Magdalena. Dear Dorothy, thank you for al l the happiness you brought into 
my l ife and for many great moments spent together! 
Last but not least, mijn  fami l ie. Drodzy Mamo i Tato! N ie jestem w stanie wyrazic sfowami mojej 
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wdzi�cznosci za wszystko to, co od Was otrzymclfem. Wiem, ze bez Waszego poswi�cenia, 
pomocy i wsparcia nie osiqgncifuym w zyciu nawet potowy tego, co uda.Jo mi si� osiqgnqc. 
Mamo, dzi�kuj� Ci za wsparcie, za l iczne porady, te wszystkie telefony, gdy ich potrzebowatem. 
Tato, dzi�ki naszym rozmowom miatem dodatkowq sit�. by pokonac wszelkie przeszkody na 
zawodowej i zyciowej drodze. Wszystkie Wasze odwiedziny tutaj, jak i moje wizyty w domu 
byty dla mnie wyjqtkowym przezyciem i n iesamowitym zastrzykiem pozytywnej energi i .  Za to 
wszystko Warn dzi�kuj�! 
Anetko, kiedys dziel�a nas roznica wieku, pozniej dziesiqtki ki lometrow, teraz sq ich setki. Jednak 
n igdy nie brakowa.Jo nam rzeczy, kt6re nas zblizaty i ktore byty d la nas wspolne. Dzi�kuj� Ci 
za wszystkie nasze rozmowy, powazne i wesote, za zaufanie, kt6rym mnie obdarzasz i ktorego 
staratem si� n igdy nie zawiesc. Mam nadziej�. ze w przysz.Josci nasze kontakty b�dq jeszcze 
cz�stsze i pozostaniemy sobie bl iscy mimo dzielqcej nas odleglnsci .  Powodzenia na studiach i w 
realizacji zyciowych planow! 
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